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Effects of A-beta Immunotherapy and Omega-3 Fatty Acid Administration in 
Alzheimer’s Transgenic Mice 
Maren T. Jensen 
ABSTRACT 
 
  Major therapeutics against Alzheimer’s disease (AD) are targeted towards 
reducing β-amyloid in the brain and improving cognitive performance.  Transgenic 
mouse models of AD have become critical in the development of such therapeutics to 
protect against or treat AD.  This dissertation examined the potential protective effects of 
both active Aβ immunotherapy and dietary omega-3 fatty acid administration to AD 
transgenic mice.  First, immunization with Aβ1-42 from 2-16½ months of age provided 
protection against cognitive impairment in APP/PS1 transgenic mice well into older age.  
At both adult (4½-6 month) and aged (15-16½ month) test points, an extensive 6-week 
behavioral battery was administered that measured multiple sensorimotor and cognitive 
domains.  Aβ immunotherapy either partially or completely protected APP/PS1 mice 
from impairment in reference learning/memory, working memory and/or 
recognition/identification at these test points.  However, behavioral protection at the later 
test point occurred without any reduction in Aβ deposition within the brain.  Therefore, 
the cognitive benefits of Aβ immunotherapy most likely involved neutralization or 
removal of Aβ oligomers from the brain.  In addition to immunotherapy, this dissertation 
 x 
also examined the behavioral and neurochemical effects of a high omega-3 (n-3) or high 
omega-6 fatty acid (n-6) diet to NT and AD transgenic (Tg+) mice from 2 through 9 
months of age.  The same 6-week behavioral test battery, as described above, was 
administered between 7½-9 months of age.  In NT mice, dietary n-3 or n-6 fatty acids did 
not result in any beneficial effects on cognitive performance.  In Tg+ mice, a high n-3 
diet improved some, but not most, cognitive skills in comparison to standard-fed Tg+ 
mice; whereas a diet high in n-6 fatty acids did not lead to widespread deficits in learning 
or memory.  In fact, there was no difference in overall performance on any behavioral 
task between Tg+ mice given a high n-3 or high n-6 diet.  Administration of dietary fatty 
acids did not result in any significant changes in soluble or insoluble Aβ levels within the 
brains of Tg+ mice and plasma cytokine levels in Tg+ mice were largely unaffected.  
Notably, neither the high n-3 nor high n-6 diet increased cortical levels of n-3 or n-6 fatty 
acids, respectively, within Tg+ mice.  However, NT mice on a high n-3 or high n-6 diet 
did show significant elevations in cortical n-3 or n-6 fatty acid levels, respectively, 
suggesting that Tg+ mice have a deficit in incorporation of dietary fatty acids in the brain.  
Collectively, these results show that life-long administration of active Aβ immunotherapy 
provides clear cognitive protection well into older age, whereas long-term dietary omega-
3 fatty acid administration does not provide extensive cognitive benefit.  Both studies 
underscore the value of using AD transgenic mice in determining the efficacy of 
prophylactics against AD. 
 
  
 
 
Introduction 
I.  Alzheimer’s Disease Background 
Alzheimer’s disease, first diagnosed by Alois Alzheimer in 1906, was not widely 
accepted as a disease affecting the elderly until the late 1960s.  Within this period 
Alzheimer’s disease (AD) arose as the most common form of senile dementia (Selkoe, 
2001).  The prevalence of AD is most common among people over 85 years of age 
(Munoz & Feldman, 2000).  Primary clinical symptoms of AD include short-term and 
long-term memory loss, paranoia, delusions, decreased language ability and an overall 
cognitive impairment.  The two hallmark pathologic features of AD include neuritic 
plaques and neurofibrillary tangles.  Silver staining was first used in the early 1900s to 
indicate neurofibrillary tangles (NFTs) within neuronal cells.  Following that discovery, 
in 1930 Divry used Congo Red staining to locate senile plaques composed of amyloid 
(Maccioni et al., 2001).  In the 1960s Kidd and Terry first described in detail the 
composition of neuritic plaques and NFTs, which are composed of paired helical 
filaments (Selkoe, 2001).  General risk factors for the disease include age, genetic 
mutations, and lifestyle influences such as high blood pressure, unhealthy diet, changes in 
hormones, and educational attainment/cognitive activity level. 
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II. AD Behavioral Deficits 
During early AD, patients experience a loss of episodic, semantic and some 
implicit memory function (Becker et al., 1996; Salmon & Fennema-Notestine, 1996; 
Greene & Hodges, 1996).  A loss of episodic memory appears similar to general amnesia 
so that patients are unable to learn new information; this denotes an impairment of 
storage and consolidation of new information (Becker et al., 1996).  There is also an 
inability to shift information from short-term into long-term stores for later retrieval.  
Semantic memory is normally linked to long-term memory function of object, facts, 
concepts and words and their meanings, however in cases of early AD, there is a mild 
impairment in this type of memory function.  A decrease in category fluency (generation 
of words from set categories, such as animals or fruits) is evident in early stages linked to 
a deficit of storage within the neural networks of the inferolateral areas of the temporal 
neocortex (Salmon & Fennema-Notestine, 1996).  There is also an impairment of reading 
(comprehension of word meaning) due to the decrease in semantic memory function 
(Mathias, 1996).  There are, however, no impairments in the lexical routes of reading, 
such as phonemic or syntactic skills at this early stage.  Deficits in visual attention, 
extrapyramidal signs (bradykinesea, rigidity or tremors), ideomotor and ideational 
apraxias as well as nociceptive reflexes (snout and palmomental reflexes) are present in 
the early stages of AD (Coslett & Saffran, 1996; Kidron & Freedman, 1996).  Despite 
discrepancies in language studies, language impairments have been shown to be evident 
in the early stages of AD (Becker et al., 1996). 
Most of the above mentioned deficits progress as AD develops with addition of 
new cognitive impairments.  From mild to moderate AD, 9-12% of subjects experience 
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hallucinations or delusions, with the range for severe AD between 40-60% (Schneider & 
Dagerman, 2004).  It is proposed that these two symptoms of psychosis represent distinct 
subtypes of AD (Cook et al., 2003).  AD subjects with psychosis undergo a more rapid 
cognitive deterioration than those with no psychotic symptoms (Cook et al., 2003; 
Schneider & Dagerman, 2004).  Psychotic symptoms, representing hallucinations and 
delusions, are mainly a product of a frontal lobe dysfunction (Schneider & Dagerman, 
2004).  However, degeneration of the major brainstem aminergic nuclei results in 
symptoms of depression for moderate AD persons, affecting between 30-50% of AD 
cases.  These subjects also have a relative preservation of the cholinergic system in 
comparison to non-depressive AD cases (Zubenko et al., 2003).  Also present in moderate 
AD is an impairment of divided attention where attention can not be split between more 
than one task (Morris, 1996a).  This is a role of executive function attributed to long-term 
memory where the deficit is nonglobal.  There are also deficits in pyramidal signs related 
to changes in white matter (Kidron & Freedman, 1996).  These include hyperactive jaw 
jerk reflex, extensor plantar responses, hyperreflexia and ankle clonus.  Also present in 
about 10% of all moderate AD cases is motor impersistence (inability to sustain a 
voluntary movement) which is a deficit in sustained attention.  More prominent in 
moderate AD is motor persistence (perseveration of movement) which is associated with 
the frontal system (Kidron & Freedman, 1996).  
The late stages of AD show progression of cognitive impairment from the 
moderate stage of AD as well as impairment in procedural memory (Becker et al., 1996).  
Almost complete loss of both episodic and semantic memory occurs in the late stages of 
AD.  In addition, late stage AD subjects that are severely impaired exhibit more of a 
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continuing loss of cognitive function compared to AD subjects with less impairment 
(Auer et al., 1994).  Also evident are severe impairments of executive function, praxis 
and visuospatial behaviors.  Severe deficits in language functioning can be seen by this 
stage including loss of fluency, echolalia, palilalia, non-verbal utterances and in some 
cases mutism (Boller et al., 2002).  Seizures are also present in about 9.8-64% of all 
autopsy-verified late stage AD cases (Kidron & Freedman, 1996).  Some cases of AD 
(20-41%) progress to a bedridden state, mostly due to the incidence of contractures that 
prevents subjects from ambulatory behaviors (Souren et al., 1995).  Late stage AD 
patients can also exhibit a vegetative state, although because of differences in 
neurological evaluations there is a strong disagreement as to the incidence of a vegetative 
state in AD subjects (Volicer et al., 1997).  Aside from additional symptoms of late stage 
AD, death is more common in severe AD cases due to pneumonia compared to non-
demented control subjects (Beard et al., 1996).  However in a retrospective study by 
Kammoun et al. (2000), there were no significant correlations between the incidence of 
AD and death due to bronchopneumonia compared to non-demented elderly control 
subjects; the authors did identify dementia as an underlying cause of death.  In contrast, 
Hui et al. (2003) did show a significant correlation between increased mortality with 
increased cognitive decline in AD subjects over a four-year period, but the authors did 
not state the cause of mortality. 
As previously mentioned a definitive diagnosis of AD is made only after death.  
This includes the presence of a large number of neurofibrillary tangle (NFT)-containing 
neurons and amyloid plaques within specific brain regions (Selkoe, 2001).  Typically, 
NFTs are found primarily in neocortex and medial temporal structures including the 
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hippocampus, amygdala and parahippocampal gyri.  Subcortical regions such as the 
thalamus, mamillary bodies, nucleus basalis of Meynert, substantia nigra and locus 
coerulus also contain NFTs later in the disease process.  In the AD brain, neuritic plaques 
appear first, and to their greatest extent in the cerebral cortex and hippocampus; 
subcortical structures such as the putamen of the thalamus, the locus coerulus and the 
hypothalamus exhibit neuritic plaques to a lesser extent later in the disease process 
(Selkoe, 2001).   
 
III. AD Pathology 
Cerebral Atrophy, Neuronal Loss. 
Alzheimer’s disease results in an average of 7-8% decrease in total brain weight 
through atrophy (Morris, 1996a).  Global atrophy is characterized by widened sulci, 
narrowed convolutions, decreased white matter and ventricular enlargement, specifically 
the lateral ventricles.  The greatest loss of brain weight occurs in the cerebral 
hemispheres.  Diffuse atrophy is associated with loss of cortex and hippocampal 
pyramidal neurons associated with the neocortex.  The presence of NFTs in the cortex 
and hippocampus may account for the substantial cell loss in the nuclei that project to the 
neocortex, such as cholinergic neurons of the nucleus basalis of Meynert, noradrenergic 
neurons from the locus coerulus, and serotonergic neurons of the raphe nuclei.  There is a 
40% decrease in the number of cells within the subiculum of the hippocampus (Morris, 
1996c).  Primary sensory and motor neurons, as well as thalamic projections experience 
minimal cell loss with AD.  In normal aged individuals, there is no neuronal loss within 
layer II of the entorhinal cortex, with minimal loss within layer III (Trillo & Gonzalo, 
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1992).  By contrast, in mild to severe AD cases there is a 50-90% loss of cells within the 
entorhinal layer II (Morrison & Hof, 1997).   There is also a substantial loss of neurons 
within region CA1 of the hippocampus in mild to severe AD cases (Price et al., 2001).  In 
addition, Fukutani et al. (2000) suggest that neuron loss in CA1 and entorhinal cortex is a 
direct result of neurofibrillary degeneration.  Neuron loss within CA1 and subiculum of 
the hippocampus in severe AD has also been shown to correlate to formation of 
neurofibrillary tangles (Rossler et al., 2002).  Specifically, pyramidal cells of the 
entorhinal cortex, CA1 and subiculum regions of the hippocampus are susceptible to 
neuronal degeneration and can lead to global disruption between association cortices 
(Morrison & Hof, 1997).  In addition to neuronal loss in hippocampal regions, substantial 
loss occurs in the cortex.  AD brains experience cortical atrophy in regions of the left 
hemisphere more than the right hemisphere (Gee et al., 2003; Thompson et al., 2003).  
Affected regions include the anterior temporal, posterolateral temporal and dorsolateral 
prefrontal regions (Gee et al., 2003), sparing the neurons of the sensorimotor cortex, 
occipital poles and cerebellum (Karas et al., 2003; Thompson et al., 2003).  Overall, the 
total brain volume changes that occur with AD subjects are related to the accumulation of 
cortical NFTs (Silbert et al., 2003). 
Measurements of regional cerebral blood flow (rCBF) by single photon emission 
computed tomography (SPECT) and positron emission tomography (PET) reveal 
decreases in brain functioning in vivo.  SPECT and PET scans show maximal changes 
within the parietal and temporal brain regions and are consistent with neurodegeneration 
(Morris, 1996c).  Correlations can be found between rCBF and neuropsychological 
functioning so that language dysfunction correlates with decreased left parietal and 
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temporal lobe rCBF.  In PET studies there is a significant decrease in the resting 
activation of the parietal lobes of AD cases compared to normal controls.  The greatest 
reductions are within regions that are impaired in early AD such as the middle and 
inferior temporal regions as well as angular and superior parietal gyri (Morris, 1996c).  
Implicated in the neurodegeneration of AD is the formation of amyloid plaques and 
development of intra-neuronal neurofibrillary tangles as discussed below. 
 
Neuritic Plaques. 
Amyloid precursor protein (APP) is a single transmembrane glycoprotein 
translated from chromosome 21.  APP is a short-lived protein that is processed within the 
endoplasmic reticulum and subsequently modified through secretory pathways (Selkoe, 
2001).  Post-translational processing of APP within the endoplasmic reticulum includes 
glycosylation and proteolytic cleavage by specific enzymes (Selkoe, 2001; Turner et al., 
2003b).  APP is oriented so that the N-terminus is the extracellular domain and the C-
terminus resides within the cytoplasm (Maccioni et al., 2001).  There are three major 
isoforms of APP including residues ending with 695, 751 and 770.  APP695 mainly 
occupies neurons, while APP751 and 770 are found in both neurons and non-neurons 
throughout the body.  These two isoforms also contain a Kunitz class of serine protease 
inhibitors, also known as a KPI domain.  Cleavage of APP occurs so that the derivatives 
are released into vesicle lumens and the extracellular spaces.  There are three cleavage 
sites along the APP peptide.  The first cleavage is provided by the α-secretase enzyme 
and releases a large soluble fragment (C83) with the COOH-terminal fragment within the 
membrane.  The second cleavage site results from β-secretase to release a 99-residue 
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(C99) into the extracellular space or vesicle lumen.  Cleavage by γ-secretase of the C99 
fragment results in a smaller peptide, β-amyloid or Aβ, composed of exons 16 and 17 
from the APP695 isoform (Selkoe, 2001; Ling et al., 2003).  Cleavage by γ-secretase of 
the C83 peptide results in a smaller fragment named p3.  APP is anterogradely 
transported to the axon terminals, the primary site for processing into Aβ.  After APP is 
processed, left-over fragments of APP can undergo retrograde transport back to the cell 
body to be recycled.  Recycling within the endosomes could lead to proteolytic cleavage 
by β- and γ-secretases to release the Aβ peptide (Selkoe, 2001).  Normal APP functioning 
includes cell adhesion, neuroprotection, neuroproliferative activation, intracellular and 
extracellular communication, as well as a cargo receptor for kinesin for microtubule 
transport and inhibition of serine proteases (Maccioni et al., 2001; Turner et al., 2003b).  
Deletion of the APP gene does not lead to any significant deleterious effects in in vivo 
experiments; however, cells cultured from APP deleted animals exhibit decreased neurite 
growth and nerve function (Selkoe, 2001).   
In 1983 Allsop and colleagues identified neuritic plaques as containing a 40-42 
amino acid peptide, known as the β-amyloid peptide (Turner et al., 2003b).  Aβ40 and 
Aβ42 are both cleaved by similar processes utilizing β- and γ-secretases from the amyloid 
precursor protein.  Diffuse plaques from APP cleavage result from accumulation of Aβ42; 
these plaques are modestly fibrillar and nontoxic.  Formation of diffuse plaques occurs 
mainly within association and limbic cortices (Roher et al., 2000).  Neuritic plaque 
formation originates with α-helix structured monomers of either Aβ40 or Aβ42 peptides.  
Amyloidogenesis proceeds with deprotonation of specific side chain residues and 
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protonation of additional residues to cause a destabilization of the α-helix and 
conformational changes to a more stable Aβ dimer with a β-helical structure (Serpell, 
2000).  The dimer formation includes a hydrophobic core surrounded by hydrophilic 
residues.  A ribbon-like protofilament is formed as a result of adjacent C-terminal binding 
between dimers to create a series of antiparallel β-sheets.  Pairs of these β-sheets form a 
tubular cylinder within the center of each protofilament (Roher et al., 2000).  Two types 
of protofilaments exist; the first includes a large diameter with periodic twists and the 
second type appears later in amyloidogenesis and forms no twists (Serpell, 2000).  Fibril 
formation is a concentration dependant nucleation mechanism that utilizes 2-5 
protofilaments.  A hollow center is formed by hydrophobic residues through an 
intertwined helical structure with the hydrophilic N-terminus on the outside of the fibril; 
after the fibril is formed the N-terminus is degraded.  Compact (dense) neuritic plaques, 
from aggregation of Aβ40 onto Aβ42 fibrils, are formed mainly in neocortex and 
hippocampus, as well as within cortical and leptomeningeal vessels (Roher et al., 2000).  
Dystrophic neurites, found in and around filamentous plaques, contain enlarged 
lysosomes, numerous mitochondria and paired helical filaments (Selkoe, 2001).  
Compact plaque cores are formed with a strong β-sheet conformation from simultaneous 
aggregation and disaggregation of Aβ fibrils.  Microglia are associated with the plaque 
perimeter and commonly express CD45 and HLA-DR antigens.  Reactive astrocytes form 
a ring surrounding the outside of the plaque with abundant glial filaments. 
The presence of activated microglia and reactive astrocytes closely associated 
with mature amyloid plaques indicates that an inflammatory response has occurred to 
fibrillar Aβ deposits (Selkoe, 2001).  Oskar Fisher first proposed that an inflammatory 
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process occurred in conjunction with amyloid fibrils in 1910.  This proposal came 
without experimental evidence, however it is now known that fibrillar Aβ deposits are 
associated with a locally induced chronic inflammatory response (Fig. 1).  The absence of 
T-cells and immunoglobulins from the Aβ plaque induced inflammation reaction 
suggests that this not a classical immune-mediated response (Eikelenboom et al., 2002).  
The inflammation associated with AD is due to the activation of local microglia from 
accumulation of fibrillar Aβ deposits.  Aβ accumulation leads to the increased production 
of free radicals from microglia and peroxidative injury of proteins and lipids that can lead 
to selective neuronal dysfunction and cell death (Fig. 1) (Selkoe, 2001).  Activated 
microglia secrete cytokines (TNF-α and IL-1β) and neurotrophic factors (TGF-β1) as 
well as generate free radicals (NO and superoxide) and fatty acid metabolites 
(eicosanoids and quilolinic acid) (Liu & Hong, 2002; Cotman et al., 1996).  Binding of 
complement factor C1q to fibrillar Aβ deposits, with co-stimulation of serum amyloid P 
component (SAP) were shown to activate associated microglial clusters to initiate the 
classical complement cascade, as well as generate production of C5a (Eikelenboom et al., 
2002; Cotman et al., 1996; Selkoe, 2001).  Although microglia begin to appear during 
thioflavin positive staining, their major recruitment occurs after the generation of a 
proinflammatory anaphylactic peptide, C5a, is activated by fibrillar Aβ (Cotman et al., 
1996).  Reactive astrocytes are recruited by activated microglia, apparently is response to 
microglial cytokine secretion.  Astrocytes are also the source of two inflammatory 
proteins which directly contributes to the formation of amyloid plaques (Selkoe, 2001; 
Potter et al., 2001)- α-antichymotrypsin (ACT) and apolipoprotein E (ApoE) (Fig. 1).  
The overexpression of IL-1, ACT and ApoE in specific brain regions showing 
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neuropathology in AD-affected individuals suggests a region-specific inflammatory 
cascade for AD (Potter et al., 2001).  Together, ACT and ApoE have been described as 
amyloid promoters or “pathologic chaperones” from in vitro and in vivo studies, 
supporting their role in the AD inflammatory cascade (Sanan et al., 1994; Wisniewski et 
al., 1994; Bales et al., 1999).  In addition, increased levels of ACT are found in AD 
patients’ serum and CSF (Sun et al., 2003) and associated with severity of AD dementia 
(Dekosky et al., 2003).  In order to increase AD pathology, possible by inhibiting Aβ 
degrading enzymes, the ACT/A signal peptide variant increases the amount of mature 
glycosylated ACT for secretion.  The level and location of APP processing to increase 
toxic C-terminal fragments can also result from an affect from ApoE.  Nilsson et al. 
(2004) conclude that ACT and ApoE can act synergistically or independently to promote 
the development of mature amyloid plaques and diffuse Aβ deposits without affecting 
monomeric Aβ levels. 
In addition to the inflammatory response, amyloid deposits also lead to a 
condition known as cerebral amyloid angiopathy (CAA) (Fig. 1).  CAA is a deposition of 
amyloid within meningeal and cerebral arteries, arterioles, venules or capillaries and can 
occur in the absence of parenchymal Aβ deposits (Jellinger, 2002; Selkoe, 2001).  The 
primary Aβ species present within blood vessels leading to CAA was determined to be 
Aβ40; recently, it was discovered that Aβ42 may also be present in amyloid angiopathy 
(Selkoe, 2001).  CAA increases with age and results in thickened vessel walls through Aβ 
accumulation.  Drainage channels and microglia take up the extracellular Aβ and deposit 
it in the vascular lumen to aid in clearance.  Hyaline necrosis surrounding the amyloid 
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deposits within the blood vessel wall can rupture and lead to cerebral hemorrhaging.  
Cerebral hemorrhages linked to CAA occur primarily within frontoparietal cortex and 
parietal cortex with lesser amounts within temporal and occipital cortices, basal ganglia 
and cerebellum (Jellinger, 2002).   Most subjects with AD do not have cerebral 
hemorrhage despite the large amounts of amyloid deposits within their blood vessels 
(Selkoe, 2001). 
The β-amyloid peptide has many implications as previously described including 
formation of plaques, it’s role within the inflammatory process, and it’s link to CAA.  In 
1991, Hardy and Allsop first described the amyloid hypothesis.  The hypothesis defined 
the root cause of AD as the overproduction and aggregation of Aβ into senile plaques 
(Turner et al., 2003b).  Multiple genetic risk factors such as an increase in the number of 
ApoE4 alleles, PS1, PS2 and APP mutations (see following sections) all increase the 
process of Aβ deposition, leading to an increased risk for developing AD.  Recent 
research has lead to two changes for the initial amyloid hypothesis; the first is that 
oligomers and fibrils, in addition to diffuse/compact Aβ deposits, contribute to the 
neuronal/cognitive dysfunction of AD, and the second is that changes in the activation of 
APP fragment molecules can also affect APP processing and Aβ production (Turner et 
al., 2003b).     
 
Neurofibrillary Tangles. 
Neurofibrillary tangles are found within neurons of the hippocampus, entorhinal 
cortex, parahippocampal gyrus, amygdala and frontal, temporal, parietal and occipital 
cortices as well as certain subcortical nuclei (Selkoe, 2001; Maccioni et al., 2001).  Some 
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transgenic mouse models suggest that Aβ stimulates NFT formation as discussed later in 
the “Animal Models” section (Fig. 1).  Tau is a microtubule-associated protein that 
normally binds tubulin to aid in assembly of microtubule formation and stabilization 
within neurons (Mudher & Lovestone, 2002).  Phosphorylation of tau by protein kinases 
cdk5 or GSK3β causes it to dissociate from the microtubule and aggregate to form 
insoluble paired helical filaments (PHF) (Maccioni et al., 2001).  Formation of PHF 
within neurons causes microtubule instability such that microtubules are eventually 
replaced by tangles (Mudher & Lovestone, 2002).  Some studies indicate that NFTs, not 
amyloid plaque burden, show a high correlation with cognitive decline (Selkoe, 2001; 
Ohm et al., 2003).  NFT formation occurs in brain regions that are implicated in memory.  
Within the cortex, tangles first form in the layer II of the entorhinal cortex prior to Aβ 
plaques (Ohm et al., 2003).  Aside from a regional specificity, there is a cellular 
specificity in NFT formation.  In some rare cases of AD only a small portion of cells are 
prone to form NFTs.  In such cases, cortical pyramidal neurons can be “tangle poor” and 
instead can form Lewy bodies composed of α-synuclein proteins.  Despite the few 
numbers of tangles that are present, these brain areas do elicit comparable amounts of Aβ 
plaques in the hippocampus with less deposition in the neocortex compared to AD brains 
that exhibit both NFTs and Aβ plaques (Terry et al., 1987).    
A combination of Aβ plaques and NFTs could account for synaptic terminal loss 
in AD.  Synaptic loss occurs at the terminal dendrite segments mainly within neocortical 
association areas, hippocampus, frontal lobe and temporal lobe.  A decrease in synaptic 
density correlates highest with cognitive impairment (Coleman & Yao, 2003).  Amyloid 
plaques have been found to alter synaptic integrity, but not to cause the loss of synapses.  
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PHF within the neuron disrupts axonal transport and results in starvation of the synaptic 
terminal and the eventual loss of the synapse (Scheff & Price, 2003).  Studies have yet to 
show a direct correlation between synapse loss and either Aβ plaques or presence of 
NFTs.        
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IV.  Genetics of AD 
Familial Alzheimer’s disease (FAD) is an autosomal dominant disease that 
accounts for 5-50% of all AD cases (Agnew, 1996; Selkoe, 2001).  With little to no 
difference in phenotypic changes between FAD and sporadic AD (SAD) the main 
difference is the earlier age of onset for FAD (e.g. before 60 years of age), which has 
been linked to point mutations on chromosomes 1, 14 or 21. 
The presenilin 2 gene from chromosome 1 can be affected by nine different 
mutations that increase the risk of developing AD; while chromosome 14 codes for the 
presenilin 1 (PS1) gene that can contain over 100 mutations (Marcon et al., 2004).  
Mutations of PS1 decrease the age of AD onset to the early 40’s and 50’s through a 
selective increase in γ-secretase cleavage of peptides C99 and C83; this mainly leads to 
an increase of Aβ42 (Selkoe, 2001).  Early-onset AD, from a PS1 deletion mutation, can 
result in verbal and visual memory impairment in addition to deficits in intellectual 
functions.  These types of impairments were related to temporoparietal hypometabolism 
that is typically found in AD subjects (Verkkoniemi et al., 2004).   One specific type of 
PS1 mutation, E280A, associates neuronal loss in the CA1 region and epileptic seizures 
of subjects with FAD (Velez-Pardo et al., 2004).  The same mutation has been shown to 
cause an increase of Aβ42, not Aβ40, in FAD brains suggesting that PS1 can alter the 
cleavage of APP at the C-terminal end (Lemere et al., 1996). 
AD risk can also be affected by mutations of the APP gene residence on 
chromosome 21.  Down’s syndrome patients (trisomy 21) have an overproduction of 
Aβ40 and Aβ42 as well as development of diffuse plaques by age 12 and neuritic 
dystrophy with NFTs in the 20’s and 30’s (Selkoe, 2001).  The formation of NFTs in 
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Down’s syndrome patients most likely occurs after the accumulation of extracellular Aβ 
deposits and inflammatory response (Mori et al., 2002).  Specifically, Hirayama et al. 
(2003) proposed that NFTs form in Down’s syndrome patients as a result of an axonal 
flow disturbance caused by the accumulation of Aβ43 within neurons of the cortex.  
Although most SAD and FAD cases have similar phenotypes, APP mutations can lead to 
an increased incidence of myoclonus, seizures and extrapyramidal signs (Agnew, 1996).  
There are up to 9 missense mutations that occur on the APP gene which facilitate 
cleavage to increase production of Aβ40 and Aβ42.  A point mutation at APP717 is 
referred to as the London mutation and typically results in an increase of Aβ42 (Selkoe, 
2001).  This mutation could result in a switch from valine to isoleucine in which case the 
onset occurs at approximately 50 years of age.  Additional mutations from valine to 
glycine or valine to phenylalanine decrease the age of onset to within the 40’s (Agnew, 
1996).  A double mutation at APP670/671 (Swedish mutation) increases the production 
of both Aβ40 and Aβ42 through increased β-secretase activation (Selkoe, 2001).  The 
production of Aβ from the Swedish mutation is a result of competition between α- and β-
secretase upon APP within Golgi-derived vesicles (Haas et al., 1995).  Human subjects 
who possess the Swedish mutation form of AD exhibit reduced glucose metabolism 
within the temporal lobe which precedes cognitive impairment (Wahlund et al., 1999), 
and reduced regional cerebral blood flow within basal and lateral temporal lobes (Julin et 
al., 1998).  Overall, although the SAD and above-mentioned FAD cases differ mainly in 
age of onset, there are also subtle differences in pathology as the disease progresses. 
Apolipoprotein E (ApoE), which is involved in lipid trafficking, expresses three 
different alleles; ApoE2 is the least common, ApoE3 is the most common with 
 18 
inheritance of ApoE4 giving rise to an increased risk for developing AD.  Chromosome 
19 contains the ApoE4 allele, which is over expressed in many AD cases.  Inheriting 1 or 
2 copies of the ApoE4 allele increases the risk for developing late onset AD in the 60’s 
and 70’s (Agnew, 1996; Selkoe, 2001).  Studies show that the ApoE4 protein results in a 
higher Aβ plaque burden although there is no change in the amount of NFTs present.  An 
increase in the number of Aβ fibrils could occur via a decrease of clearance or increased 
deposition of Aβ40 within the cerebral cortex and microvasculature (Selkoe, 2001).  
ApoE4 and ACT together promote deposition of monomeric and/or oligomeric Aβ 
filaments (Potter et al., 2001), in essence by acting as pathologic chaperones in binding to 
Aβ filaments.  Glöckner et al. (1999) proposes that the action of ApoE primarily occurs 
at the early stages of AD.  They found changes in hippocampal ApoE expression only 
within the brains of subjects during the beginning stage of AD (Glöckner et al., 1999).   
 
V. Diagnosis of AD 
The diagnosis of Alzheimer’s disease occurs with complete assurance only after 
death by the presence of high numbers of amyloid plaques and NFTs within the brain.  
Prior to death, there are multiple cognitive exams designed to predict the presence of a 
cognitive impairment as an indicator for the development of AD.  A diagnosis of AD 
follows three stages, the first is an initial screening into the patients’ personal history; this 
establishes the subtype of the disease.  The second stage involves a formal 
neuropsychological exam which determines the provisional diagnosis of the specific 
conditions of AD.  The third stage includes a neurological exam and CT scan in order to 
exclude alternative forms of dementia not related to AD (Gray & Sala, 1996).  Some of 
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the neurological screening methods used include the Mini-Mental State Exam (MMSE), 
which results in numbered scores administered to the patients.  A score ranging from 0 to 
17 implies severe cognitive impairment, whereas a score between 18 and 23 indicates 
mild to moderate impairment.  Lastly, a score from 24 to 30 denotes an uncertain or 
absent degree of cognitive impairment (Crum et al., 1993).  Additional cognitive exams 
include a brief telephone questionnaire or a paper and pencil skills test to screen for early 
signs of impairment, as well as multiple verbal memory tests.  Some of these exams 
include the Cognitive Capacity Screening Examination, the Mental Status Questionnaire, 
the Short Portable Mental Status Questionnaire and the Dementia Rating Scale (Gray & 
Sala, 1996).  Neurological screening exams are able to detect specific changes in memory 
function from early to moderate to severe forms of AD. 
Additional screening methods include computed tomography (CT), magnetic 
resonance imaging (MRI), magnetic resonance spectroscopy (MRS), functional MRI 
(fMRI), single photon emission computed tomography (SPECT) and positron emission 
tomography (PET).  CT and MRI scans can detect anatomic changes within the brain, 
whereas MRS imaging measures metabolites as an indicator of brain function.  For 
example, N-acetylaspartate (NAA) is a metabolite found within axons, choline (Cho) is in 
the myelin membrane and creatine (Cr) is involved in neuronal metabolic activity (Lee et 
al., 2003).  PET and SPECT are additional forms of functional neuroimaging for glucose 
metabolism that can be measured within the brain.   
In early AD, prior to cognitive decline, CT and MRI scans show cerebral atrophy 
and ventricular enlargement, including a progressive increase of cortical subarachnoid 
spaces.  Some studies using CT scans show atrophy of the medial temporal lobes in AD 
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and volume loss of the hippocampus with MRI compared to non-demented controls (Lee 
et al., 2003).  Glucose metabolic PET imaging with fluorodeoxyglucose (FDG) has the 
potential to detect early neocortical dysfunction before neuropsychological testing reveals 
dementia.  As questionable dementia progresses toward mild AD, PET imaging detects 
abnormalities in the parietal lobe which exhibit asymmetrical differences in metabolism 
(Demetriades, 2002).  PET imaging also shows a metabolic decrease in the posterior 
cingulate cortex, cinguloparietal transitional cortex, middle temporal cortex, inferior 
temporal cortex as well as angular and superior parietal gyri in early AD compared to 
age-matched controls (Demetriades, 2002).  PET imaging can also detect amyloid 
deposition with labeled probes in early AD and presumably before cognitive symptoms 
are present.  Multiple compounds have been tested as possible probes to bind Aβ within 
the brain such as a thioflavin-T analogue (Mathis et al., 2002), (18)F-labeled IMPY 
derivative (Cai et al., 2004), BF-108 (Suemoto et al., 2004), stilbene derivatives (Ono et 
al., 2003) and the Pittsburgh Compound-B (Klunk et al., 2004).  Mathis et al. (2002) 
found that the thioflavin-T analogue, [(11)C]-labeled 6, has a high uptake within the 
brain of transgenic mice and resulted in labeled cerebral plaques and cerebrovascular 
amyloid deposits.  The BF-108 compound was found to label senile plaques, 
neurofibrillary tangles and vessels laden with amyloid within temporal cortex and 
hippocampus of AD patients.  BF-108 also labeled plaques within the brains of transgenic 
mice (Suemoto et al., 2004).  In addition, the Pittsburgh Compound-B (PIB) had a high 
binding affinity within association cortex, most prominently within frontal, parietal and 
occipital cortices as well as the striatum.  In areas such as the pons and cerebellum where 
there is minimal amyloid pathology, there was similar binding to that of non-AD control 
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subjects.  The same study also found an inverse correlation between PIB retention within 
cortex and cerebral glucose metabolism (Klunk et al., 2004).  Overall, the use of labeled 
probes by PET scanning to detect Aβ within the brain prior to cognitive impairment or in 
early AD is a useful tool for diagnosis and shows high affinity for amyloid plaques. 
In moderate AD, MRS detects a decrease in NAA within temporoparietal, 
hippocampal and parahippocampal regions.  A decrease in the NAA/Cr ratio of the 
occipital lobes confers a decrease in the involvement of functional neurons; a decrease 
within medial temporal lobes corresponds to cognitive decline (Lee et al., 2003).  PET 
imaging studies show a global decrease in cerebral glucose metabolism, specifically the 
neocortical structures including the parietal, frontal and posterior temporal association 
cortices (Demetriades, 2002).  A decreased metabolism of the parietotemporal cortex is a 
possible diagnosis for AD because of its high sensitivity and specificity to distinguish AD 
from other dementias.  A substantial decrease is present in AD subjects of the resting 
activation of parietal lobes with the most amount of decrease within the occipital cortex 
(Morris, 1996c).  PET studies also exhibit a hypometabolism within primary cortices, 
medial temporal cortex and posterior cortical regions (Demetriades, 2002).  A bilateral 
hypometabolism of temporoparietal association cortex is present in AD and other 
dementias (Demetriades, 2002; Lee et al., 2003).  PETs reveal a preservation of primary 
sensorimotor and visual cortices, cerebellum and striatum (Demetriades, 2002).  
Together, PET and SPECT studies show maximal changes within the parietal and 
temporal regions with a negative correlation between regional cerebral blood flow and 
neuropsychological functioning (Morris, 1996c).  Language dysfunctions have been 
associated with left parietal temporal changes, whereas praxis disturbances correlate to 
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decreased regional cerebral blood flow within bilateral and temporal lobes (Morris, 
1996b).  In more severe cases of AD, there is a decreased metabolism within the frontal 
cortex (Demetriades, 2002; Lee et al., 2003).   
For cases of FAD where subjects are homozygous for ApoE4, there is a 
significant decrease in the metabolic rate of glucose within posterior cingulate, prefrontal, 
temporal and parietal regions (Demetriades, 2002).  In the same subjects prior to 
cognitive decline there is significant hypometabolism within the temporoparietal region 
(Lee et al., 2003).  PET imaging of bitemporal and biparietal regions in FAD cases 
involving mutations of the APP gene show decreases in metabolism compared to age-
matched controls (Demetriades, 2002).   
Additional biomarkers for diagnosis of AD include cerebrospinal fluid (CSF) 
testing for the presence of total tau (t-tau), phosphorylated tau (p-tau) and Aβ1-42.  Tau is 
a protein found within neuronal axons that has six different isoforms and 21 possible 
phosphorylation sites.  The t-tau found within CSF of patients with MCI that progressed 
to AD is significantly increased compared to those with MCI that did not develop AD 
(Blennow & Hampel, 2003).  The detection of t-tau has a sensitivity of 90% and 
specificity for distinguishing MCI from non-demented subjects of 100% (Blennow & 
Hampel, 2003; Hampel et al., 2003).  Distinguishing early AD from normal aging using t-
tau from the CSF reveals a sensitivity of 85% and a specificity of 75% (Hampel et al., 
2003).  In addition to Alzheimer’s disease, increased CSF levels of t-tau are also found in 
other dementias including vascular dementia, frontotemporal dementia, lewy body 
dementia and semantic dementia (Blennow & Vanmachelen, 2003; Hampel et al., 2003).  
There are also studies showing a significant correlation between t-tau and cognitive 
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decline (Kanai et al., 1998; Nishimura et al., 1998), while additional studies show no 
correlation (Arai et al., 1995; Vigo-Pelfrey et al., 1995; Hulstaert et al., 1999). 
Levels of p-tau are used to distinguish AD from control subjects through 
monoclonal antibodies specific to different epitopes.  Overall, there is a mean sensitivity 
of 70% and a mean specificity of 94% with a mean increase in p-tau of 250% compared 
to age-matched controls (Blennow & Vanmachelen, 2003).  At baseline, MCI patients 
have an increased level of p-tau versus control subjects (Buerger et al., 2002a; Andreasen 
et al., 2003).  With progression from MCI to AD, levels of p-tau correlate with cognitive 
decline (Buerger et al., 2002a).  Because levels of p-tau can distinguish MCI from non-
demented control subjects, using CSF p-tau levels to diagnose AD prior to clinical 
dementia would improve treatment methods.  CSF p-tau levels have also been inversely 
correlated with the age of onset for SAD and FAD subjects (Thaker et al., 2003) and 
positively correlated with the intensity of disease progression marked by a presence of 
ventricular widening during AD advancement (Wahlund & Blennow, 2003).  CSF levels 
of p-tau correspond to the levels of p-tau within the brain and formation of tangles in AD; 
there are, however lower measurable levels of p-tau in vascular dementia, frontotemporal 
dementia and lewy body dementia as compared to levels present in AD (Blennow & 
Hampel, 2003).  Using p-tau to accurately distinguish AD from other types of dementia is 
challenging.  However, AD can be significantly distinguished from frontotemporal 
dementia by increased CSF p-tau of AD subjects (Buerger et al., 2002b). Hampel et al. 
(2004) also found that AD can significantly be distinguished from dementia with Lewy 
bodies by measuring CSF levels of p-tau.  They conclude that because there is significant 
difference of CSF p-tau between two types of similar dementias, that p-tau must have 
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different roles within AD as compared to dementia with Lewy bodies (Hampel et al., 
2004).    
Overall, there is a decrease in the level of CSF Aβ1-42 in AD as detected by 
ELISA with specific antibodies to Aβ.  As previously discussed APP results in Aβ by 
cleavage first by β-secretase releasing the C-terminus of APP into the extracellular space 
followed by cleavage by γ-secretase to release monomeric Aβ.  Because of the close 
association between the CNS and CSF, Aβ can flow into the CSF and levels can be 
measured for diagnosis.  The mean sensitivity and specificity for Aβ1-42 is 85% for 
distinguishing AD from age-matched controls (Blennow & Vanmachelen, 2003).  There 
is also a strong association between decreased levels of Aβ1-42 in CSF and increased 
number of plaques within hippocampus and neocortex (Blennow & Hampel, 2003).  
Some studies suggest that the decreased levels of CSF Aβ are due to increased trapping 
of brain-produced Aβ into amyloid plaques, although in Creutzfeldt-Jakob disease there 
are no deposited plaques despite a decrease in CSF Aβ  (Hampel et al., 2003). 
Another indicator for developing AD is the inheritance of mutated forms of APP, 
PS2 or PS1 genes.  APP, primarily exons 16 and 17, and PS2 mutations are detected from 
genomic DNA analysis of peripheral blood leukocytes amplified by polymerase chain 
reaction (PCR) and sequenced to give the exact gene.  The PS1 mutations are commonly 
detected by extraction of total RNA from peripheral blood leukocytes for DNA 
amplification by a reverse transcriptase-PCR (RT-PCR) protocol.  The entire PS1 gene is 
then sequenced to identify any possible mutations.   
 25 
FAD from mutations of the APP gene are not prominently used as diagnostic 
markers for the detection of early-onset AD.  Zekanowski et al. (2003) verified the 
presence of two APP mutations, T714A and V715A, in a population of patients with 
early-onset AD from Poland.  They averaged the age of onset from either mutation 
around 55 years of age (Zekanowski et al., 2003).  A second study found additional APP 
mutations in non-demented carriers, KN670/671ML and E693G (Almkvist et al., 2003).  
These APP mutant carriers exhibited no clinical abnormalities compared to non-carriers 
(Almkvist et al., 2003).  Mutations from the PS2 gene are also not major contributors to 
FAD.  However, one mutation of PS2, Q228L, decreases the age of onset to around 55 
years of age (Zekanowski et al., 2003).  Mutations of the PS1 gene are more common and 
carriers exhibit much of the same pathology from SAD subjects.  This includes evidence 
of neuritic plaques, amyloid angiopathy, NFTs (Takao et al., 2002), diffuse plaques 
(Larner & du Plessis, 2003) and cortical degeneration mainly within the primary motor 
cortex (Miklossy et al., 2003).  The average age of onset for some of the many PS1 
mutations range from 25 years (Miklossy et al., 2003) to around 55 years (Zekanowski et 
al., 2003). 
 
 
VI.  Risk Factors for AD 
The primary and most significant genetic risk factor for the development of late-
onset AD is inheritance of at least one copy of the ApoE4 allele.  Each ApoE4 allele 
inherited increases risk and decreases the age of onset for developing AD.  About 80% of 
all FAD cases and 64% of SAD cases contain at least one copy of the ApoE4 allele, 
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whereas it is present in only 31% of control subjects (Corder et al., 1993).  ApoE is 
synthesized within the brain and secreted by astrocytes.  It plays a major role in lipid 
transport through the CNS (Olsen, 1998).  However, the primary mechanism that ApoE4 
affects to increase risk of AD is not through lipid transport, but most probably by 
affecting Aβ deposition.  The binding of ApoE4 to Aβ42 increases Aβ deposition (Olsen, 
1998) and density of neuritic plaques (Strittmatter & Roses, 1995; Nilsson et al., 2004).  
PDAPP transgenic mice, homozygous for murine ApoE4 had increased diffuse Aβ 
deposition within cerebral cortex compared to PDAPP ApoE knock-out (ApoE-KO) mice 
(Nilsson et al., 2004).  The PDAPP + ApoE transgenic mice also had increased 
deposition of congophilic-positive compact Aβ plaques within cerebral cortex and 
hippocampus versus ApoE-KO mice.  Together with the plaque pathology, ApoE mice 
exhibited significant memory deficits evident by spatial learning impairments and 
working memory impairments illustrated by the Morris Water maze and radial arm water 
maze tasks (Nilsson et al., 2004). 
A second significant risk factor for the development of AD is high blood 
cholesterol levels.  Increased total serum cholesterol level in mid- and late-life is 
positively associated with carrying the ApoE4 allele (Kivipelto et al., 2002).  Accounting 
for this factor, a high level of total serum cholesterol is still a significant risk factor for 
developing MCI and AD (Kivipelto et al., 2002; Reitz et al., 2004).  The mechanism of 
how cholesterol levels affect development of AD is unknown; however it is thought that 
Aβ production is indirectly increased by serum cholesterol levels, perhaps through 
stimulation of β-secretase processing of APP.  Refolo et al. (2000) first determined that a 
high cholesterol diet results in increased amyloid deposition in the brains of AD 
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transgenic mice.  Specifically, this study found increased amounts of β-C terminal 
fragments from APP cleavage resulting from β-secretase activity.  Inversely, the 
increased β-secretase activity most likely resulted in a decrease of α-secretase activity 
which also led to the increased deposition of Aβ.  Simons et al. (1998) also supported the 
theory that cholesterol affects β-secretase activity in cultured hippocampal neurons.  In 
contradiction to the above studies, Burns et al. (2003) suggest that γ-secretase activity is 
highly affected by cholesterol accumulation in a mouse model of Niemann-Pick type C 
disease to increase production of Aβ40 and Aβ42.  Also, Wahrle et al. (2002) found an 
inhibition of γ-secretase activity in cultured brain cells with cholesterol depletion 
suggesting that γ-secretase activity is cholesterol-dependent.  Also, treatments with 
cholesterol-lowering drugs as discussed in the next section have been shown to inhibit 
Aβ production through stimulation of α-secretase and decrease AD risk. 
In addition to the affects of increased fat and decreased fish consumption on AD 
risk, reduced dietary intake of fruits and vegetables also contribute to the risk factor.  To 
date, there have been no clinical longitudinal studies performed that administered DHA 
and/or EPA to test their protective effects against AD development; however some 
studies have administered fish oil supplements or a combination of omega-3 and omega-6 
fatty acids to test their effects.  Because of this, it is not known whether DHA and EPA, 
specifically, are conferring protection against dementia, or whether it is some additional 
aspect within the fish oil that results in beneficial effects.  Specifically, clinical studies 
have shown that a high intake of fish, high in the polyunsaturated fatty acids DHA and 
EPA, is associated with a reduced risk for developing cognitive impairment, particularly 
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AD (Kalmijn et al., 1997a; Kalmijn et al., 1997b, Kalmijn et al., 2004).  Kalmijn et al. 
(1997a) reported that an increased intake of total fat, saturated fat and cholesterol were all 
significantly associated with an increased risk for developing dementia, whereas 
increased fish consumption was the major factor associated with a reduced risk.  Kalmijn 
et al. (1997b) also showed a significant correlation between increased fish consumption 
and decreased risk for developing dementia.  The elderly subjects that developed 
dementia over the 8-year study were shown to have a higher intake of total fat, and the 
omega-6 fatty acid linoleic acid (LA) with a lower intake of fish, docosahexaenoic acid 
(DHA) and eicosapentaenoic acid (EPA) compared to those subjects that did not develop 
dementia.  In contrast to the above studies, most recently Morris et al. (2005) reported a 
weak association between dietary intake of fish and rate of age-related cognitive decline.  
Instead, the authors suggested that overall fat consumption led to a greater risk of 
dementia.  An additional study by Morris et al. (2003) also suggested that other fats play 
the primary role predicting the risk associated with developing AD.  This study reported 
that saturated and trans-unsaturated fats were associated with developing AD, whereas n-
3 fatty acids did not contribute or protect against risk of developing AD (Morris et al., 
2003).   
Aside from the possible involvement of nutrients from fish, dietary vitamin intake 
plays a role in risk for developing AD.  A reduced dietary intake of vitamin B leads to 
increased plasma homocysteine levels (Selhub & Miller, 1992) and accumulation of 
DNA damage that contributes to AD risk (Kruman et al., 2002).  Memory function is 
positively associated with intake of vitamins E, C and A (Solfrizzi et al., 2003; Meydani, 
2003).  Specifically, supplementation with vitamin E and vitamin C resulted in a 
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decreased risk of age-associated diseases including cognitive impairment (Meydani, 
2003) and dementia (Haan & Wallace, 2004).  Although some clinical studies have 
reported that vitamins E and C have no protective benefits against development of AD 
(Masaki et al., 2000; Laurin et al., 2004), additional clinical studies show a significant 
reduction of risk for developing AD with supplementation/intake of vitamins E and C 
(Morris et al., 1998; Engelhart et al., 2002b; Zandi et al., 2004).  Animal studies 
involving non-transgenic rats (Joseph et al., 1998; Joseph et al., 1999) and mice (Shukitt-
Hale et al., 1999) show improved cognitive performance with supplementation of various 
fruits and vegetables such as strawberries, blueberries or spinach.  Supplementation with 
apple juice has also been shown to improve cognition and decreased oxidative stress in 
mice (Rogers et al., 2004).  Overall, sporadic AD risk factors primarily include genetic 
predisposition (ApoE4 allele), high blood cholesterol (LDL) levels, high dietary intake of 
fats, and low dietary intact of fish, fruits and vegetables.  Because SAD can not be 
accurately predicted, it is probably a combination of the above mentioned risk factors that 
all contribute to the development of AD. 
 
VII.  Treatment of AD 
All of the US Food and Drug Administration approved treatments for Alzheimer’s 
disease are aimed at providing relief from symptoms associated with cognitive decline.  
Current treatments include acetylcholine esterase inhibitors: donepezil (Aricept), 
galantamine (Reminyl), rivastigmine (Exelon), as well as the NMDA antagonist, 
memantine.  Additional treatments have been tested in animal models, in vitro and 
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clinical trials including anti-inflammatory drugs, antioxidants and behavior 
modifications.   
Tacrine was the first acetylcholine esterase inhibitor (AChEI) approved for AD 
symptoms.  In a clinical trial tacrine relieved symptoms of hallucinations, anxiety, apathy 
and disinhibition in individuals with moderate dementia (Kaufer et al., 1996).  A second 
clinical trial found improvements in language production, comprehension, word 
recognition and delusions in AD subjects with mild to moderate dementia (Raskind et al., 
1997).  Donepezil was approved as a noncompetitive and reversible AChEI for mild to 
moderate AD symptoms.  It is metabolized in the liver by cytochrome P450 enzymes and 
uridine-diphosphate glucuronosyl transferase.  Because of its long half-life (~ 70 hours) 
only one daily dose is needed (Scarpini et al., 2003).  A clinical trial for 1 year including 
mild to moderate AD patients resulted in improved cognition and activities of daily living 
versus placebo-treated patients (Winblad et al., 2001).  An additional study of moderate 
to severe AD subjects for 24 weeks showed that Donepezil improved cognition and 
decreased delusions, anxiety, disinhibition and irritability in these patients compared to 
placebo-treated subjects (Feldman et al., 2001).  Galantamine was approved as a selective 
and reversible AChEI.  It also functions as an allosteric ligand at nicotinic ACh receptors 
in order to increase presynaptic release of ACh and postsynaptic neurotransmission 
within pyramidal neurons.  Galantamine is also metabolized in the liver by cytochrome 
P450 enzymes which results in a 5 hour half-life and therefore requires two daily doses 
for treatment (Scarpini et al., 2003).  A clinical trial utilizing galantamine found it to 
decrease symptoms of anxiety, disinhibition, hallucinations and aberrant motor behaviors 
associated with mild to moderate AD, as well as improve cognition (Tariot et al., 2000).  
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Some therapies comparing the acetylcholine esterase inhibitors found differences in 
cognitive outcome.  Jones et al. (2004) found a greater cognitive improvement with the 
use of donepezil versus galantamine whereas Wilcock et al.  (2003) had opposite effects 
resulting in a significant cognitive effect of galantamine over donepezil.  Despite 
differences from other studies, six months of treatment by the Cochrane Dementia Group 
with donepezil (Birks et al., 2002a), galantamine (Birks et al., 2002b) or rivastigmine 
(Olin et al., 2002) resulted in similar effects for all three drugs.  Also, a similar study by 
Wilkinson et al. (2002) found no cognitive difference between donepezil and 
rivastigmine as treatments for patients with mild to moderate AD.  All three acetylcholine 
esterase inhibitors show a stabilization of cognition through 6 months of treatment and as 
long as 36 months of treatment.  At 6 months, donepezil (Tariot et al., 2001) and 
galantamine (Raskind et al., 2000; Patterson et al., 2004) were both found to maintain the 
improved cognitive performance in comparison to placebo-treated subjects.  Following 
12 months of treatment with galantamine (Raskind et al., 2000; Kurz et al., 2003) or 
rivastigmine (Doraiswamy et al., 2002) cognitive performance was maintained as 
compared to improved cognition after 6 months of treatment.  Additional studies show 
maintenance of cognitive improvement through 18 months of treatment with donepezil 
(Matthews et al., 2000), 24 months of treatment with rivastigmine (Grossberg et al., 
2004) and even 36 months of treatment with galantamine (Raskind et al., 2004). 
Additional treatments include the use of statins and non steroidal anti-
inflammatory drugs (NSAIDs).  Statin use has been associated with a 39% (Zamrini et 
al., 2004) - 70% (Jick et al., 2000) decrease in the risk of developing AD.  The 
mechanism by which statins decrease AD risk might be through a shift from γ- and β-
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secretases to α-secretase to decrease Aβ production (DeKosky, 2003).  In vitro studies 
show that β-secretase functions best in a high cholesterol environment so that a decrease 
in cholesterol leads to a decrease in BACE function.  Statin therapy has been shown to 
lower cholesterol in cultured cells by blocking 3-hydroxy-3-methylglutaryl-CoA 
reductase (HMG-CoA reductase) and thereby inhibiting Aβ production (Simons et al., 
1998; Fassbender et al., 2001).  Guinea pigs fed a diet supplemented with simvastatin 
showed a strong decrease of cerebral Aβ40 and Aβ42 levels from CSF and brain 
(Fassbender et al., 2001).  AD transgenic mice fed a high cholesterol diet had increased 
β-amyloid deposition within the brains (Refolo et al., 2000).  Additional mechanisms of 
statins may be that they remove Aβ from the brain or have a direct anti-inflammatory 
effect on AD through undetermined pathways (DeKosky, 2003).  Because statins do not 
cross the blood-brain barrier their effects must be from a peripheral pathway that is not 
yet determined. 
NSAIDs have been proposed to inhibit COX and therefore decrease the synthesis 
of prostaglandins, specifically PGE2 and PGI2 which are pro-inflammatory (Aisen, 
2002a).  Prostaglandins may potentiate glutamatergic transmission through NMDA 
receptors by inhibiting the reuptake of glutamate by astrocytes which leads to an excess 
of glutamate in the extracellular spaces (in ‘t Veld et al., 2002).  In AD there is an 
increase of extracellular glutamate which leads to an increased activation of NMDA 
receptors and therefore an increase in intracellular calcium levels.  The increased calcium 
could lead to neurotoxicity and neuronal cell death (Scarpini et al., 2003).  The use of 
NSAIDs could inhibit this pathway.  However, numerous studies have suggested that 
NSAIDs exert their protective effect independent of COX inhibition, by acting to inhibit 
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γ-secretase or its substrate.  In vitro, the addition of ibuprofen, indomethacin or sulindac 
decreased the release of Aβ42 within cultured cells that over express APP (Sascha et al., 
2001).  Along this line, a study involving cultured cells treated with either ibuprofen, 
indomethacin or sulindac sulphide found reduced Aβ42 peptide independent of COX 
activity, most likely due to selective activity from γ-secretase to alter Aβ production 
(Weggen et al., 2001).  Additional work by Weggen and colleagues (2003) and Eriksen et 
al. (2003) also support the findings that NSAID activity can decrease levels of Aβ42 
within cultured cell lines and AD transgenic mouse models independent of COX 
inhibition.  Weggen et al. (2001) found a significant reduction of Aβ42 within the brains 
of APP transgenic mice with no change in Aβ40 following treatment with ibuprofen.  The 
authors suggest that this difference in Aβ production is due a selective shift of γ-secretase 
activity.  Similarly, administration of ibuprofen to APP transgenic mice resulted in a 
lower brain Aβ42 levels (Sascha et al., 2001).  NSAIDs could also inhibit inflammation 
by suppressing the expression of specific proinflammatory genes or by directly blocking 
the induction of interleukins 1 (IL-1), IL-1β and possibly IL-6 (in ‘t Veld et al., 2002).  A 
six month oral supplementation of ibuprofen to AD transgenic mice resulted in a 
significant decrease in Aβ brain burden and microglial response (Lim et al., 2000).  In 
addition, the NSAID NCX2216 has been shown to decrease Aβ plaques in APP/PS1 mice 
more than ibuprofen or celecoxib (Jantzen et al., 2002).     
Treatment with some NSAIDs resulted in no improvement in cognition in 
humans.  A study by Van Gool et al. (2001) involving early AD subjects showed no 
cognitive or behavioral changes using the NSAID hydroxychloroquine versus the placebo 
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group.  An additional study administering nimesulide to subjects with probable AD 
resulted in no significant effect on measures of cognition, activities of daily living or 
behavioral aspects compared to the placebo subjects (Aisen et al., 2002b).  Aisen et al. 
(2003) also found no benefit to naproxen treatment with mild to moderate AD patients.  
A clinical trial for mild to moderate AD patients using indomethacin showed improved 
cognition with the drug compared to a decline of cognition in the placebo-treated group.  
However, indomethacin use had a low tolerance illustrated by adverse reactions to the 
drug and thus far there are no additional studies utilizing it (Rogers et al., 1993).  
Prednisone treatment to AD subjects also resulted in negative effects and decline in 
behavior with no change in cognition, after a 4-week period compared to placebo-treated 
subjects (Aisen et al., 2000).   
In addition to anti-inflammatory drugs, antioxidants have been used as therapeutic 
treatment for AD.  The aggregation of Aβ during AD progression can directly and 
indirectly induce oxidative stress.  Regarding indirect induction of oxidative stress by Aβ, 
the interaction of Aβ with the receptor for advanced glycation end products (RAGE) in 
neuronal cell lines induces an increase of lipid peroxidation (Yan et al., 1998; Gasic-
Milenkovic et al., 2003).  Also, the interaction of Aβ with endothelial cells or blood 
vessels results in an increase in superoxide radicals leading to oxidative stress in the 
vasculature (Thomas et al., 1996).  An additional mechanism for the indirect formation of 
oxidative stress by Aβ is through macrophages.  Work by Klegeris et al. (1994) and El 
Khoury et al. (1996) both demonstrate the association between Aβ and macrophages to 
increase reactive oxygen species (ROS) such as nitric oxide.  Regarding more direct 
actions, Aβ25-35 has been shown to directly generate ROS in the presence of O2 (Hensley 
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et al., 1994).  In addition, the aggregation of Aβ1-40 can lead to generation of free radicals 
that induce neurodegeneration through neuronal insults, such as lipoperoxidation or 
damage to intracellular proteins (Harris et al., 1995).   
Ginkgo biloba has been defined as containing antioxidant and anti-inflammatory 
properties as well as being a memory enhancer.  In a clinical trial involving patients with 
mild to severe AD there was a stabilization of cognitive and social function with 6 
months to 1 year of Ginkgo biloba extract treatment (Le Bars et al., 1997).  Mild to 
severe AD subjects showed improvements in cognition and daily behaviors following 
treatment from 3 months (Maurer et al., 1997) to 1 year (Le Bars et al., 2002) with high 
or low doses of the extract, EGb 761.  In contrast to the above studies, mild to moderate 
AD patients supplemented for 24 weeks with high or low doses of EGb 761 did not show 
improved cognitive function (van Dongen et al., 2000; van Dongen et al., 2003).  Other 
antioxidants, vitamins E and C, exert neuronal protection against oxidative damage and 
cell death.  A Rotterdam study found a 34 – 43% decreased AD risk with supplements of 
vitamins C and E, respectively (Engelhart et al., 2002b).  Vitamin E, α-tocopherol, has 
been associated with a decreased risk of AD in patients that were not carrying the ApoE 
allele (Morris et al., 2002).  α-Tocopherol acts as an antioxidant by inhibiting lipid 
peroxidation within membranes as a free radical oxygen scavenger.  It is the primary 
antioxidant candidate for AD and exerts significant beneficial effects on functional 
decline for patients with moderate to severe AD (Sano et al., 1997).   
Aside from drugs and supplements, nonpharmacologic AD treatments include 
multiple types of behavioral modification.  Few studies that try to improve cognitive and 
non-cognitive behaviors have been performed on AD patients.  In 1989, Quayhagen & 
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Quayhagen administered a cognitive stimulation protocol including memory exercises, 
communication skills and problem-solving activities to AD patients.  This resulted in 
maintenance of cognitive function across the treatment period, whereas the group that did 
not receive the treatment declined in cognition.  More recently Sobel et al. (2001) tested 
the effect of the game of Bingo on subjects with AD versus AD patients that underwent 
daily physical activity.  The AD subjects that played Bingo had improved performance of 
short-term memory, word retrieval and word recognition tasks.  These alternatives can 
result in an increase of self-care skills as well as appropriate ambulation and 
socialization.  Additional types of behavior modification include sensory and 
environmental intervention, structured activities and behavior therapy (Cohen-Mansfield, 
2001). 
 
VIII.  Animal Models 
Animal models have been used to aid in determining the functions of 
genes/proteins that were isolated from in vitro studies or to study the phenotypic results 
from gene changes, such as relocation of developmental transcription factors.  In 
addition, transgenic animals from an overexpression or mutation in single or multiple 
genes are used to model human diseases and can therefore facilitate in determining 
possible preventions or treatments for such diseases.  Most Alzheimer disease studies use 
mice as transgenic models.  Even with the longer gestation and developmental period 
compared to invertebrates (Drosophila & C. elegans) commonly used as research 
models, physiologically mice are more closely related to humans and therefore provide a 
better foundation for a research model.  Rats cannot generally be used to model human 
 37 
disease and its effect on learning because of a lack of generation of developmental stem 
cell lines needed to generate rats lacking/over expressing a specific gene (Piccioto & 
Wickman, 1998).  Due to this, mice are the most common and advantageous model used 
to study human neurodegenerative diseases such as Alzheimer’s disease. 
The generation of an AD transgenic animal requires the selection of the specific 
transgene cDNA to be transcribed downstream of a certain promoter sequence.  The 
transgene DNA includes 1) the specific cDNA sequence that is to be over expressed, 2) 
the appropriate promoter specific for brain cells for neurodegenerative diseases that will 
create new mRNA and 3) a polyadenylation signal site that will stabilize the novel 
mRNA.  The promoter is primarily important for determining the level of gene 
expression and the site and temporal pattern of expression.   
The most common protocol for creation of transgenic animals is via pronuclear 
injection into a single-cell animal embryo.  The fertilized eggs are removed from the 
female and injected with the transgenic cDNA.  Multiple embryos (10-20) are then 
implanted into a pseudopregnant female foster mouse.  A pseudopregnant female is 
generated by placing her, during a normal cycling period, with a vasectomized male.  The 
transgene is either incorporated into the mouse genome or is degraded by endonucleases 
within the cell.  If the transgene is incorporated early in development, all cells would 
inherit the transgene and be passed on to offspring.  At weaning, 3 weeks of age, 
offspring are typically genotyped by polymerase chain reaction (PCR) for the presence of 
the transgene of interest.  If the incorporation of the transgene is successful, roughly half 
of the offspring should inherit at least one copy of the gene and can pass it on to future 
generations.  Alzheimer’s disease research is performed with multiple lines of transgenic 
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mouse models as described in detail below in order to provide the most diversity for 
researching preventions and treatments. 
 
PDAPP Transgenic Mice. 
The PDAPP model is generated from a V717F mutation of the APP gene, also 
called the London mutation.  Multiple studies have been done to characterize the 
pathology and behavior of the PDAPP model at various time points.  Beginning at 3-4 
months, PDAPP mice display an increase in synaptic density within cingulate, 
frontoparietal and parietal cortices (Dodart et al., 2000b).  At this early age, there was 
also a substantial decrease in the size of the dorsal hippocampus as compared to the wild 
type mice.  Mature Aβ deposits (plaques with dense cores) were first detected at 3-4 
months within CA1 of the hippocampus, the medial part of the cingulate cortex and the 
corpus callosum level to the dorsal hippocampus.  By 6-7 and 10-12 months, PDAPP 
mice display mature Aβ deposits with dense cores and significantly decreased dorsal 
hippocampus.  Both age ranges displayed increased synaptic density within cingulate and 
parietal cortex, and decreased synaptic density in the dentate gyrus and septum.  The 10-
12 month mice also showed decreased synaptic density within region CA1 and the 
frontoparietal cortex (Dodart et al., 2000b).   
One factor that plays a role in the amount of pathology present in this model is the 
number of transgenes present (heterozygous compared to homozygous).  Between 3-4 
months, all of the homozygous PDAPP mice exhibited some extent of mature Aβ 
deposits, whereas only half the heterozygous PDAPP mice revealed mature deposits 
(Dodart et al., 2000b).  The 6-7 month homozygous mice had more Aβ deposits than the 
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10-12 month heterozygous mice.  At the latter age, there was 3-4 times more Aβ deposits 
in homozygous than heterozygous PDAPP with the largest difference evident within the 
cortical regions (Dodart et al., 2000b).   
In opposition to the above study by Dodart et al. (2000b), Games et al. (1995) 
measured plaque density and Aβ deposits and found no adverse pathology in 
heterozygous mice at 4-6 months of age.  Only at 6-9 months of age were Aβ deposits 
detected within hippocampus, corpus callosum and cerebral cortex.  By 9 months of age 
there was a decreased synaptic and dendritic density within the dentate gyrus.  The study 
also reported that Aβ plaques from 9 month old heterozygous PDAPP mice were 
surrounded with GFAP positive reactive astrocytes and distorted neurites.  In addition, 
the neocortex from these mice showed diffuse activation of microglia (Games et al., 
1995).   
Masliah et al. (1996) compared some of the AD-like pathology from 8-12 month 
old heterozygous PDAPP mice to tissue samples from AD brains.  This study found 
similarities in amyloid deposition, dystrophic neurites and glial cell reactivity between 
the PDAPP mice and AD brains.  The dense core structure of the PDAPP mouse plaques 
from hippocampus resembled the deposits found within frontal cortex of the AD brain.  
Similarities in dystrophic neurites and the dysfunction of their synaptic junctions were 
also seen.  The synaptic junctions exhibited damage evident by enlargement of the nerve 
terminals and fewer synaptic vesicles.  The majority of this damage was seen within 
plaques, not in the adjacent area surrounding the deposits.  PDAPP mice also displayed 
glial cell reactivity (strong GFAP staining), similar to AD, associated with neuritic 
plaques and the neuropil of the neocortex and hippocampus.  However, the transgenic 
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mice showed a stronger reactivity of astroglial cells and less microglial reaction 
compared to AD brains (Masliah et al., 1996).  Overall, this study shows that the 8-12 
month PDAPP mouse exhibits marked Aβ pathologic similarities to the AD brain. 
In aged PDAPP mice, 16-17 months of age, Chen et al. (2000) found increased 
plaque density within multiple layers of the entorhinal cortex, the dentate gyrus, striatum 
and the moleculare lecunosum of CA1.  At 18-21 months diffuse plaques were located 
within the hippocampus and cingulate, insular and entorhinal cortices (Chen et al., 2000).   
Dodart et al. (1999) behaviorally tested heterozygous and homozygous PDAPP 
mice at 3, 6 and 9 months of age compared to age-matched non-transgenic littermates.  
Over all ages tested, PDAPP mice had increased activity and decreased rearings in a 50-
minute open field task compared to wildtype (WT) mice; however there were no 
differences between any of the groups in a simple motor task indicating similar 
locomotive behaviors between all groups.  Young (3-4 month old) PDAPP mice were 
found to be impaired in reference memory errors in the radial arm maze compared to WT 
mice.  Working and reference memory impairment was correlated positively with 
increased synaptic density within cingulate and parietal cortices (Dodart et al., 2000b).  In 
addition, reference memory impairment was positively associated with increased synaptic 
density in frontoparietal cortex and regions CA3 and dentate gyrus of the hippocampus.  
Over all 8 days of radial arm maze testing, the PDAPP mice did not show any learning 
effect, while the WT mice did show significant learning over all test days (Dodart et al., 
1999).  At this young age the PDAPP mice were not impaired in object recognition; 
however they had significantly fewer presses than wild type control mice in an operant 
memory bar task indicating memory impairment.  Adult (6 months of age) and aged (9 
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months old) PDAPP mice also exhibited impairments in working and reference memory 
errors in the 8-arm radial maze task.   As was the case for young PDAPP mice, there was 
also no learning effect evident compared to WT mice over the 8-day task for both 6 and 9 
month ages.  Adult and aged PDAPP mice were also impaired in object recognition 
showing a lower time spent exploring the novel object compared to the familiar object.  
Only at the 6 month age, there was a significant negative correlation between synaptic 
density in CA1 and the object recognition index (Dodart et al., 2000b) 
Dodart et al. (2000a) also found an impairment of object recognition in 10-12 
month old PDAPP and PDAPP+ apolipoprotein E Knock-Out (PDAPP/ApoE-KO) mice 
compared to age-matched WT and ApoE-KO littermates.  This study also found a lack of 
habituation on day-1 of a two-day open field task for PDAPP and PDAPP/ApoE-KO 
mice; however WT and ApoE-KO mice did elicit habituation.  The significance regarding 
the lack of habituation is suspect due to the fact that the activity of the PDAPP and 
PDAPP/ApoE-KO mice at the beginning of the trial equaled that of the WT and ApoE-
KO mice at the end of the trial (i.e., after their significant habituation). 
In contrast to Dodart, Chen et al. (2000) found normal object recognition in 6-9, 
13-15 and 18-21 month old PDAPP mice compared to WT age-matched control mice.  In 
a modified “working memory” version of the water maze task where mice were required 
to reach a criterion prior to changing locations of a submerged platform, 6-9 and 13-15 
month old PDAPP mice exhibited a higher latency for each new platform location 
compared to wild type control mice indicating impairment of spatial acquisition memory.  
From 6 through 21 months, there was a significant negative correlation between the 
learning capacity in the modified water maze task and plaque burden (Chen et al., 2000).  
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Huitron-Resendiz et al. (2002) also found impairment of spatial memory; 
however it was evident only in aged PDAPP mice.  Young (3-5 months of age) and aged 
(20-26 months old) mice were tested in a 12-day circular platform maze consisting of two 
trials per day.  Young PDAPP mice performed similarly to WT mice initially and 
exhibited a significant increase in errors to locate the escape on the last block of testing 
only.  In contrast, the aged PDAPP mice were significantly impaired to locate the escape 
on all trials as measured by errors made into non-escape holes.  These results indicate a 
significant impairment of spatial memory that becomes slightly apparent at 3-5 months 
and prominent by 20-26 months of age in PDAPP mice. 
Most recently, Nilsson et al. (2004) demonstrated the importance of inflammatory 
proteins, ApoE and ACT, within the PDAPP transgenic mouse lines.  All four lines, 
PDAPP/ApoE/ACT, PDAPP/ApoE, PDAPP/ApoEKO/ACT and PDAPP/ApoEKO had 
similar amounts of soluble and membrane bound Aβ1-40 and Aβ1-42 in hippocampus and 
cerebral cortex at 2 months of age.  At this age, all lines exhibited no sensorimotor, 
learning or memory deficits compared to non-transgenic mice.  However, by 18 months 
of age, differences in pathology and cognition were evident between the different lines.  
PDAPP/ApoEKO/ACT mice had increased levels of Aβ deposition within hippocampus 
and cerebral cortex compared to PDAPP/ApoEKO mice.  Also, PDAPP/ApoE/ACT mice 
had increased deposition of compact Aβ plaques in cerebral cortex and hippocampus due 
to an increase in plaque density compared to mice lacking ACT.  In addition, both lines 
of ApoEKO mice showed no congophilic Aβ deposition in cerebral cortex or 
hippocampus, indicating a primary role for ApoE to promote formation of compact 
plaques.  Similar to the younger transgenic mice, none of the 18 month old PDAPP mice 
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showed any sensorimotor deficits compared to non-transgenic mice.  However, all 
PDAPP/ApoE mice had increased latency (acquisition deficit) in the Morris water maze 
task compared to PDAPP/ApoEKO and non-transgenic mice.  In addition, PDAPP/ApoE 
mice exhibited overall working and reference memory deficits in the radial arm water 
maze task compared to PDAPP/ApoEKO and non-transgenics.  More specifically, 
PDAPP/ApoEKO/ACT showed deficits in working memory compared to 
PDAPP/ApoEKO and non-transgenic mice, indicating that ACT promotes the formation 
of amyloid, as described earlier, and cognitive decline in addition.  This study also 
positively correlated reference memory from the radial arm water maze task to 
immunoreactive Aβ deposits and mature compact deposits in the hippocampus.  Lastly, 
PDAPP/ApoEKO mice that showed diffuse Aβ in hippocampus had impaired working 
memory compared to PDAPP/ApoEKO that showed no diffuse Aβ, indicating the 
association between diffuse Aβ and working memory deficits.  Overall, this study 
showed the importance of the PDAPP transgenic model interaction with ApoE and ACT 
genes (Nilsson et al., 2004).  Using the same four PDAPP lines mentioned above, Leighty 
et al. (2003) found significant associations, between cognitive impairment in the Morris 
water maze, platform recognition task and the radial arm water maze task to Aβ 
deposition in the hippocampus and cerebral cortex in transgenic mice at 15-16 months of 
age.  More specifically, working memory and recognition impairments were correlated 
with Aβ deposition in hippocampus and cerebral cortex.  This study strongly supported 
the association between memory/ learning impairments to Aβ deposition within the 
PDAPP transgenic mouse (Leighty et al., 2003). 
 
 44 
APPsw Transgenic Mice. 
In addition to the PDAPP mutation, a commonly over expressed FAD double 
mutation at residues 670 and 671 of the APP gene has been termed the Swedish model, 
APPsw.  Multiple APPsw models have been used with different backgrounds, providing a 
variety of results.  APPsw model with an FVB/N background is highly vulnerable to 
neuronal cell death within the hippocampus (Mohajeri et al., 2004).  Necrosis, apoptosis 
and astrogliosis within the hippocampus and cortex are also found within this mouse 
strain (Moechars et al., 1996).  This mouse model also exhibits decreased glucose 
utilization and astrogliosis within the cerebellum (Hsiao et al., 1995).  There were, 
however, no differences in levels of Aβ40 or Aβ42 compared to other FVB mixed 
backgrounds that do not exhibit the previously mentioned CNS disorders (Carlson et al., 
1997).  A predominant negative feature of mice with the FVB/N background is the 
prevalence of retinal degeneration that occurs around post-natal day 5 for transgenic mice 
and post-natal day 9 for non-transgenic mice (Vinores et al., 2003); therefore cognitive 
evaluation of this strain becomes difficult.  With this in mind, FVB/N mice are 
spontaneously hyperactive and aggressive; in addition, these mice exhibit poor 
performance in spatial and non-spatial tasks (Voikar et al., 2001; Mineur & Crusio, 
2002).  Additional behavioral studies suggest that the prevalence of premature death, 
neophobia, aggression and seizures are dependent on the level of APP expression (Hsiao 
et al., 1995; Carlson et al., 1997).  Neophobia has been associated with thigmotaxis, 
agitation and tremulousness as early as one month of age (Carlson et al., 1997).   
A second model of the APPsw mouse is the APP23 model, generated by insertion 
of the mutated gene into an XhoI site of an expression cassette containing the murine 
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Thy-1.2 gene (Sturchler-Pierrat et al., 1997).  At 6 months of age, this line shows rare Aβ 
deposits, but at 24 months there is a substantial deposition of Aβ plaques, with dense 
cores, including an increase in size and number of plaques associated with an increase of 
age.  Deposits occupied regions of the thalamus, olfactory nucleus, caudate putamen, 
neocortex and hippocampus; these regions also contained a massive glial response.  Aβ 
deposits were associated with a decrease in the number of adjacent cell bodies in 
hippocampal pyramidal cells and were also surrounded by dystrophic neurites (Sturchler-
Pierrat et al., 1997).  Robust plaque deposits were present even at 14-18 months of age 
throughout the neocortex and hippocampus of heterozygous and homozygous APP23 
mice (Calhoun et al., 1998).  The plaque load within region CA1 of the hippocampus 
inversely correlated with the number of pyramidal neurons within this area constituting a 
significant neuronal loss compared to non-transgenic control mice.  There was, however 
no significant neuron loss within the neocortex despite the high load of plaques present.  
Amyloid was also detected within vessels of the meningeal, neocortical and thalamic 
vasculature at the same age of 14-18 months (Calhoun et al., 1998).   
Spatial memory deficits exhibited by the Morris water maze task preceded the 
formation of plaque deposition within APP23 heterozygous mice (Van Dam et al., 2003).  
At 3 and 6 months of age, these mice showed significant learning and memory deficits in 
Morris water maze acquisition and retention; however significant formation of plaques 
occurred first at 6 months (Van Dam et al., 2003). 
In agreement with Van Dam, 3, 18 and 25 month old APP23 mice were found to 
be impaired in the Morris water maze, as exhibited by increased latency and distance 
swum to the hidden platform (Kelly et al., 2003).  Also at all ages, APP23 mice had 
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fewer annulus crossings in the memory retention trial compared to the non-transgenic 
mice; however, only at 3 and 18 months did the APP23 mice have a lesser amount of 
time spent in the former platform-containing quadrant versus age-matched non-transgenic 
mice in this memory retention trial.  Because all mice performed similarly to age-
matched non-transgenic mice in the visible platform version of the water maze, the 
authors suggested that the spatial impairment of the APP23 mice was not due to sensory, 
motor or motivational alterations. 
As opposed to the above findings, Lalonde et al. (2002) found impairment of 
acquisition in the Morris water maze of 16 month old APP23 mice; however, there was 
no impairment in the probe trial (memory retention).  These mice also exhibited 
hypoactivity in contrast to the hyperactivity found in mice ranging from 6 weeks to 6 
months of age (Van Dam et al., 2003). 
An additional model of the APPsw mouse was created with a C57BL/6 X 
C57BL/6/SJL background, the Tg2576 mouse model.  Multiple studies have focused on 
analyzing various markers to characterize the Tg2576 mouse such as Aβ plaque 
deposition, and inflammatory, synaptic and oxidative markers as indicators of an AD-like 
pathology within a mouse model.  Hsiao et al. (1996) first classified the Tg2576 APP 
mouse by analyzing brain Aβ1-40 and Aβ1-42 levels as well as senile and diffuse plaques 
within 2-8 month and 11-13 month old transgenic mice.  As early as 2 months of age, 
Tg2576 APP mice showed increased neurochemical levels of Aβ1-40, with a 5-fold 
increase by 11 to 13 months of age, and Aβ1-42 with a 14-fold increase by 11 to 13 
months.  In addition to brain levels of Aβ, amyloid deposits were seen in the older (11-13 
month) transgenic mice within the frontal, temporal and entorhinal cortices, in addition to 
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the hippocampus and cerebellum.  Associated with these Aβ deposits were 
immunoreactive astrocytes and dystrophic neurites (Hsiao et al., 1996).   
In agreement with Hsiao et al. (1996), Pratico et al. (2001) showed that the 
Tg2576 APP mice exhibit Aβ40 and Aβ42 at low levels in the brain from 4-8 months with 
high levels seen at 12 months, progressing into 18 months of age within the cerebral 
cortex and hippocampus.  Scattered Aβ deposits within cerebral cortex and hippocampus 
were not evident until 12 months of age with more abundant deposits seen in the 
neocortex and hippocampus at 18 months (Pratico et al., 2001).  
In conjunction with Pratico, Benzing et al. (1999) found moderate Aβ deposits 
within 12 month old Tg2576 mice with considerable deposition occurring by 18 months 
of age.  However, the Aβ deposition was predominately found within temporal and 
cingulate cortices and to a lesser extent within frontoparietal cortex and hippocampus.  
This study also examined the presence of astrocytes and microglial cells and their 
association with plaque deposition.  Astrocytes were mainly localized near fibrillar 
deposits typically on the periphery of the plaque; microglial positive activity was detected 
around Aβ deposits at 12 and 18 months.  In conjunction with the absence of Aβ deposits 
at 3 months of age, there was also no detection of astrocyte or microglial activity.   The 
presence of the inflammatory markers, CD-45 and MAC-1 were positively associated 
with microglial activation and fibrillar Aβ deposits at 12 and 18 months, whereas IL-6 
immunoreactivity was associated with astrocyte activation near fibrillar Aβ deposits also 
at 12 and 18 months within the Tg2576 mouse (Benzing et al., 1999). 
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In contrast to the above studies, Mehlhorn et al. (2000) did not detect any 
deposition of fibrillar Aβ plaques within cortex of Tg25765 mice through 13 months of 
age.  At 14 months, a low burden of Aβ deposits was detected within cerebral cortex and 
hippocampus with the presence of reactive astrocytes detected around the plaques.  This 
study also detected IL-1β immunoreactive cells around Aβ plaques that co-localized with 
the astrocyte activation at 14 months (Mehlhorn et al., 2000). 
Irizarry et al. (1997) detected Aβ deposition in Tg2576 mice at 16 months of age 
within the cingulate cortex, molecular layer of the dentate gyrus, entorhinal cortex and 
region CA1 of the hippocampus.  At the subcortical levels, rare deposits were evident in 
the internal capsule and the basal ganglia at this late age.  In conjunction with the above 
references, positive astrocyte activation was associated with neuritic plaques.  This study 
also looked at neuronal pathology in reference to the progression of AD.  They found that 
dystrophic neurites were found surrounding and within Aβ deposits, however there was 
no difference in the actual number of neurons within region CA1 compared to non-
transgenics, despite the amount of Aβ deposits within that area.  This study also showed 
no difference in synaptophysin staining (a glycoprotein located in neuronal synapses and 
vesicles) of the outer, middle or inner molecular layers of the dentate gyrus between 
Tg2576 and non-transgenic animals (Irizarry et al., 1997). 
Although there were no differences seen in synaptophysin staining at 14 months 
by Irizarry et al. (1997), King and Arendash (2002b) noted strong staining within interior 
cortex and hippocampus of 19 month old Tg2576 APP mice compared to non-transgenic 
mice, but not at any of the younger ages.  The strongest staining occurred in the plaque 
periphery, with minimal staining present within the core of plaques.  Tg2576 mice 
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exhibited a linear plateau of synaptophysin staining from 3 to 19 months, whereas the 
non-transgenics have a decreasing trend up to 19 months creating the significant 
difference between the genotypes.  Thus, synaptophysin was higher within the neocortex 
of Tg2576 mice at 19 months compared to non-transgenic mice.   As well, the outer 
molecular layer and polymorphic layer of the dentate gyrus had increased synaptophysin 
staining in the 19 month APP mice versus non-transgenics (King & Arendash, 2002b). 
In addition to the pathologic markers that are exhibited in the Tg2576 APP model, 
changes occur in oxidative stress markers as well.  Pratico et al. (2001) isolated and 
quantified the presence of isoprostanes (sensitive markers of lipid peroxidation and 
oxidative stress) within urine, plasma and brain tissue of Tg2576 APP mice from 4 to 18 
months of age.  Human AD subjects exhibit increased isoprostane (IsoP) levels within 
urine, plasma and CSF, therefore this oxidative marker could be used as a useful 
peripheral indicator for AD.  After 6 months of age, APP mice show significant 
elevations of IsoP levels within the urine with a maximum plateau occurring after 12 
months of age compared to non-transgenic control mice.  Plasma levels of IsoPs are 
significantly increased after 8 months in APP mice versus non-transgenic animals.  As a 
general reference, there was no difference found within the non-transgenics at any age 
within urine or plasma IsoP levels.  Prior to 8 months there was no difference in brain 
levels of IsoPs, specifically cerebral cortex and hippocampus.  At 8 months and older, 
cerebral cortex and hippocampus exhibit increased levels of IsoPs compared to non-
transgenics with no difference at any age within the cerebellum (Pratico et al., 2001).   
In agreement with Pratico, Smith et al. (1998) found increased oxidative stress 
markers in 13-25 month old Tg2576 APP mice.  This study specifically analyzed 
 50 
hemeoxygenase-1 (HO-1) and HNE (lipid peroxidation marker).  Both HO-1 and HNE 
were found to be associated with the peri-plaque regions and neuronal cell bodies that 
were distant from Aβ deposition.  Their presence at the distant locations indicates a 
global increase of oxidative stress.  However, the detection of reactive oxygen species 
(ROS) was only found to be present at the sites of Aβ deposition (Smith et al., 1998).  In 
a similar age of mice, Pappolla et al. (1998) detected an increase of superoxide dismutase 
(SOD) by 21-25 months of age.  The presence of SOD overlaps with the evidence of 
dystrophic neurites and Aβ plaque deposition.  The authors suggest that the overlap 
between SOD detection and Aβ deposition supports the idea that Aβ is neurotoxic and 
that toxicity is mediated by free radicals (Pappolla et al., 1998). 
Aside from the plethora of pathologic evidence used to characterize this mouse 
model, behavioral analyses of learning and memory are also present to further support the 
similarities between the progression of AD in humans and in mouse models.  At 3 months 
of age, the Tg2576 mouse was found not to be impaired in sensorimotor tasks, Y-maze 
alternation or entries, Morris water maze or visible platform (Holcomb et al., 1999).  
However by 6 and 9 months of age, they exhibit a significant decrease in Y-maze 
alternation compared to non-transgenic mice indicating a deficit in basic memory 
function.  This study found no impairment in visible platform or Morris water maze 
acquisition or retention even at 9 months of age.  Whereas Holcomb et al. (1999) found 
no impairment in visible platform at 9 months, King and Arendash (2002a) found a 
significant increase in latency at 9, 14 and 19 months for the Tg2576 mouse compared to 
non-transgenic mice.    
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In agreement with Holcomb, King and Arendash (2002a) found no impairment at 
3 months age in Morris water maze, visible platform and Y-maze entries, as well as 
circular platform.  They did, however, find impairment in Y-maze alternation, an increase 
of open field activity and poor balance beam performance at this early age.   This study 
behaviorally tested mice from 3-19 months of age which resulted in overall impairment 
in open field activity, balance beam performance, string agility and Y-maze alternation in 
comparison to age-matched non-transgenic mice (King & Arendash, 2002a).  
In contrast to King and Arendash, Hsiao et al. (1996) did not observe an 
impairment of Y-maze alternations at 3 months, but did see impairment at 10 months of 
age within Tg2576 mice.  Also at 10 months of age the mice exhibited acquisition 
deficits, evident by increased latencies in the Morris water maze as compared to non-
transgenic control mice.  Mice between 9 to 15 months had a significant impairment of 
memory retention also within the Morris water maze.  Overall, the authors suggest an 
association between the appearance of Aβ40 and Aβ42 neurochemically within the brains 
of 2 month old APP mice that progressively increased through 13 months to the 
progression of learning deficits that were observed in these ages (Hsiao et al., 1996). 
Westerman et al. (2002) also found significant impairment of memory retention 
within the probe trial of the Morris water maze in groups of mice ranging from 6 to 25 
months of age, however no impairment was evident in very young mice (4-5 months old).  
The presence of insoluble Aβ was detected in all mice over 10 months old; therefore the 
authors suggested an association between the presence of Aβinsol and the occurrence of 
memory impairments within this mouse model (Westerman et al., 2002). 
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APP/PS1 Transgenic Mice. 
The last model of Alzheimer’s disease reviewed here is a double transgenic 
mouse involving the APPsw mutation and a missense mutation of the presenilin 1 gene.  
In general, APP/PS1 mice exhibit an accelerated amyloid deposition compared to the 
single transgenic APP mouse.  Some studies even suggest that deposition begins to occur 
as early as 3 months of age.  Holcomb et al. (1998) detected the presence of a modest 
amount of compact Aβ deposition between 12-16 weeks of age.  By 24-32 weeks of age 
the deposition was increased and the plaques became surrounded by reactive astrocytes 
(Holcomb et al., 1998).  In agreement with Holcomb, Takeuchi et al. (2000) detected Aβ 
deposition in the double transgenic model at 3 months of age.  Specifically, plaques were 
found in cingulate, superior frontal and parietal neocortices with a lesser amount detected 
within the hippocampus.  From this age, the deposition progressed to include larger 
compact plaques scattered throughout the cortex and small diffuse plaques displayed by 6 
months of age.  By 9 to 12 months, larger dense plaques and small diffuse plaques had 
increased in number and were found within the neuropil of the entire neocortex.  Despite 
the increased number of plaques found by 12 months, Takeuchi et al. (2000) did not see 
any changes in the number of neurons present in region CA1 or in synaptophysin 
immunoreactivity in the molecular layer of the dentate gyrus and CA1 compared to age-
matched non-transgenic and single APP transgenic mice. 
In contrast to the above studies, Gordon et al. (2002) did not detect any Aβ 
deposition at 3 months of age in APP/PS1 mice; the first deposits were identified at 6 
months, mainly within frontal and entorhinal cortices and hippocampus.  These deposits 
were also associated with reactive astrocytes and dystrophic neurites.  Diffuse deposits in 
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striatum, thalamus and brainstem were defined in 12 month old APP/PS1 mice.  
Progression of deposition density and number of diffuse plaques occurred at 15 months; 
however no deposits were found in granular and pyramidal cell layers of the 
hippocampus or the corpus callosum.  At this late age, GFAP staining for reactive 
astrocytes was greatly increased throughout the brain, mainly concentrated in the striatum 
and cerebral cortex, compared to their first detection from 6 month old mice (Gordon et 
al., 2002). 
Although Borchelt et al. (1997) also detected substantial Aβ deposition within 
cortex and hippocampus in 12 month old APP/PS1 mice, no deposition was found in any 
other region in contrast to Gordon et al. (2002) that found plaques in striatum, thalamus 
and brainstem.  Borchelt et al. (1997) also reported a progression of deposition from 9 to 
12 months with increased number of plaques within hippocampus and occipital and 
frontal cortices.  In conjunction with the previous studies, many of the deposits were 
associated with reactive astrocytes (Borchelt et al., 1997).  Overall, the APP/PS1 
transgenic model develops modest Aβ deposition associated with reactive astrocytes 
around 3-6 months of age with a progression in density and number within cortex and 
hippocampus thereafter. 
Numerous behavioral studies have been performed similar to the previously 
discussed models to characterize the development of cognitive impairment.  At 3 months 
of age, APP/PS1 mice were found to exhibit no deficits in sensorimotor tasks, but did 
become impaired in Y-maze alternation and exhibit increased activity in Y-maze entries 
by 6 to 9 months of compared to age-matched non-transgenic mice (Holcomb et al., 
1999).  However, even at 9 months there were no sensorimotor deficits or memory 
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deficits revealed by visible platform or water maze acquisition or retention trials 
(Holcomb et al., 1999). 
By contrast Arendash et al. (2001b) found no difference of APP/PS1 mice from 
non-transgenics at 5-7 months in Y-maze alternation; however, they did have increased 
activity as measured by Y-maze entries.  The same study also found impairment in a 
balance beam task at this age with no impairments in any additional tasks including 
sensorimotor and learning or memory tasks (Arendash et al., 2001b).  At 15-17 months of 
age, double transgenic mice exhibited increased activity in open field and Y-maze entries 
versus non-transgenics with additional impairments in balance beam, string agility, 
Morris water maze acquisition and radial arm water maze  (RAWM) working memory 
(Arendash et al., 2001b).  Within this study correlation analyses revealed a significant 
positive relation between working memory errors in the radial arm water maze task and 
Congo red staining in the frontal cortex (Gordon et al., 2001).  There was also a 
significant negative correlation between total Aβ load in the frontal cortex and 
hippocampus and radial arm water maze acquisition error reduction between trial 1 and 
trial 4 (Gordon et al., 2001). 
Of the three AD transgenic models presented, the APP/PS1 mouse has certain 
advantages, including considerably earlier Aβ deposition and a comprehensive behavioral 
evaluation at multiple time points.  It is, therefore, ideally suited for studies of this 
dissertation, which involve the testing of vaccination and dietary therapeutics against 
behavioral impairment and AD neuropathology provided by that model. 
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IX.  AD Vaccination 
Current treatment options for AD include cholinesterase inhibitors, NSAIDs, 
statins and a variety of antioxidants as previously reviewed.  However, these therapies are 
largely aimed at the symptomatic basis of the disease instead of the underlying pathology 
involved.  Utilization of immunotherapy as a possible treatment of AD involves inducing 
an immune response to fight misfolded proteins or aggregates of proteins that accumulate 
in the pathogenesis of AD.  Therefore, immunotherapeutic approaches toward AD hold 
valid opportunities to treat this neurodegenerative disease through a humoral or cellular 
immune-mediated response. 
 
In Vitro Studies.   
In 1996, Solomon et al. first experimented with monoclonal antibodies (mAbs) to 
test their effectiveness against Aβ peptide aggregation, fibrillization and toxicity in vitro.  
They found that mAbs against Aβ1-28 were effective at converting fibrillar Aβ to an 
amorphous state.  In 1997 Solomon et al. then showed that the mAb 6C6 against Aβ1-16 
significantly solubilized fibrillar Aβ in comparison to control cells.  Starting in 1998 
Frenkel et al. began to determine the specific epitope for antibody binding which was 
responsible for completely inhibiting Aβ fibril formation.  They determined that the 
EFRH epitope corresponding to Aβ3-6 was most effective at solubilizing fibrillar Aβ.  
These results support the studies previously performed by Solomon et al. (1996, 1997), 
who determined that mAbs against Aβ1-28 or Aβ1-16 were more successful than mAbs 
against Aβ8-17 or Aβ13-28 for disaggregating Aβ fibrils.  Following these studies were Aβ 
 56 
immunotherapy experiments in multiple transgenic models to determine the efficacy of 
previously determined in vitro results in an in vivo environment. 
 
Active Aβ Immunotherapy. 
Schenk et al. (1999) first explored active Aβ immunization by administering the 
Aβ1-42 peptide to 6 week old PDAPP mice once monthly until 13 months of age.  The 
vaccination sequence resulted in almost complete prevention of Aβ deposition.  
Immunization of 11 month PDAPP mice until 15 and 18 months resulted in arrest of total 
Aβ deposition within the cortex to the level present at 11 months.  Immunization resulted 
in the generation of blood anti-Aβ antibodies and activation of microglia found near 
plaques; therefore one possible mechanism for Aβ clearance, before or after plaque 
formation, could be due to anti-Aβ antibodies triggering microglial cells to clear Aβ 
through an Fc receptor-mediated phagocytosis.  Schenk et al. (1999) concluded that 
active immunization could be used as both a prevention and therapy to block or retard the 
pathological development within an AD-like pathology.  Disappointingly, there were no 
behavioral measures performed on these mice to determine if the improved pathology 
could also retard behavioral impairments.  In 2001, Dickey et al. vaccinated 5-month old 
APP+PS1 mice with the Aβ1-42 peptide monthly for 7 months.  They found that more than 
three vaccinations are necessary to induce a 50% maximal antibody titer that 
progressively increased after the 6th booster vaccination.  A competition binding 
inhibition assay was used to determine binding efficacy and specificity of the sera from 
the immunized mice.  Aβ1-16 was the only truncated Aβ peptide from the sera that 
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inhibited binding of antibodies to Aβ1-42.  Also, the Aβ1-42 was more effective that Aβ1-40, 
indicating the importance of the 2 amino acid difference between the peptides in antibody 
binding.  Because Aβ1-42 forms fibrils more readily than Aβ1-40, this conformational 
change could significantly contribute to the preferential recognition by the immune 
system.  Lastly, T-cell proliferation was increased in spleen cells of APP+PS1 
vaccination mice (Dickey et al., 2001).   
Recently, Koller et al. (2004) vaccinated APP mice with Aβ1-42 cross-linked with 
an Hsp70 homolog of Escherichia coli, DnaK, beginning at 6 weeks of age (prior to onset 
of plaque deposition), with 3 inoculations ending at 12 weeks of age.  In opposition to 
Dickey et al. (2001), measurable antibody titers against Aβ42 were detected after only one 
inoculation with the DnaK-Aβ42 vaccination.  At 6-9 months, brain levels of Aβ were 
determined for human and murine Aβ in brain homogenate.  The DnaK-Aβ42 immunized 
mice showed a surprising increase of extractable Aβ indicating an increase of Aβ 
aggregates as a result of the vaccination.  This change occurred without any significant 
plaque deposition.  By 12-14 months of age, both DnaK-Aβ42 immunized and control 
APP mice showed low levels of plaque burden in the neocortex with no difference 
between the two groups.  Also at this age, the extractable total Aβ and Aβ42 were 
increased in the brains of the DnaK-Aβ42 immunized mice compared to the non-
immunized APP mice.  Both immunized and non-immunized APP transgenics exhibited 
Aβ deposits in the walls of cerebral blood vessels.  There was a trend toward a slightly 
higher Aβ deposition in the brains of immunized mice, as evidenced by their having Aβ 
deposits within smaller cerebral blood vessels in addition to Aβ deposits in large cerebral 
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blood vessels.  The authors propose a possible link between the increased Aβ aggregates 
resulting from vaccination and the non-significant increase in Aβ within small cerebral 
vessels.  The authors propose that this link may be a direct result of the vaccination, 
however there is no significant evidence to support this association. 
Monsonego et al. (2001) immunized APP Tg2576 transgenic mice with Aβ1-40 at 
5 weeks of age, with blood samples collected ten days later for antibody and T-cell 
analysis.  Immunized APP mice had lower levels of anti-Aβ antibodies compared to 
immunized wild-type littermates; the APP control vaccinated mice did not produce any 
detectable levels of anti-Aβ antibodies.  The Aβ1-40 APP immunized mice also had 
decreased T-cell proliferation, INF-γ, and IL-2 secretion compared to non-transgenic 
littermates.  In opposition to Dickey et al. (2001), Monsonego et al. (2001) did not show 
an increase in T-cell proliferation.  The difference could largely be due to the number of 
inoculations given, type of vaccination, and/or the difference in transgenicity used in the 
animal models.  The sera from the APP immunized mice were used to positively stain 
neuritic plaques in brains of mature APP mice; sera from non-immunized mice did not 
positively stain any neuritic plaques.  The authors suggest that the APP immunized mice 
exhibit a hyporesponsive immune response to the Aβ1-40 vaccination, as evident by 
reduced T-cell and anti-Aβ antibody production.  They relate this impaired immune 
response of the APP mice to humans that have chronic elevations of brain and peripheral 
Aβ, resulting in their also exhibiting an impaired immune response to Aβ vaccinations. 
Aside from the previous studies that used direct injections of the Aβ1−42 peptide, 
Weiner et al. (2000) performed nasal administration of the less amyloidogenic Aβ1−40 
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peptide to 4.5 month old PDAPP mice once weekly for 7 months.  Mucosal 
administration has the ability to induce an anti-inflammatory immune response which is 
antigen-specific within lymphoid tissue.  This response then acted systemically to 
significantly reduce Aβ deposition within cortical and hippocampal tissues.  This 
occurred in conjunction with a decrease in microglia and astrocyte activation within these 
areas (Weiner et al., 2000).  More recently, Lemere et al. (2003) showed that 5 week old 
APP+PS1 mice immunized intranasally with a cocktail of Aβ peptides (3 parts Aβ1-40, 1 
part Aβ1-42) twice weekly for 8 weeks exhibited a 75% reduction in cerebral Aβ plaque 
number and 58% decrease in neurochemical levels of Aβ1-42 in the brain.  There was also 
a large increase in serum Aβ antibody levels compared to untreated control transgenics.  
The authors concluded that because most of the serum Aβ was bound to antibodies, that 
the antibodies attached to serum Aβ to aid in clearance.  
McLaurin et al. (2002) vaccinated TgCRND8 mice with protofibrillar aggregates 
of Aβ1-42 or control vaccinations.  This resulted in recognition of Aβ42 monomers, 
tetramers, hexamers and large oligomers by Aβ42-immune sera.  The Aβ42-immune sera 
did not activate the Th1 helper cell pro-inflammatory cascade, but instead the Th2 helper 
cell response was activated, which promotes B cells to make anti-Aβ antibodies.  
Specifically, they found that Aβ4-10 peptide was highly recognized by the anti-Aβ42 IgGs.  
Aβ fibril formation and toxicity were inhibited by anti-Aβ4-10 without activation of 
surrounding microglia.  Overall, McLaurin et al. (2002) concluded that using small-
molecules could decrease some of the detrimental problems seen in immunotherapy such 
as a pro-inflammatory response.  This study had similar results compared with previous 
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work by Frenkel et al. (1998), who first reported that the epitope of Aβ1-42 is the Aβ4-10 
segment; Frenkel et al. proposed the segment specifically corresponded to Aβ3-6.   
Additional active immunization animal studies have been done to prevent against 
AD progression.  These studies administer Aβ active immunization prior to Aβ 
deposition in transgenic models and behaviorally assess changes that could occur in 
conjunction with Aβ pathology.  Vaccination of 6 week old TgCRND8 mice with Aβ42 
for 3½ months resulted in a 50% decrease in the number and size of Aβ-positive dense 
core plaques within the hippocampus and cortex (Janus et al., 2000).  At various age 
points from 11 to 23 weeks, Morris water maze testing was done; improved performance 
of the Aβ42 vaccination group in comparison to control immunized mice was observed at 
several, but not all, test points (Janus et al., 2000).  Morgan et al. (2000) began 
administration of Aβ1-42 peptide to APP+PS1 transgenic (Tg+) mice at 5-7 months of age 
— prior to Aβ deposition and behavioral deficits.  The inoculations were given monthly 
until 15.5 months of age.  High antibody titers were found in immunized Tg+ and non-
transgenic (Tg-) mice; control vaccinated and untreated mice did not produce any 
detectable antibodies to Aβ42, indicating that transgenic mice do no spontaneously 
produce anti-Aβ antibodies.  A modest, non-significant, decrease in Aβ burden in the 
frontal cortex was produced in the brains of Tg+ immunized mice; however, there was a 
significant reduction in Congo red-positive compact plaques within the frontal cortex of 
Tg+ immunized mice.  Trends toward reduced Aβ burden and Congo red staining were 
found in the hippocampus of vaccinated mice.  All mice were behaviorally pretested 
before vaccination began, ~5-7 months of age, and similarly behaviorally tested at ~16 
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months of age after 8 months of Aβ inoculations.  At the 16 month test point, vaccinated 
Tg+ mice performed similar to Tg- mice in radial arm water maze working memory, and 
significantly better than control Tg+ mice (Morgan et al., 2000).  Despite 8 months of 
vaccinations, Tg+ mice remained impaired in balance beam compared to Tg- mice 
(Arendash et al., 2001a).  In order to relate Aβ deposition to behavioral performance, 
correlation analyses were performed.  These analyses showed significant correlations 
between Aβ1-40 deposition in hippocampal region CA1 and radial arm water maze 
working memory impairment for all Tg+ mice grouped together.  Additionally, Aβ1-40 
deposition and Congo red staining in frontal cortex correlated with radial arm water maze 
working memory impairment for both Tg+ groups combined.  The authors suggest that 
the behavioral protection offered by an Aβ vaccine selectively and primarily preserves 
hippocampal-associated working memory function (Arendash et al., 2001a).  
Additionally, the authors propose that the significant prevention of memory deficits 
exhibited in the radial arm water maze task, coupled to the slightly reduced but still 
substantial Aβ load, could be due to the ability of Aβ antibodies to neutralize soluble, 
non-deposited Aβ (Morgan et al., 2000).  This type of Aβ has been implicated in memory 
loss due to synapse loss in dentate gyrus.  A second proposed theory to account for the 
observed results is through a clearance of deposited Aβ by activated microglia; however 
the lack of significant difference in Aβ deposition between the vaccinated and control 
transgenic groups does not support this theory (Morgan et al., 2000).   
Recently, Sigurdsson et al. (2004) immunized 6 to 8-month old Tg2576 APP mice 
with monthly inoculations of nontoxic Aβ1-30 or K6Aβ1-30 until 19 to 21 months of 
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age.  K6Aβ1-30 binds specifically to residues 1-11 and 22-28 of Aβ42 without adopting a 
β-sheet conformation and is therefore less toxic.  Immunization with Aβ1-30 produced 
no difference in amyloid plaque burden or soluble Aβ levels.  Likewise, vaccination with 
K6Aβ1-30 to the APP mice did not produce a significant change in overall amyloid 
burden; however, there were reductions in small and medium-sized plaques in the 
vaccinated group compared to control-immunized APP mice.  There was also no change 
in soluble Aβ levels between the K6Aβ1-30 mice and the control group.  In addition to 
the pathologic markers, Sigurdsson et al. (2004) showed that APP mice vaccinated with 
K6Aβ1-30 had improved cognitive performance, as shown by a decrease in errors in the 
radial arm maze task compared to control vaccinated APP mice.  Both the K6Aβ1-30 
vaccinated and control wild-type mice exhibited a learning effect, as shown by a decrease 
in errors from day 1 to day 9; the control vaccinated APP mice did not show any learning 
effect.  Overall, because the K6Aβ1-30 vaccinated mice showed an improvement in 
learning with minimal changes in amyloid burden, the authors suggest that this type of 
immunization clears Aβ oligomers which are linked to behavioral performance.   
In comparison to vaccination studies for prevention against AD, few studies have 
focused on the use of immunization as a treatment option for AD.  Wilcock et al. (2001) 
immunized 3 groups of APP+PS1 mice with the Aβ1-42 peptide beginning at 7.5, 13 and 
14.5 months of age for 9, 3 and 5 months, respectively.  Overall, all groups exhibited 
decreases in Congo Red staining in hippocampus, but not in frontal cortex.  In another 
study, Sigurdsson et al. (2001) vaccinated 11-13 month old Tg2576 mice with a 
nonamyloidogenic, non-toxic Aβ homologous peptide for 7 months until the age of 18-20 
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months.  This resulted in decreased amyloid burden in cortex and hippocampus as well as 
decreases in Congo Red staining and soluble Aβ42 deposition in comparison to control 
vaccinated mice.  In opposition to Wilcock et al. (2001), a decrease in Congo red staining 
was observed in frontal cortex.  The discrepancy between Wilcock and Sigurdsson is 
most likely due to the difference in vaccination protocol used between the two groups, 
non-toxic Aβ homologous peptide versus Aβ1-42 peptide.   
In 2003, Frenkel et al. injected the EFRH epitope, corresponding to Aβ3-6, into 
16-month old PDAPP mice monthly for 4.5 months.  In agreement with Dickey et al. 
(2001), antibody titers reached high levels after 6 injections.  They demonstrated that 
monoclonal antibodies that disaggregate Aβ also bind to the EFRH-phage; conversely, 
monoclonal antibodies that do not disaggregate Aβ, do not bind to the EFRH-phage.  
Incubation of prepared Aβ fibrils with anti-EFRH sera resulted in disaggregation of the 
fibrils into an amorphous state.  Likewise, plaques from the hippocampus of PDAPP 
mice and AD human subjects were positively stained with the anti-EFRH anti-sera.  
Analysis of 21-month old PDAPP vaccinated mice showed a significant reduction in 
amyloid burden compared to the control-vaccinated PDAPP mice.  The authors suggest 
that the EFRH-phage induced an auto-immune response by PDAPP mice to produce anti-
EFRH that binds and disaggregates Aβ fibrils to reduce the number of Aβ plaques in the 
brain (Frenkel et al., 2003). 
Austin et al. (2003) performed biweekly injections of Aβ1-42 for 6 weeks in 
cognitively impaired 16 month old APP+PS1 mice.  Mice were pre-tested in radial arm 
water maze and platform recognition tasks prior to the first vaccination.  All Tg+ mice 
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exhibited impaired working memory retention within both tasks.  Within the platform 
recognition task, overall both groups of Tg+ mice had increased latency compared to Tg- 
mice, but by the end of the task (day 4) they exhibited similar performance to Tg- mice.  
Following the vaccination period, aged transgenic mice exhibited working and reference 
memory impairment in the radial arm water maze task that was not corrected with Aβ 
immunization.  However, both groups of Tg+ still showed similar performance to Tg- 
mice in platform recognition by having decreased latencies by day 4 in this task.  By 20 
months of age after the final behavioral assessment, anti-Aβ antibody levels were 
detected in all Tg+ mice that were vaccinated; in opposition, no antibody levels were 
detected in control vaccinated mice. The authors concluded that a longer vaccination 
immunotherapy might provide a better cognitive advantage to aged APP+PS1 mice.   
 
Passive Aβ Immunotherapy. 
Passive immunization studies involving injection of antibodies against Aβ1-42 
have been performed in Aβ-depositing transgenic mouse models.  Pfeifer et al. (2002) 
suggest that the binding of an antibody to soluble Aβ has the potential to cause a local 
inflammatory reaction and can destabilize weakened vessel walls.  Transgenic APP23 
mice (which develop amyloid angiopathy) were immunized with a monoclonal antibody 
against Aβ that recognized Aβ3-6.  This resulted in a significant increase in hemorrhage 
severity mainly within amyloid-rich vessels.  The authors suggest that the weakening of 
the vessels could be due to an Aβ-induced increase in vascular permeability, resulting in 
the loss of smooth muscle cells.  In addition, they suggest that an increase of antibody 
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binding to soluble Aβ in the blood could lead to increased risk of cerebral hemorrhage.   
However, no other passive immunization studies use mouse models that develop cerebral 
amyloid angiopathy and therefore do not show an increased risk for cerebral hemorrhage 
to support these findings.  Also, the immunization resulted in a 23% decrease of Aβ load 
in neocortex, mainly due to a reduction of diffuse deposits (Pfeifer et al., 2002).   
Bard et al. (2000) however, showed that PDAPP mice immunized weekly with 
monoclonal antibodies, 10D5 or 21F12, beginning at 8 to 10 months of age for 6 months 
had more than an 80% decrease in plaque burden within frontal cortex with the 10D5 
antibody.  The 10D5 monoclonal antibody is specific to Aβ residues 3-6, whereas 21F12 
is specific to Aβ42 residues 34-42.  The same group also immunized 11.5 to 12 months 
old PDAPP mice with monoclonal antibodies, 3D6 and 16C11 for 6 months.  A 
significant decrease in frontal cortex plaque burden was seen only with 3D6 and in the 
absence of T-cell proliferation within splenocytes.  3D6 is specific to Aβ residues 1-5, 
whereas 16C11 is specific to Aβ residues 33-42.  The authors concluded that this type of 
passive immunization against Aβ is sufficient to induce decreases in amyloid deposition 
without T-cell mediated cellular immunity.  In agreement with Schenk et al. (1999), these 
authors suggested that the mechanism for Aβ clearance involves antibodies entering the 
CNS and binding to Fc receptors on microglial cells to trigger phagocytosis of deposited 
Aβ peptide (Bard et al., 2000).   
DeMattos et al. (2001) vaccinated 4-month old PDAPP mice for 5 months with 
the m266 monoclonal antibody, which is specific to Aβ13-28.  M266 vaccinated mice had 
marked reductions in Aβ deposition in the cortex and dorsal hippocampus compared to 
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control vaccinated PDAPP mice.  Despite the reduction of Aβ deposition, m266 did not 
bind to Aβ deposits within the brains of PDAPP mice.  In addition, Aβ levels in the 
plasma were increased 1000-fold in vaccinated transgenics compared to control mice.  
Since, m266 does not cross the blood brain barrier, the authors suggested that m266 acted 
as an Aβ sink to bind and sequester Aβ from the CNS to significantly increase plasma Aβ 
to aid in clearance.  Specifically, the authors suggested that m266 altered the plasma and 
brain Aβ equilibrium to favor Aβ in the plasma and therefore reduce deposition in the 
brain (DeMattos et al., 2001).   
An additional passive immunization treatment study involved a single ICV 
injection of a monoclonal antibody AMY33 (specific to Aβ1-28), into the third ventricle of 
10-month old Tg2576 APP mice (Chauhan & Siegel, 2003).  The authors claim that 
AMY33 immunization reduced the size of compact plaques, at one-month after the 
injection, compared to control vaccinated APP mice; however, the figures do not support 
this statement and no quantification of plaques was performed.  There seems to be no 
difference in staining between the treatment and control groups.  The study also claimed 
that AMY33 immunization decreased the number of immunoreactive microglia 
surrounding compact cerebral plaques.  Overall, AMY33 does not seem to be effective at 
reducing AD-related pathology such as Aβ burden or microglial response. 
A similar short-term passive vaccination study topically applied the anti-Aβ 
antibody 10D5 by craniotomy to the cortex of 19-23 month old PDAPP mice (Lombardo 
et al., 2003).  The antibodies were only effective to the immediate cortical area where 
they are applied; remote areas from the application site were not affected by the antibody.  
Amyloid burden was decreased significantly only in the immediate area of application at 
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4 and 32 days after topical treatment with 10D5.  Also in the immediate area from 4 to 32 
days post-treatment, neurites from 10D5 immunized PDAPP mice appeared normal 
similar in fact to those in non-vaccinated Tg- mice; neurites in a remote area of PDAPP 
mouse brains (not exposed to 10D5) had a greater curvature ratio.  The authors concluded 
that the curvature neurite abnormalities exhibited in the remote area of PDAPP brains are 
linked to Aβ deposition and that these neurites undergo rapid restoration to a normal 
morphology following Aβ plaque clearance (Lombardo et al., 2003).  
Kotilinek et al. (2002) found that intraperitoneal administration of BAM-10 (a 
monoclonal antibody that recognizes Aβ residues 1-12) for one week resulted in no 
change in neurochemical Aβ40 or Aβ42 levels within brains of  9-11 month old Tg2576 
mice versus Tg+ controls.  However, the BAM-10 group did perform significantly better 
in Morris water maze acquisition and probe trial retention compared to a pretreatment 
performance within the same group.  The authors propose that toxic Aβ assemblies or 
oligomers are responsible for cognitive impairment seen in Tg+ mice; therefore, 
neutralization of these Aβ species could lead to cognitive improvement.  This is the 
proposed mechanism of action of BAM-10 since resulting improvement in memory/ 
learning of Tg+ mice occurred without alterations in brain Aβ levels. 
In contrast to the prevention study performed by DeMattos et al. (2001), Dodart et 
al. (2002) found that a 6 week treatment with the antibody m266 in 24 month old PDAPP 
mice resulted in no change in Aβ burdens in hippocampus or cortex, but the vaccinated 
mice given high doses of m266 did perform significantly better in an object recognition 
task than Tg+ mice given PBS injections.  Since m266 does not cross the blood-brain 
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barrier, the mechanism is thought to be through the peripheral clearance or sequestration 
of soluble Aβ in order to efflux Aβ from the brain.  This theory stems from the detection 
of an Aβ/m266 complex in the plasma and CSF at high doses of m266.  The authors 
suggested that the high doses are necessary for m266 to enter the central compartment 
and draw soluble Aβ from the brain into the plasma (Dodart et al., 2002).  
More recently, Wilcock et al. (2004) vaccinated 19-month old Tg2576 APP mice 
weekly with the anti-Aβ antibody 2286 (specific to Aβ28-40) for 1, 2, or 3 months.  
Serum Aβ antibodies were detected at high levels after 1 month of vaccination and 
associated with high circulating serum Aβ levels.  However, by 2 and 3 months of 
vaccination, serum Aβ decreased, but remained elevated compared to control vaccinated 
APP mice.  Both compact and diffuse Aβ deposition were reduced in the cortex by ~60% 
and hippocampus by ~55% of APP mice vaccinated for 2 and 3 months compared to 
control vaccinated APP mice.  Also, transient microglial activation was seen in 
vaccinated APP mice at 2 months of treatment compared to control APP mice.  By 3 
months of treatment, microglial activation returned back to levels found at 1 month of 
treatment.  At 22 months of age, a behavioral assessment was done to evaluate the effects 
of the vaccination.  All groups were tested in the Y-maze task, which indicates general 
memory function and activity.  APP vaccinated mice had improved performance shown 
by a higher percent alternation compared to APP control vaccinated mice.  Also, the APP 
control mice, in addition to APP mice vaccinated for 1 month, had significantly increased 
arm entries versus non-transgenic mice.  However, following 2 or 3 months of 
vaccination treatment, APP mice exhibited similar activity levels to that of the non-
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transgenic mice.  The authors suggested that anti-Aβ antibodies are able to enter the brain 
and activate Fc receptors on microglial cells to stimulate phagocytosis, as first described 
by Schenk et al. (1999). 
 
Aβ Immunotherapy in Humans. 
Following the evidence that both active and passive immunization of mouse 
models decrease Aβ deposits within brain regions and reduce cognitive deficits, human 
trials began with immunization of Aβ1-42 (AN-1792) by Elan and Wyeth-Ayerst 
Laboratories.  After a few months during Phase II trials, about 5% of the participants 
receiving the vaccine developed severe inflammation in the spinal cord and brain, so the 
trials were halted.  However in a Zurich cohort there was no significant correlation 
between the production of antibodies and the incidence of aseptic meningoencephalitis 
(Hock et al., 2003).  This trial included 30 participants with mild to moderate AD; 24 
patients received the vaccination of AN1792 and developed antibodies.  After all the 
trials were halted, antibody production and reactivity, due to the vaccination, were 
analyzed. They discovered that human sera produced antibodies that reacted with β-
amyloid plaques and vascular amyloid on brain sections of APP+PS1 transgenic mice 
and β-amyloid from human brains (Hock et al., 2002).  Following a one-year follow-up, 
19 of 28 patients that developed antibodies showed a stabilization of cognitive 
performance, as measured by the MMSE, compared to subjects that did not produce 
antibodies and exhibited cognitive decline.  The patients that developed antibodies also 
had preserved hippocampal function as shown through the Visual Paired Associates Test 
versus patients that did not develop antibodies.  Lastly, due to unchanged CSF and 
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plasma levels of Aβ40 and Aβ42, the antibodies produced from the vaccine did not 
sequester serum Aβ in order to alter cognition (Hock et al., 2003).  Despite the above 
beneficial results from human Aβ1-42 vaccination, the serious inflammatory complications 
from the vaccine do not allow for additional human trials with this approach.  Passive 
immunization or vaccinations with modified forms of Aβ have been recommended to 
circumvent some of the problems associated with active immunization, such as stroke, 
encephalitis and sterile meningitis (McGeer & McGeer, 2002).  Proposed mechanisms 
that could account for the unexpected inflammatory reactions seen in a few of the patients 
in the clinical trials include: 1) autoimmune disorder due to antibody reactivity with host 
proteins and 2) autodestruction due to the host cells being damaged by the membrane 
attack complex (MAC).  Under normal conditions antibodies are generated against 
foreign material; however spontaneous generation against host proteins can lead to 
disorders known as autoimmune diseases.  Autodestruction occurs when MAC, which 
normally protects host cells by attacking bacterial and viral pathogens, is over activated 
as occurs during AD; this results in more complement activation and destruction of 
neurons leading to an increase of damage to host cells (McGeer & McGeer, 2002). 
 
 
IX.  Omega-3 Fatty Acids 
General Background.   
Omega-3 fatty acids are found mainly enriched within fish and fish oil 
supplements.  The specific fatty acids at high concentrations within these foods include 
docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA).  Omega-3 fatty acids can 
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also be found in hemp oil, flax oil and green leaves (Haag, 2003).  Retrospective studies 
indicate that a high intake of n-3 fatty acids is associated with a reduced risk of dementia, 
specifically AD, prevention of cardiac arrhythmias, through reduced thrombosis, 
decreased inflammation including arthritis and decreased weight loss to reduce the risk of 
death associated with cancer and AD (Kalmijn et al., 1997a; Kalmijn et al., 1997b; 
Horrocks and Yeo, 1999; Knittweis, 1999).  Omega-6 fatty acids are found mainly within 
meats and vegetable oils such as sunflower oil, evening primrose oil, corn oil and 
safflower oil (Haag, 2003).  Arachidonic acid, an omega-6 fatty acid, can specifically be 
found in meats, eggs, shrimp and prawns (Das, 2003). 
Essential fatty acids (EFAs) include linoleic acid (LA) and α-linolenic acid 
(ALA). These fatty acids can not be produced de novo and must be provided by dietary 
intake.  All of the polyunsaturated fatty acids (PUFAs) are synthesized from these two 
EFAs; LA gives rise to all of the omega-6 fatty acids while ALA synthesis results in all 
of the omega-3 fatty acids.  Fatty acids are named to identify the structure of the 
molecule so that DHA is denoted as 22:6n-3.  The first number, 22, refers to the number 
of carbon atoms in the hydrocarbon backbone, the 6 represents the number of double 
bonds and the 3 gives the position of the last double bond.  N is equal to the number of 
total carbon atoms so that n-3 represents the number of carbon atoms from the last double 
bond to the terminal methyl group.   
As indicated from animal studies, the primary supplier of brain DHA levels is 
from the plasma.  Plasma DHA is either obtained from dietary intake or from precursors 
synthesized into DHA by the liver.  Additional studies indicate that DHA can be 
synthesized directly from the brain and it’s concentration can be regulated by n-3 
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precursors or the availability of preformed DHA.  Specifically, DHA synthesis occurs 
within astrocytes, which provide DHA in high concentrations to neurons and blood-brain 
barrier endothelium cells (Williard, et al., 2001). 
Because mammals do not possess the enzyme omega-3 desaturase they can not 
convert omega-6 fatty acids into omega-3 fatty acids.  The synthesis of fatty acids within 
the liver consists of desaturation and elongation reactions within the endoplasmic 
reticulum and peroxisomes as illustrated below in Figure 2.  Initially, ALA receives an 
additional double bond to change from an 18:3n-3 fat into an 18:4n-3 fatty acid by δ-6-
desaturase.  Elongation of the carbon chain occurs to produce 20:4n-3 which is then 
altered by δ-5 desaturase to yield EPA (20:5n-3).  EPA is then elongated by two separate 
reactions to produce 24:5n-3.  ∆-6 desaturase then adds another double bond to produce 
24:6n-3, which undergoes β-oxidation to yield DHA (22:6n-3) (Ferdinandusse, 2001; 
Haag, 2003).  Unfortunately only 5% of the dietary ALA is ultimately converted into 
DHA (Sarsilmaz et al., 2003).  Initially it was proposed that all of the fatty acid 
conversion to DHA were performed within the endoplasmic reticulum (ER), however 
recent research has proven than the final β-oxidation step to yield DHA occurs within the 
peroxisomes.  The potential enzymes responsible for this conversion have been identified 
as either a straight-chain acyl-CoA oxidase (SCOX) or a D-bifunctional protein (DPB) 
(Ferdinandusse, 2001).  Omega-6 fatty acid conversion from LA (18:2n-6) undergoes the 
same path using the same enzymes to ultimately yield 20:4n-6 (arachidonic acid, AA). 
Additional products are also produced at several stages in the pathway by both 
omega-3 and omega-6 fatty acids.  Di-homo-linoleic (DGLA) acid, an n-6, can give rise 
to precursors for 1-series eicosanoids.  Eicosanoids encompass prostaglandins and 
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thromboxanes.  Arachidonic acid (AA), also an n-6, can form precursors to 2-series 
eicosanoids, while EPA, an n-3 fatty acid, can produce precursors for 3-series 
eicosanoids (Fig. 2).  The 2-class is pro-inflammatory whereas the 3-class of eicosanoids 
is anti-inflammatory in function (Das, 2003). 
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Fig. 2.  Fatty acid synthesis within liver from dietary intake of α-linolenic acid (ALA; 
18:3n-3) and linoleic acid (LA; 18:2n-6) to ultimately give rise to docosahexaenoic 
acid (DHA; 22:6n-3) and arachidonic acid (AA; 20:4n-6) 
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Dietary Manipulation of n-3 and n-6 Fatty Acids. 
Most of the impacts from fatty acids occur following their incorporation into 
cellular membranes.  DHA has the potential to influence membrane fluidity, hormone 
production, enzyme activities and the formation of lipid peroxidation products (Stillwell 
& Wassall, 2003).  While affinity for DHA incorporation into membranes is highest in 
retinal cells (Alessandri, 2003), it is also present in synaptosomes and sperm cell 
membranes (Stillwell & Wassall, 2003), whereas the hippocampus and cerebral cortex 
show the lowest affinity for DHA membrane incorporation (Alessandri, 2003).  Heart, 
skeletal muscle, liver and kidney membranes also contain levels of DHA within their 
phospholipids (Turner et al, 2003a).  Particular phospholipids (PL) classes incorporate 
DHA at distinct rates and affinities.  Stillwell and Wassall (2003) determine that within 
plasma membrane and mitochondria, DHA first integrates into phosphotidylethanolamine 
(PE) followed by incorporation into phosphotidylcholine (PC) and the remainder of the 
PL classes.  Within these two PL classes, cerebral cortical cell membranes from hamsters 
fed an omega-3 deficient diet contained significant decreases in DHA and 
docosapentaenoic acid (DPA) levels as well as total n-3 fatty acids.  Supplementation of 
these cells with DHA resulted in increases of DHA and EPA in a dose-dependent manner 
in addition to a decrease of AA and total n-6 fatty acids (Champeil-Potokar et al., 2004).  
In another study, synaptic plasma membranes from ApoE-deficient mice contained an 
increased amount of DHA within PC and phosphotidylserine (PS) classes possibly due to 
an overcompensation of DHA transport due to the decreased transport of other PUFAs 
from the ApoE deficiency (Igbovboa, 2002).   
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Animal studies show that aged rat (21-24 month) hippocampus (Favreliere et al., 
2003) and whole brains (Bacelo-Coblijn et al., 2003) have significantly less DHA in PE, 
phosphotidylserine (PS) and plasmenylethanolamine (PmE) phospholipids classes versus 
young rat (2 month) brains.  Within some phospholipid classes, such as 
phosphotidylinositol (PI), sphingomyelin and PS, the levels of AA, C16 (palmitic acids), 
total n-6 and n-3 fatty acids have also been shown to be lower in aged rat (27 month) 
whole brains in comparison to adult rat (7 month) brains; there were no differences 
shown specifically in hippocampus (Ulmann et al., 2001).  Old rats supplemented with 
fish oil for one month had restored levels of DHA within ethanolamine 
phosphoglycerides of whole brains compared to the levels in young control-fed rats 
(Barcelo-Coblijn et al., 2003).  In addition, 3 months of DHA supplementation to adult 
rats (18 month) resulted in significant increases of AA, DHA and total n-6 PUFAs in 
hippocampal phospholipid classes, PE and PmE, in comparison to unsupplemented 
control fed rats (Favreliere et al., 2003).  Young mice have even benefited from 
supplementation with fish oil.  Puskas et al., (2004) supplemented 4½ month old mice for 
2 months with cholesterol alone, cholesterol plus fish oil, or standard chow.  Mice that 
were supplemented with only cholesterol had a reduced amount of DHA in whole brain, 
whereas mice fed both cholesterol plus fish oil had increased DHA in whole brain and 
retina as compared to mice fed the standard chow.  In addition to measuring fatty acid 
levels in the brain and retina, this study also analyzed gene expression, specifically 
peroxisome proliferators-activated receptors (PPARs), sterol-regulatory element binding 
proteins (SREBPs), fatty acid binding proteins (FABPs) and inflammatory proteins, all of 
which will be discussed in the following sections. 
 77 
Many animal studies focus on young animals and involve n-3 deficiency or 
supplementation for several generations.  Two similar studies by Ikemoto et al. illustrate 
that rats fed an n-3 deficient (safflower oil as main fat source) diet for two generations 
supplemented with either DHA (2001) or EPA (2000) exhibit a restored level of DHA 
within the whole brain compared to control mice fed an n-3 sufficient diet.  The n-3 
deficiency led to increased levels of n-6 PUFAs, AA and 22:5n-6 within whole brain 
compared to supplementation with either DHA or EPA (Ikemoto et al., 2000; Ikemoto et 
al., 2001).  Gamoh et al. (2001) demonstrated that rats fed a fish oil-deficient diet for 2 
generations and subsequently supplemented with DHA showed a significant increase in 
DHA content and DHA/AA ratio within the cerebral cortex, with no difference between 
fatty acid levels within the hippocampus.  Similarly, Moriguchi et al. (2001) fed rats 
either an n-3 adequate or n-3 deficient diet for 2 generations.  The F2 generation rats on 
the n-3 deficient diet were weaned onto the n-3 adequate diet at 7 weeks of age and then 
groups were sacrificed immediately and every 2 weeks thereafter for 8 weeks.  
Specifically, this study measured the recovery rate of serum, retina, liver and brain of 
fatty acid levels after 2 generations on an n-3 deficient diet, as compared to being raised 
on an n-3 adequate diet.  For the serum, recovery of n-3 fatty acids to levels seen in the n-
3 adequate rats were accomplished after 2 weeks of switching diets.  The liver, was the 
most rapidly recovering of all the tissue measured in that liver n-3 levels were 
comparable to those of the n-3 adequate group after only 1 week.  In contrast, the brain 
had a slower recovery rate, such that even after 8 weeks of being fed an n-3 adequate 
diet, levels of DHA were still not comparable to the mice originally fed the n-3 adequate 
diet.  With a faster recovery than the brain, the retina had full recovery of DHA in the rats 
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that had been on the n-3 adequate diet for 8 weeks.  The authors analyzed the recovery 
rate for each of the tissues in order to normalize the data.  They found that the serum 
actually had the slowest recovery rate per tissue weight, which was most likely a 
reflection of the low content of DHA in the serum compared to the other tissues.  The 
brain and retina had higher recovery rates than the plasma with respect to tissue weight.  
Because of their higher recovery rates yet longer recovery time within the brain and 
retina; this indicates an inability in uptake or delivery of fatty acids to rapidly replenish 
these areas of the nervous system (Moriguchi et al., 2001).   
Even without generations of n-3 deficiency, many animal studies show significant 
changes in fatty acid composition within plasma or brain lipids following an n-3 deficient 
diet.  In general, rodents fed an n-3 deficient diet exhibit decreases in total n-3 PUFAs 
including DHA and EPA as well as increases in total n-6 PUFAs such as AA; diets 
enriched in n-3 fatty acids show the opposite results (Jensen et al., 1996; Minami et al., 
1997; Suzuki et al., 1998;  Wainwright et al., 1999; Lim & Suzuki, 2000; Petursdottir et 
al., 2002; Aid et al., 2003; Du et al, 2003;  Champeil-Potokar et al., 2004).  To date, there 
is minimal work being performed using AD transgenic mice to study effects of n-3 
deficiency or supplementation.  Hashimoto et al. (2002) did, however, experiment with 
rats infused with the Aβ1-40 peptide into the left ventricle to gain similar results that could 
be seen from an AD transgenic model.  Rats infused through osmotic minipumps with the 
Aβ1-40 peptide for 3 weeks  and supplemented with DHA for 12 weeks prior to Aβ 
infusion and continued for 3 weeks after infusion showed a decreased level of AA lipid 
content within blood plasma, the cortex, and the hippocampus compared to 
unsupplemented Aβ-infused rats.  There was also a higher level of DHA lipid content 
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detected in blood plasma, the cortex and the hippocampus of the Aβ-infused group with 
DHA supplementation.  The authors suggest that the decrease in AA for the DHA 
supplemented group could be due to a physical replacement of AA within blood plasma, 
the cortex, and the hippocampus by DHA or through an unexplained mechanism to 
decrease AA synthesis by increased DHA synthesis.  The study also found significant 
positive correlations between cortical and plasma DHA levels as well as between 
hippocampal and plasma DHA levels.  These two associations suggest a high degree of 
integration of DHA into the cortex and hippocampus from the plasma.  Rats that were 
infused with the Aβ1-40 peptide not supplemented with DHA exhibited decreased plasma 
DHA versus vehicle rats (Hashimoto et al., 2002).  This result is similar to that seen in 
patients with Alzheimer’s disease where plasma levels of DHA are decreased compared 
to age-matched non-demented control subjects (Conquer et al., 2000; Tully et al., 2003).   
A more recent study by Hashimoto et al. (2005) used rats fed a fish-oil deficient 
diet for 3 generations after which they were infused with either Aβ1-40 or vehicle.  Rats 
from each group were administered either DHA or vehicle and fatty acid levels in the 
plasma, cerebral cortex and hippocampus were determined.  The results were similar to 
those in the authors’ previous work, such that there was an increase of DHA and a 
reduction in AA content in all three regions analyzed for groups administered DHA 
irrespective of Aβ infusion.  In addition to fatty acid levels, the authors also measured 
oxidative stress in the cerebral cortex and hippocampus.  TBARS and ROS levels were 
increased in the Aβ-infused group compared to the remaining three groups.  These results 
suggest that infusion of Aβ1-40 is sufficient to produce oxidative damage to specific 
regions of the brain, so that administration of DHA reduced the levels of oxidative 
 80 
damage to those of the vehicle group.  The authors suggest that the reduction in AA 
content in the brain played a role in the ability for DHA to correct the oxidative damage 
generated by the infusion of Aβ1-40 (Hashimoto et al., 2005).   
Recently, Calon et al. (2004) fed 17 month old non-transgenic (Tg-) and Tg2576 
APP mice for ~3½ months a control diet, n-3 deficient safflower oil diet and n-3 deficient 
supplemented with DHA.  Analysis of the frontal cortex of the APP mice showed that the 
n-3 deficient diet resulted in a decreased amount of DHA content compared to the control 
and DHA-supplemented diets.  Also, the DHA-supplemented APP frontal cortex showed 
a decrease in the amount of AA compared to the n-3 deficient mice.  Within the Tg- 
mice, the DHA-supplemented group had an increased amount of DHA content and 
decreased AA content in the frontal cortex versus the n-3 deficient Tg- mice.   
Aside from frontal cortex fatty acid content, the study by Calon et al. (2004) also 
measured dendritic spine pathology.  Fractin is a caspase-cleaved fragment of actin that is 
labeled within dendrites of tangle-bearing neurons. The fractin/actin ratio was measured 
in the cortex of aged (22 month) APP mice in comparison to age-matched non-transgenic 
mice.  The APP mice had an increased ratio in the cortex however, the level of 
synaptophysin staining did not differ between the groups and the level of drebrin 
(dendritic spine actin-regulating protein), was decreased in APP mice.  In comparison, 
temporal cortex from AD brains showed decreased content of drebrin and synaptophysin 
in comparison to control brains.  To test the hypothesis that DHA directly plays a role in 
regulating caspase activity in the synapses of dendrites, Calon et al. (2004) measured the 
fractin/actin ratio in the cortex of APP and Tg- mice and found that DHA 
supplementation reversed the increased ratio of the control and n-3 deficient APP mice.  
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In order to determine if the caspase activity was induced by pre- or post-synaptic 
changes, drebrin (postsynaptic marker) was compared to SNAP-25 (presynaptic marker).  
The n-3 deficient APP mice exhibited a significant decrease of drebrin in the membrane 
fraction with an increase within the cytosolic fraction, leading the authors to conclude 
that drebrin is not a caspase substrate.  The cytosolic increase of drebrin is consistent with 
its retention by intact F-actin filaments.  The APP control and DHA-supplemented groups 
appeared to have opposite effects of drebrin versus the n-3 deficient diet group.  The 
postsynaptic marker, SNAP-25 did not differ between any of the groups indicating that 
caspase activity is not altered postsynaptically by n-3 deficiency or DHA 
supplementation.  In order to account for the presynaptic change associated with DHA 
supplementation, neuronal loss was examined.  Consequently, no differences in neuronal 
number were found in cortex or hippocampus between APP or Tg- mice despite dietary 
intervention (Calon et al., 2004).  Enrichment of mouse neuroblastoma cells with DHA 
showed a protection against apoptosis via phosphotidylinositol 3-kinase (PI3-K) (Akbar 
& Kim, 2002).  In order to determine this effect in an AD mouse model, Calon et al. 
(2004) measured the levels of a protein subunit of PI3-K protein, p85α.  The n-3 deficient 
APP mice showed a significant reduction on p85α in the cortex; DHA supplementation 
resulted in an increased amount of p85α compared to the n-3 deficient mice, but still 
significantly less that the controls.  From this, the authors suggest that n-3 depletion in 
APP animals disables the PI3-K pathway to prevent caspase activation which leads to 
postsynaptic pathology similar to that seen in AD subjects.   
Calon et al. (2004) also investigated oxidative stress markers following n-3 
depletion and DHA supplementation, as measured by dinitrophenylhydrazin (DNPH) 
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derivatized carbonyls in the cortex.  The n-3 deficient group exhibited an increased 
amount of carbonyls compared to the APP control and DHA-supplemented groups.  The 
authors conclude that caspase-mediated actin cleavage and loss of drebrin in an APP 
mouse model exhibiting AD pathology is regulated by n-3 PUFAs within the brain.  Also, 
DHA, specifically, is involved in maintaining the PI3-K pathway to decrease apoptosis; 
however, there were no differences in neuronal number found between any of the diet 
groups. 
Despite the lack of a DHA effect on the post-synaptic marker, SNAP-25, Calon et 
al . (2005) analyzed the effect of DHA on NMDA receptors within the same groups of  
APP transgenic mice .  Both n-3 deficient and DHA supplemented Tg+ mice had reduced 
levels of NR2A, NR2B receptors, as well as reduced calcium/calmodulin-dependent 
kinase II (CaMKII) within the cortex compared to control Tg+ mice.  Although, the DHA 
supplemented Tg+ mice had slightly elevated levels of NMDA receptor subtype 2A 
(NR2A), NMDA receptor subtype 2B (NR2B) and CaMKII, there was no significant 
difference between the dietary groups.  However, the authors state that the addition of 
DHA resulted in a protective effect with respect to the loss of NR2A, NR2B and CaMKII 
(Calon et al., 2005).   The authors offer no clear explanation as to how the n-3 depletion 
and DHA addition affected NMDA receptors.  However, evidence shows that an 
increased number of NMDA receptors can lead to increased learning and memory in 
transgenic mice (Tang et al., 1999).  Conversely, a reduction of NMDA receptor subtype 
1 (NMDAR1) in the hippocampus of mice led to impairment of spatial learning (Tsien et 
al., 1996).  The previous studies provide support for the improved memory that resulted 
from DHA supplementation as will be discussed in a later section.  However, Lesné et al. 
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(2005) showed that activation of NMDA receptors in cell culture led to an increase of 
calcium influx, thereby activating CaMK and increasing production of Aβ peptides.  
Although the present study examined in vitro conditions, the implication exists that an 
alteration of NMDA receptor activation in a system that is prone to Aβ production will 
result in over-secretion of toxic Aβ peptides, ultimately leading to cognitive impairment 
(Lesné et al., 2005).   
Lim et al. (2005) reported alterations of Aβ within 17 month old Tg2576 APP 
mice that were fed a control diet, n-3 deficient safflower oil diet and n-3 deficient 
supplemented with DHA for ~3½ months.  The DHA supplemented mice had reduced 
levels of insoluble Aβ as compared to the n-3 deficient group, but there was no difference 
with respect to control mice.  There were also no differences in soluble Aβ levels 
between any of the three groups.  Despite the lack of effect of soluble Aβ, the DHA 
supplemented group had an overall reduction in Aβ plaque burden compared to the n-3 
deficient mice.  However, there was no comparison between the DHA supplemented 
group and the control group with respect to plaque burden.  In addition, there was no 
difference in soluble Aβ, insoluble Aβ or Aβ40 between the DHA supplemented mice and 
the control APP mice, indicating minimal affects on Aβ by DHA.     
 
Human Studies Involving Fatty Acids.  
There have been numerous human trials examining fatty acid composition within 
blood or brain tissue of normal elderly and elderly subjects with dementia.  Payet et al. 
(2004) performed a study using non-impaired elderly subjects to simply measure the 
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incorporation of fatty acids into erythrocyte membranes and plasma.  DHA was 
supplemented for 9 months and resulted in a significant increase in total PUFAs within 
the blood mainly due to the increase of DHA and AA in the plasma and erythrocyte 
membranes.  The observed increase of AA could have been the result of an increased 
amount of this fatty acid within the DHA supplementation diet compared to the control 
group’s diet.  There was no follow-up to indicate changes in cognition or everyday 
function (Payet et al., 2004).  In a  similar study, Boston et al. (2004) administered EPA 
for 12 weeks to AD patients.  This study assessed cognitive improvement, as well as 
erythrocyte membrane composition of fatty acids both before and after treatment.  At 
baseline, erythrocyte membrane fatty acid levels did not differ between AD and non-
demented control patients.  In short, the 12 week period of EPA administration was 
unsuccessful at altering any of the cognitive measures.  However, treatment with EPA did 
result in significant increases in total n-3 fatty acids, specifically EPA and 22:5n-3 
(DPA), compared to baseline levels (Boston et al., 2004).   
In an earlier study, Tully et al. (2003) reported that low plasma levels of total n-3 
PUFAs (specifically DHA) were associated with an increased risk of developing AD.  
This is in opposition to the above study by Boston et al. (2004) who found no difference 
in blood fatty acid levels between AD and non-demented subjects.  The increased risk for 
AD with low plasma n-3’s as reported by Tully et al. (2003) could be attributed to a lack 
of protection against cardiovascular disease, an increased production of pro-inflammatory 
cytokines, or a lack of nervous system homeostasis due to low plasma DHA and/or total 
n-3 PUFA content that would normally protect against these pathologies.  Analysis of the 
MMSE scores of AD versus non-impaired subjects revealed that blood serum levels of 
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DHA and total saturated fat were significant predictors of AD (Tully et al., 2003).  
Engelhart et al. (2002a) found an association between risk of developing AD and an 
increased intake of total fat, saturated fat, transaturated fat and cholesterol.  However, 
there were no significant associations between intake of total PUFA, n-6, or n-3 and the 
risk of AD (Engelhart et al., 2002a).   Prior to much of the above information regarding 
the association between AD risk and n-3 intake/membrane content, Yehuda et al. (1996) 
showed that subjects with existing AD that were supplemented with SR-3 (which is a 
mixture of ALA and LA to yield a ratio of 4 to 1 of n-6 to n-3 fatty acids) had improved 
behavior, including enhanced short-term and long-term memory, more cooperation, better 
mood, increased appetite and more organization skills.  This paper suggests that many of 
the improved symptoms offer benefit to the patient as well as the caregiver. The authors 
do not propose a mechanism of action for this compound, but suggest that changes in 
neuronal membranes due to SR-3 could lead to increased function of the neuronal system 
thereby yielding the above improvements (Yehuda et al., 1996). 
Fatty acids, specifically DHA, rapidly incorporate into numerous different cell 
types, primarily into the phospholipids layers of their plasma membranes and 
mitochondria (Stillwell & Wassall, 2003).  Most human AD studies involving analysis of 
fatty acids measure plasma levels or post-mortem brain tissue phospholipid levels.  Early 
studies indicated that post-mortem brain tissue sections from subjects with AD or some 
other type of dementia had decreased levels of n-3 PUFAs, including ALA, DHA and 
EPA; decreases in n-6 PUFAs including AA and LA were also observed.  In 1998, 
Corrigan et al. reported lower levels of total n-3 PUFAs, specifically decreased ALA in 
the parahippocampal phosphotidylcholine (PC) fractions from AD brains.  The authors 
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suggest that the decrease in ALA is most likely due to a deficiency within the PC fraction 
to properly incorporate ALA into the phospholipid.  Because no other PL fraction 
contained a significant decrease of ALA, the difference could not be accounted for by a 
change in dietary intake or liver synthesis of FAs between AD and control subjects.  This 
study also found decreases in n-6 PUFAs, including AA, mainly within the 
phosphotidylethanolamine (PE) fraction of phospholipids of AD brains compared to age-
matched controls (Corrigan et al., 1998).   Prasad et al. (1998) also found a decreased 
level of AA in PE phospholipids, specifically within parahippocampal gyrus and the 
inferior parietal lobe of AD brain tissue compared to normal elderly brain tissue.  DHA 
was only found to be significantly below normal levels within the PE fraction of the 
parahippocampal gyrus and PC fraction within the cerebellum.  There were, however, 
decreased levels of total fatty acids in phospholipid classes within the parahippocampal 
gyrus and the inferior parietal lobe.  Also measured were phospholipids within the 
superior and middle temporal gyri, where the only difference was a decrease of oleic acid 
in AD brain tissue in comparison to control brain tissue.  This study also determined that 
there was a significant increase of senile plaque density within all three areas measured, 
parahippocampal gyrus, inferior parietal lobe and the superior and middle temporal gyri.  
The cerebellum contained only diffuse plaques.  One of the possible links between the 
presence of senile plaques and the decreases of various fatty acids could be due to 
changes in the biosynthesis or degradation of the membrane phospholipids.  The overall 
conclusion from Prasad et al. (1998) was that the changes in phospholipids content were 
due to the oxidative cascade present in AD brain tissue.  Previous studies have indicated 
that the Aβ peptide is a prominent source of free radical generation.  These free radicals 
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could be the source of oxidative damage to the phospholipids classes resulting in 
decreased levels of many of the fatty acids present in the membrane PLs.  Additional 
mechanisms that could impact membrane PL composition are neuronal loss, changes in 
ion channel function or cellular biosynthesis mechanisms all due to the presence of Aβ 
plaques or NFTs (Prasad et al., 1998).   
In contrast to both of the above studies, Skinner et al. (1993) found an increase in 
DHA in white matter of the parietal cortex from AD patients, in addition to an overall 
reduction in n-6 fatty acids in white matter of the frontal and parahippocampal cortices.  
However, this study also reported increases in adrenic acid (22:4n-6) in grey matter from 
the parietal, frontal and parahippocampal cortices, resulting in an increase of total n-6 
fatty acids in the grey matter of the frontal cortex.  The authors suggest that the changes 
in fatty acid composition between white and grey matter of the brain in AD patients could 
be due to an irregularity in the transportation of essential fatty acids to the brain (Skinner 
et al., 1993). 
Recent evidence shows that not only brain tissue but plasma levels of fatty acids 
are different between AD subjects and normal elderly control subjects.  AD subjects 
exhibit decreased plasma levels of DHA, EPA and total n-3 PUFAs in comparison to 
normal elderly controls (Conquer et al., 2000; Tully et al., 2003).  Tully et al. (2003) 
determined no significant difference in total n-6 PUFA content in plasma levels; Conquer 
et al. (2000), however, found that AD subjects had a significantly lower n-3 to n-6 fatty 
acid ratio within plasma with a significant increase in the level of total n-6 PUFAs.  The 
authors suggested that the mechanism by which these fatty acid levels become lower in 
AD subjects is simply a decrease in the dietary intake of these fatty acids (Conquer et al., 
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2000).  The authors also suggested that the lower levels could be due to an increase in the 
breakdown of DHA within the brain or a decreased amount within the plasma PC content 
which is the main source for plasma DHA.  DHA content was not measured within the 
liver, therefore decreased liver synthesis of DHA could also account for the difference in 
plasma levels.  Similar to Conquer, Heude et al. (2003) found a direct association 
between total n-6 fatty acids in erythrocyte membranes and risk of cognitive decline in a 
group of subjects during a 4 year study.  Likewise, this study also determined that 
subjects with increased levels of n-3 fatty acids had a reduced risk of cognitive decline.  
However, this study did not include any information regarding dietary intake, therefore 
the reasons for the changes in fatty acid levels is unknown and could be due to alterations 
in liver metabolism, intake or transportation of essential fatty acids throughout the body. 
Incorporating adequate amounts of omega-3 fatty acids into daily dietary intake is 
not plausible for the population as a whole.  Metcalf et al. designed a study to survey 
healthy individuals for their n-3 consumption by providing foods enriched with n-3 
PUFAs (2003).  This study showed that people could consume adequate amounts of n-3 
fatty acids in their diet to decrease plasma compositions of AA, LA and total n-6 fatty 
acids, as well as increase plasma levels of EPA, DHA and total n-3 fatty acids (Metcalf et 
al., 2003).  However, trying to incorporate everyday foods with n-3 fatty acids will 
probably never occur.  Kang et al. (2004) provided an alternative to enriching foods to 
obtain n-3 PUFAs.  As previously mentioned, mammals can not convert n-6 fatty acids 
into n-3 fatty acids; however integrating a fat-1 gene from C. elegans into a mouse allows 
this conversion to occur.  Transgenic mice carrying this gene fed an n-3 deficient/n-6 rich 
diet had a higher percentage of n-3 fatty acids in tissues (muscle, heart, brain, liver, 
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kidney, lung and spleen) compared to non-transgenic mice fed the same diet.  The n-6 to 
n-3 ratio within the transgenic mice was 1:1 whereas the non-transgenic ratio was 20-
50:1 (Kang et al., 2004).  This implies that dietary intake does not have to be altered in 
order to increase incorporation of n-3 fatty acids into tissues and plasma membranes.  
Yancy et al. (2004) and Stern et al. (2004) both show that a low fat diet results in less 
weight loss than a low carbohydrate diet at 6 months after dietary intervention.  The low 
carbohydrate diet allowed for unlimited amounts of animal foods which implies increased 
protein and fat intake.  This diet resulted in significantly more adverse side effects versus 
the low fat diet.  These side effects included increased headaches, muscle cramps, 
diarrhea, general weakness and rash (Yancy et al., 2004).  The low fat group was 
encouraged to decrease their fat intake to less that 30% of their daily energy.  This group 
over one year lost the same amount of weight as the low carbohydrate group; neither 
group had any significant adverse side effects (Stern et al., 2004).   
 
Neurochemical Effects of n-3 Fatty Acids. 
Incorporation of fatty acids from fish oil into neuronal membranes has been 
shown to increase neuronal sensitivity to oxidation.  Because of the high number of 
double bonds within DHA, it is more likely to be oxidized than other fatty acids, such as 
AA.  Peroxidation of PUFAs can lead to damage to genes, membrane lipids and 
enzymatic proteins.  Despite this, PUFA supplementation has been shown to correct the 
effects of oxidative stress by decreasing free radicals within the brain (Yehuda et al., 
2002).  Specifically, EPA can reduce reactive oxygen species (ROS) produced by lipid 
peroxidation by inhibiting the phospholipase A2 enzyme and stabilizing membrane 
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structure.  Lipid peroxidation products can contribute to neurodegeneration by inhibiting 
glutamate or glucose transport within the brain.  Supplementation with essential fatty 
acids for 30 days can decrease production of TBARS (end product of lipid peroxidation), 
xanthine oxidase (source of ROS) and nitric oxide (gaseous free radical) as well as 
increase superoxide dismutase (enzyme antioxidant) within the corpus striatum of adult 
rats (Sarsilmaz et al., 2003).  In addition, enhanced activation of catalase and glutathione 
peroxidase, enzymes that decrease ROS, were evident in macrophages from ApoE-KO 
mice fed a diet supplemented with fish oil.  These macrophages also had reduced levels 
of ROS and superoxide anion after treatment with fish oil back to normal levels (Wang et 
al., 2004).  Increased production of lipid peroxides occurs in cerebellum and some 
cortical regions with age and in certain neurodegenerative disease, such as AD.   
Specifically in AD, increased lipid peroxidation markers are detected within CSF, 
urine, plasma and the brain including all cortical lobes, hippocampus and cerebellum 
(Montine et al., 2004).  The free radical induced peroxidation of AA yields a 
prostaglandin F2-like compound named F2-isoprostane (F2-IsoP).  Peroxidation of EPA 
produces F3-IsoPs and peroxidation of DHA forms F4-IsoPs also known as F4-
neuroprostanes (F4-NP) because of their presence specifically within neurons (Roberts II 
et al., 1998; Nourooz-Zadeh et al., 1999).  In some regions, brains of AD patients 
undergo significantly more lipid peroxidation than normal aging controls (Montine et al., 
2004).  Using an indicator that could reflect the amount of DHA oxidation within the 
brain could be used as a marker for detecting AD.  Multiple studies have investigating the 
detection of DHA peroxidation within AD brains post-mortem and found significantly 
more F4-NPs in occipital and temporal lobes in addition to the cerebral cortex (Nourooz-
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Zadeh et al., 1999; Reich et al., 2001).  This provides a sensitive indicator for oxidative 
damage to neurons because of the high concentration of DHA within the neurons.  The 
peroxidation of DHA could be due to the outcome of the AD pathology or simply a 
predisposition to increase vulnerability to developing AD.  However, following brain 
ischemia-reperfusion, DHA is released from the phospholipids membrane via PLA2 and 
induces neuroprotection via suppression of pro-inflammatory cytokines, anti-apoptotic 
genes and formation of a novel docosanoid, NPD1 (Lukiw et al., 2005).  NPD1 (10, 17S-
docosatriene) is a bioactive DHA-derived lipid mediator.  Lukiw et al. (2005) found that 
in vitro production of Aβ was attenuated with addition of DHA to the medium.  The 
addition of DHA also produced an increase in NPD1 in these cultured cells, suggesting 
that the attenuation of Aβ peptide release could be partially due to the appearance of 
NPD1.  The authors also determined a dose-dependent increase of NPD1 by sAPPα in 
conjunction with DHA, suggesting a positive feedback regulation between sAPPα and 
the DHA/NPD1 pathway to protect cells against neuronal damage.  Lastly, Lukiw et al. 
(2005) found that NPD1 protected cultured cells from Aβ42-induced apoptosis by up-
regulating anti-apoptotic genes, Bcl-xl, Bcl-2 and Bfl-1(A1).   
Some research indicates that fish oil supplementation have anti-inflammatory 
actions, including decreases of some pro-inflammatory cytokines (IL-1β, IL-2, IL-6, 
TNF-α) and increases of anti-inflammatory cytokines (IL-10, TGF-β).  Few studies have 
focused on the effects of DHA and/or EPA specifically on inflammatory measures.  
Tomabe et al. (2000) showed that dietary DHA, but not EPA, supplementation resulted in 
a decrease of CD4-positive T lymphocytes to reduce ear swelling of mice with contact 
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hypersensitivity.  In addition, DHA decreased the expression of pro-inflammatory IFN-γ, 
IL-6, IL-1β and IL-2 mRNA within the ears (Tomobe et al., 2000).  
In contrast to the lack of effect on inflammatory cytokines by EPA by Tomobe, 
Komatsu et al. (2003) found that a high dose of EPA inhibited nitric oxide (NO) 
production by LPS-activated peritoneal macrophages from mice.  However, EPA did not 
have any effect on the inducible NO synthase (iNOS) protein.  Treatment with DHA 
resulted in a significant inhibition of NO production and iNOS expression by murine 
peritoneal macrophages dose-dependently.  The authors showed that the DHA treatment 
suppressed activation of the transcription factor nuclear factor (NF)–κB most likely 
through inhibition of intracellular peroxides induced by IFN-γ and LPS, which lead to the 
suppression of NO production and iNOS expression.  Within the macrophages, DHA 
treatment resulted in an up-regulation of intracellular glutathione (GSH); lowering GSH 
levels reversed the effects induced by DHA on NO production and NF-κB.  Therefore, 
the authors suggested that DHA inhibited NO production via suppression of NF-κB and 
mediated by an up-regulation of GSH (Komatsu et al., 2003).   Peritoneal macrophages 
from mice fed a control diet supplemented with menhaden fish oil for 15 weeks had 
decreased production of IL-1β and TNF-α in addition to a reduction of mRNA for IL-1β 
and TNF-α (Renier et al., 1993).  Billiar et al. (1988) found an anti-inflammatory 
response exhibited by decreased IL-1 production by Kupffer cells of rats fed a fish oil 
supplemented diet for 6 weeks.  N-3 PUFA supplementation, mainly DHA and EPA, in 
older women (51-68 years) for 3 months resulted in decreased production of all pro-
inflammatory cytokines measured in the blood, including IL-1β, TNF-α and IL-6 
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(Meydani et al., 1991).  Specifically, IL-2 expression was reduced as a result of a 
decrease in helper-T cells, with fish oil supplementation leading to an anti-inflammatory 
result.   In addition, there was an increase in the number of suppressor T cells detected 
that aid in the anti-inflammatory reaction by secreting IL-10 and/or TGF-β (Meydani et 
al., 1991).   
In some contrast to the above studies, Puskas et al. (2004) reported a combination 
of pro-inflammatory and anti-inflammatory effects within mice enriched with fish oil and 
cholesterol.  Puskas et al. (2004) fed mice a cholesterol-rich diet or a cholesterol-rich plus 
fish oil enriched diet for 2 months beginning at 4½  months of age.  Within whole brain 
of mice fed the cholesterol-rich diet with fish oil, the pro-inflammatory cytokines (IL-6 
and TNF-α) were down-regulated in addition to an anti-inflammatory cytokine, IL-10.  
Whereas within the retina, for the same group, an opposite result was seen, so that there 
was an up-regulation of TNF-α.  The authors suggested that the eye was more sensitive 
to the high fat content of the diet and therefore and increased pro-inflammatory gene 
expression in which the addition of fish oil was not able to correct.  However, the 
addition of the fish oil led to an overall anti-inflammatory result within the brains of mice 
fed a diet enriched with cholesterol plus fish oil, so the authors’ suggestion is unclear.  In 
addition, the positive effects expected by the fish oil could not be seen without including 
a group that was only administered fish oil without the addition of excess cholesterol.  
Without this group, it is difficult to draw conclusions without cholesterol confounding the 
results.  
Additional studies find that n-3 supplementation results in net pro-inflammatory 
reactions.  Lipopolysaccharide-stimulated macrophages from mice given fish oil 
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exhibited an increase in TNF-α secretion as well as a decrease of IL-10 secretion 
(Petursdottir et al., 2002).  Liver phospholipid content showed a significant increase of n-
3 PUFA content and a decrease of n-6 PUFA content in mice fed the fish oil supplement.  
The authors propose that the increased TNF-α secretion was mediated by a decrease in 
prostaglandin production. As discussed previously, AA and EPA can form prostaglandin 
intermediates; AA results in PGE2 whereas EPA synthesis can lead to PGE3 production.  
EPA and AA both compete for prostaglandin synthesis so that increased amounts of n-3 
fatty acids (e.g. EPA) displace production of PGE2 by production of PGE3.  However, 
PGE3 is not as mitogenic or inflammatory as PGE2 (Bagga et al., 2003).  An additional 
study reported an inverse relation between PGE2 production and TNF production in LPS-
stimulated macrophages from mice fed a diet with a high n-3 to n-6 ratio (Watanabe et 
al., 1993).  The authors suggested that PGE2 was acting as a negative feedback effector 
on TNF-α production; decreased TNF-α production from n-3 enriched macrophages 
concomitantly with increased production of PGE2.  However, no established mechanism 
was suggested to explain the inverse relationship.  It is therefore difficult to determine the 
mechanism responsible for this pro-inflammatory response from fish oils.  In support of 
the findings by Petursdottir, Wallace et al. (2003) found that fish oil supplementation to 
healthy adults (18-39 years of age) resulted in a significant increase of IL-6 expression in 
blood mononuclear cells.  There were no other changes evident in any of the other 
cytokines (TNF-α, IL-1β, IL-2, IFN-γ) or inflammatory markers (T- and B-cell 
lymphocytes).  The authors concluded that the dosage was not high enough to induce 
changes in additional cytokine production (Wallace et al., 2003).  Overall, the 
mechanisms that PUFAs use to induce changes in the inflammatory cascade are 
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unknown, but it appears that dosages and duration of fish oil enrichment highly affect 
cytokine production positively and negatively. 
DHA has also been shown to have effects on the cholinergic system.  Increased 
aging results in decreased ACh levels in hippocampus, striatum (Ikegami et al., 1992), 
cingulate cortex (Baxter et al., 1999) and pyramidal neurons of the cerebral cortex (Casu 
et al., 2002); in addition there is an age-related decrease of DHA incorporation into 
membrane phospholipids within the whole brain, and specifically the hippocampus 
(Bacelo-Coblijn et al., 2003l; Favreliere et al., 2003). The mechanism whereby DHA 
affects the cholinergic system is not well understood.  A study by Jones et al. (1997) 
showed that an intravenous injection of a cholinergic agonist, arecoline, resulted in 
increased incorporation of DHA into membrane phospholipids and microsomal fractions 
within the rat brain after intravenous infusion of DHA.  There was no change in response 
to an injection of saline or in combination with palmitic acid.  The possible pathway 
involves the activation of phospholipase A2 by arecoline to induce the release of DHA 
from the phospholipid PE, the main storage site of DHA (Jones et al., 1997).  This 
suggests that the reduction in ACh levels leads to decreased DHA incorporation into 
neuronal membranes within the brain during aging.   
Multiple studies illustrate the effect of DHA supplementation on the age-
dependent dysfunction of the cholinergic system.  PET scanning of the somatosensory 
cortex of aged monkeys fed a diet enriched with DHA showed a significant increase in 
their regional cerebral blood flow (rCBF) compared to control fed monkeys (Tsukada et 
al., 2000).  Previous work has demonstrated that the cholinergic system induces an 
increase in rCBF so that the addition of a cholinergic antagonist resulted in decreased 
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rCBF.  Overall, the authors propose that the change in the rCBF is due to the ability of 
DHA to modulate neuronal activation via the cholinergic system; specifically they 
speculate that DHA acts directly on cholinergic receptors to facilitate signal transduction 
and increase rCBF (Tsukada et al., 2000).  Additional rodent studies also show that 
dietary supplementation of DHA for 3 months to aged (18 month) rats reverses an age-
dependent cholinergic dysfunction so that basal ACh levels are similar to those of young 
rats (Favreliere et al., 2003).  In stroke-prone spontaneously hypertensive rats, a 
significant increase in basal ACh levels in hippocampus and cortex is seen with the 
addition of DHA to the diet.  Under control conditions these mice exhibit a dysfunction 
of the cholinergic system; DHA supplementation reversed that dysfunction (Minami et 
al., 1997).  However, Aid et al. (2003) found that rats fed an n-3 deficient diet also 
increased basal ACh within the hippocampus compared to control fed rats.  The authors 
suggested that this increase could be due to an increased release or decreased catabolism 
of ACh within the synaptic cleft due to changes in neuronal membrane composition 
which affects ion channels and therefore ACh levels (Aid et al., 2003). A diet rich in 
DHA results in increased KCL-induced release of ACh from the right ventral 
hippocampus in aged rats compared to aged rats on a control diet (Favreliere et al., 2003).  
The authors suggest that this release could be due to an increase of synaptic transmission 
or a decrease of membrane rigidity due to DHA incorporation into the plasma membrane.  
Similar to these results, an n-3 deficient diet results in decreased KCL-induced ACh 
release in hippocampus compared to control-fed rats (Aid et al., 2003).   
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Effects of n-3 Fatty Acids on 2nd Messengers. 
N-3 and n-6 fatty acids have been shown to impact intracellular signaling, 
including second messenger systems.  Briefly, within the visual transduction pathway, G 
protein (Gt) is activated by coupling to metarhodopsin (MII), resulting in closure of 
cGMP-gated channels within the rod outer segment (ROS) and induction of the neuronal 
response to light.  Specifically, rhodopsin is photoactivated into MII by absorption of a 
photon of light and subsequently coupled to Gt.  This coupling activates a cGMP-specific 
phosphodiesterase (PDE); hydrolysis of cGMP leads to closing of the cGMP-gated 
channels, changes in the transmembrane potential, and initiation of the neuronal response 
to light (Salem et al., 2001).  MII formation has been determined to be a function of 
phospholipid acyl chain unsaturation; thus, DHA-enriched phospholipids from ROS 
membranes of rats raised on an n-3 adequate diet result in an increase of MII formation 
(Mitchell et al., 2003).  Also, the rate of coupling of MII to Gt is increased in DHA-
enriched bilayers compared to less unsaturated phospholipids.  Conversely, the activity of 
PDE from ROS membranes of rats raised on an n-3 deficient diet was decreased 
(Mitchell et al., 2003).  Also, the inclusion of cholesterol in ROS membrane bilayers 
results in a decrease of MII formation and PDE activation, in addition to a slower 
coupling of MII to Gt.  The addition of cholesterol in conjunction with DHA, however, 
results in increases of MII formation and PDE activation as well as a faster coupling of 
MII to Gt (Litman et al., 2001).  The authors conclude that DHA promotes optimal 
functioning of the G-protein coupled signaling pathway in the retina and suggest that a 
deficiency of n-3 fatty acids, specifically DHA, could lead to a decreased efficiency in 
related neurotransmitter functioning and the visual signaling pathway.   
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Cyclic AMP and GMP activation have also been implicated as being affected by 
DHA and/or EPA enrichment.  Cultured neonatal rat ventricular myocytes were grown in 
a DHA- or EPA-enriched medium (Picq et al., 1996).  Cultures from both fatty acids 
resulted in increased basal levels of cAMP and more prominently cGMP.  Also, 
stimulation of cGMP was increased in n-3 enriched myocytes (Picq et al., 1996).  
Likewise, cultured rat myocardial cells have been studied to determine the impact of 
DHA or EPA incubation on adrenoceptor function (Grynberg et al., 1995).  Incubation 
with either fatty acid resulted in similar n-6 to n-3 ratios within the cultured cells.  
However, the DHA-enriched cells showed a significantly higher stimulation of beta-
adrenergic receptors with no change in the actual number of receptors.  Also, DHA 
enrichment resulted in a decreased affinity of the beta-receptor for the ligand, 
dihydroalprenolol, and a decrease in beta-adrenergic induced cAMP production.  To 
account for the enhanced stimulation of beta-adrenergic receptors and decrease of cAMP 
production, the authors incubated the myocardial cells with a permeant analogue of 
cAMP in conjunction with DHA; this resulted in a positive chronotropic response.  
Overall, they concluded that DHA enrichment of rat myocardial cells results in a positive 
effect on beta-adrenergic transduction via an increase of cAMP efficiency (Grynberg et 
al., 1995).  In addition to the affect of DHA and/or EPA on cAMP and cGMP, activation 
of the cAMP pathway affects DHA release from rat brain astrocytes (Strokin et al., 
2003).  Because astrocytes are a source of DHA synthesis for the CNS, the study 
investigated the role of specific second messengers on DHA release for use in the CNS.  
Initially, addition of ATP to astrocytes stimulated release of DHA mediated by a Ca2+-
independent phospholipase A.  Additional neurotransmitters which cause comparable 
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release of DHA were bradykinin, glutamate and thrombin.  Adenylyl cyclase, protein 
kinase A (PKA) and cAMP all caused an increased release of DHA, which is blocked by 
inhibitors of adenylyl cyclase and PKA (Strokin et al., 2003).  Despite the data to support 
the relationship between n-3 fatty acids and second messenger systems, such as cAMP 
and cGMP pathways, no strong evidence is shown to illustrate a mechanism causally 
linking fatty acids to these intracellular systems. 
In addition to inducing effects on cAMP, DHA has also been shown to affect Ca2+ 
and Na+ channels.  PUFAs have previously been shown to inactivate voltage-gated 
sodium channels so that cardiac myocytes remain in a hyperpolarized state, similar to the 
effect seen by local anesthetics and anticonvulsant drugs (Xiao et al., 1995).  Similarly, 
Vreudgenhil et al. (1996) showed that incubation of rat CA1 pyramidal neurons with 
either DHA or EPA resulted in a decrease in neuronal excitability via inactivation of 
voltage-gated sodium and calcium.  Monounsaturated fatty acids, saturated fatty acids 
and LA were also incubated with the CA1 neuronal cells, but did not result in any change 
in neuronal excitability or sodium or calcium currents (Vreudgenhil et al., 1996).  This 
implies that some specific mechanism is utilized by DHA and EPA to alter voltage-gated 
sodium and calcium channels.  Bonin and Khan (2000) illustrate that DHA induces a 
mobilization of calcium from intracellular stores in the endoplasmic reticulum pool by 
the opening of Ca2+ release-activated Ca2+ (CRAC) channels.  Human (Jurkat) T-cells 
were cultured and incubated with either AA, EPA or DHA.  DHA induced a dose-
dependent calcium release intracellularly resulting in a spike with eventual return to 
baseline concentration; minimal response was seen with EPA and AA.  DHA was also 
shown to cause an increase in intracellular calcium concentration, exhibited by refilling 
 100 
of the ER pools.  This effect was independent of IP3, an intracellular messenger that 
facilitates the opening of calcium channels on the ER to refill the intracellular pools.  
However, the effect of DHA was found to be a result of increased influx of extracellular 
calcium through CRAC channels.  Overall, DHA has the ability to influence intracellular 
calcium concentrations via CRAC channels and can therefore influence additional 
intracellular systems.   
Gene expression can also altered by the addition of a fish oil-rich diet.  Fish oil 
supplementation to two-year old male Wistar rats for 1 month resulted in a significant 
increase in the expression of transthyretin (TTR) within the hippocampus (Puskas et al., 
2003).  Barcelo-Coblijn et al. (2003) also found an up-regulation of TTR in whole rat 
brains after supplementation with a fish oil-enriched diet.  TTR is a thyroid hormone 
transport protein that is secreted by hepatocytes into the serum, and by the choroids 
plexus into the cerebral spinal fluid (CSF).  Importantly, previous studies have shown 
that TTR inhibits aggregation of Aβ within the CSF (Schwarzman & Goldgaber, 1996) 
and binds to insoluble Aβ to prevent polymerization into plaques (Redondo et al., 2000).  
AD transgenic mouse models that exhibit Aβ plaques do not exhibit other 
neuropathologies observed in AD human subjects, such as neurofibrillary tangle 
formation or the neuronal loss characteristic in AD.  However, APP transgenic mice 
express high levels of α-secretase cleaved APP (sAPPα) and TTR.  However, infusion of 
an antibody, into the midscapular region, against TTR into the aged (18 month) APP 
mouse resulted in increased Aβ accumulation, tau phosphorylation, neuronal loss and 
apoptosis all within region CA1 (Stein et al., 2004).  The authors concluded that TTR 
expression is protective in the APP transgenic mouse against some of the 
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neuropathologies present in AD human subjects, mainly Aβ deposition, neuronal loss and 
abnormal tau phosphorylation.  Likewise, human AD subjects express lower levels of 
TTR compared to age-matched non-demented control subjects (Stein et al., 2004).  
Therefore, fish oil supplementation could induce an increase of TTR expression and in 
turn provide protective benefits against AD neuropathological progression. 
In addition to alterations in TTR expression, changes in peroxisome proliferator-
activator proteins (PPARs), sterol-regulatory element-binding proteins (SREBPs), and 
fatty acid binding proteins (FABPs) have been observed with fish oil supplementation.  
Puskas et al. (2004) fed 4½  month old mice for 2 months standard chow, a cholesterol-
rich diet or a combined diet of high cholesterol plus fish oil.  There was an up-regulation 
of PPAR-α and PPAR-γ within the whole brain of the mice fed the combined diet 
compared to standard-fed mice.  However, there was also an up-regulation of PPAR-α in 
the brain of mice fed the cholesterol-rich diet as well.  PPARs play an important role in 
regulating lipid and glucose metabolism and are activated by a diversity of ligands, 
specifically including PUFAs and fatty acid metabolites.  PPAR-α has been shown to 
increase fatty acid catabolism, thereby having an overall lipid lowering effect (Schmitz & 
Langmann, 2005).  This effect was most likely in response to the increased intake of 
cholesterol despite fish oil supplementation.  However, PPAR-γ was up-regulated within 
the combined diet group only.  PPAR-γ regulates genes that control cell proliferation and 
differentiation and is highly concentrated in adipocytes (Schmitz & Langmann, 2005).  
The authors offer no direct explanation for the changes in PPAR gene expression 
between the diets (Puskas et al., 2004).  There was also an up-regulation of retinoid X 
receptor-γ (RXR-γ) in the whole brain of the mice fed the combined diet of cholesterol 
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and fish oil versus the standard diet.  RXR-γ is increased during neuronal maturation, 
implicating an important role during development.  In addition, RXR-γ is also implicated 
in working memory function related to the frontal and perirhinal cortices (Wietrizych et 
al., 2005).  However, Puskas et al. (2004) did not behaviorally evaluate these animals, 
thereby not determining if the increase in RXR-γ is sufficient to provide cognitive 
benefit.   
SREBPs are essential in maintaining fatty acid and cholesterol homeostasis.  
Within the different isoforms, the main role for  SREBP-1a is to regulate lipogenesis and 
cholesterol synthesis proteins, while SREBP-2 regulates genes involved in cholesterol 
metabolism.  In Puskas et al (2004), mice fed the cholesterol-rich diet had increased 
expression of both SREBP-1a and SREBP-2 within whole brain and retina as compared 
to the standard fed mice.  In contrast, the addition of the fish oil to the cholesterol diet 
returned these levels back to those found from the standard-fed mice.  Therefore, the 
addition of the fish oil attenuated the affect induced by the high cholesterol within both 
brain and eye of these mice. 
Lastly, Puskas et al. (2004) measured different forms of FABP within the brain 
and eye.  Of the four types of FABPs measured (brain, epidermal, liver, and heart), the 
cholesterol-rich diet did not alter any of these proteins.  However, addition of fish oil to 
the cholesterol-rich diet induced an increased expression of both epidermal FABP and 
heart FABP in both the whole brain and retina.  Because FABPs regulate fatty acid 
content in various tissues (Verekamp & Zimmerman, 2001), the authors suggested that 
the FABPs compensated for the addition of the fish oil which caused an accumulation of 
fatty acids in the retina and the brain (Puskas et al., 2004). 
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Effects of n-3 Fatty Acids on LTP. 
Long-term potentiation (LTP) has been associated with learning and memory 
functions.  Increased aging is also associated with a decline of learning and memory and 
therefore also with an impairment of LTP.  The mechanism involved in the age-
dependent impairment of LTP is not know, however the possible mechanism could 
involve a decrease in the release of glutamate which normally assists in maintaining LTP 
within the perforant path of CA1 of the hippocampus (McGahon et al., 1999; Martin et 
al., 2002).  As previously mentioned, increased aging is associated with a reduction of 
PUFA concentration within the neuronal membranes which leads to a decrease of 
membrane fluidity.  This factor could contribute to the decreased release of glutamate and 
impaired LTP seen in aged individuals.  Supplementation of PUFAs including AA+GLA, 
EPA (Martin et al., 2002) and DHA (McGahon et al., 1999) to aged rodents results in a 
reversal of the age-related impairment of LTP.  Specifically, the effect by DHA is 
proposed to involve increasing membrane fluidity to affect neurotransmitter release 
(McGahon et al., 1999). Within the dentate gyrus (DG), DHA induced an excitatory 
effect on the excitatory post-synaptic potentials (EPSPs), but did not affect LTP within 
this region (Itokazu et al., 2000).  The authors suggested that the effect of DHA on the 
EPSPs is mediated through potassium channels.  DHA has previously been shown to 
block potassium channels which is abolished by the presence of zinc (Poling et al., 1995).  
Because zinc is more abundant within DG, the effect of DHA on potassium channels to 
cause a stimulatory effect on EPSPs should have been inhibited in DG.  However, the 
authors’ saw a stimulation of EPSPs with DHA.  Thus, their explanation of results is 
flawed and is contradictory to the role of potassium channels as having inhibitory effects 
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on neurons.  DHA, in combination with zinc in the DG, should have resulted in an overall 
inhibitory effect on EPSPs, not excitatory, if their explanation was correct.  In contrast to 
the DG, within region CA1 the addition of DHA induced a dose-dependent inhibitory 
effect on EPSPs (Itokazu et al., 2000).  Previous work has shown that DHA promotes the 
opening of NMDA receptors via a DHA-binding site on the receptor; however addition of 
an NMDA antagonist does not affect the EPSP in DG or CA1 resulting from 
supplementation with DHA (Itokazu et al., 2000).  Young et al. (2000) also showed that 
DHA can act independent of the post-synaptic NMDA receptor.  The authors suggest that 
DHA blocks sodium channels to stabilize presynaptic membranes at the resting 
membrane potential in order to decrease glutamate release which would lead to an 
inhibition of EPSPs (Young et al., 2000).  Because of maintenance of the resting 
membrane potential, Ca2+ would not be released from intracellular stores to bind to 
glutamate autoreceptors, thereby decreasing a release of glutamate from the presynaptic 
cell.  Overall, n-3s, specifically DHA, have been shown to have an inhibitory affect on 
EPSPs primarily through closures of sodium and potassium channels. 
 
Behavioral Effects of n-3 Fatty Acids in Animals. 
Numerous animal studies show associations between n-3 or n-6 intake and 
behavioral performance, as seen in Table 1 below.  In reference to general locomotor 
activity, Carrie et al. (2000) showed that sardine oil supplementation for 2 generations 
resulted in an increase of activity in F2 young (7-11weeks) mice, where adult (9-10 
months) and aged (17-19 months) mice showed no difference with respect to palm oil fed 
animals.  In contrast, Chalon et al. (1998) also found that fish oil supplementation for 2 
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generations decreased activity in young (2 month) rats.  Within the same study, there 
were no differences in entries or time in open arm for the elevated plus maze task with 
young rats either fed a diet enriched with fish oil or control diet (Chalon et al., 1998).  
Rats that underwent surgery that occludes the common carotid arteries (2VO) had 
impaired spatial learning abilities.  De Wilde et al. (2002) showed that n-3 PUFA 
administration from 3 weeks to 4 month of age to 2VO rats did not result in any 
differences seen in the elevated plus maze task at 5 months of age in comparison to 
vehicle control rats. 
Changes in learning and memory performance are also associated with n-3 dietary 
intake.  Ikemoto et al. (2001) weaned 1-month old rat pups onto either a diet 
supplemented with DHA or safflower oil from dams fed a safflower oil rich, n-3 
deficient, chow.  Between 11 and 18 weeks of age the rats were tested in a brightness 
discrimination task.  Rats that received DHA supplementation performed similarly to rats 
not supplemented with DHA (Ikemoto et al., 2001).  This shows that the cognitive 
impairment measured by a brightness discrimination task caused by an n-3 deficient diet 
is not reversible.  Impairment present in stroke-prone spontaneously hypertensive 
(SHRSP) rats was also reversed for a passive avoidance test (Minami et al., 1997).  In 
that study, SHRSP rats were given either a control diet with 0, 1 or 5% DHA beginning at 
1½ months of age for 3½ months.  SHRSP rats fed the DHA had increased latency (better 
memory) in passive avoidance testing compared to SHRSP rats fed 0% DHA (Minami et 
al., 1997).  In another study, Carrie et al. (2000) showed that young rats (2-3 months) fed 
a diet enriched with sardine oil for 2 generations showed an increase in active avoidance 
performance compared to young control rats only on day 1 of the 5-day task, indicating a 
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lack of an overall effect of the sardine oil enrichment.  There were also no differences in 
active avoidance performance between sardine oil supplemented and control diet groups 
composed of adult and aged rats (Carrie et al., 2000).  Consistent with Carrie et al. 
(2000), de Wilde et al. (2002) found that adult (5 month) 2VO rats given dietary DHA 
and EPA since 1½ months of age showed no difference in active avoidance compared to 
non-supplemented and vehicle control rats.  In another study, Hashimoto et al. (2002) 
administered a shuttle avoidance task, similar to active avoidance, to adult (9-month) rats 
that had been fed a DHA rich or control diet for 3 months followed by either sham 
surgery or infusion of the Aβ1-40 peptide into the left ventricle.  The avoidance task was 
given 1, 2 and 3 weeks after the surgery.  The Aβ-infused mice were impaired in this task 
compared to the vehicle infused mice.  Notably, DHA administration significantly 
improved avoidance learning for both the sham and Aβ-infused groups compared to both 
groups with no DHA supplementation (Hashimoto et al., 2002). 
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Table 1.  Summary of behavioral studies involving n-3 deficiency or supplementation to 
rodents. 
Study Animal Model 
Dietary 
Supplementation 
Duration of 
Supplementation Task Results 
Barcelo-
Coblijn 
et al., 
2003 
2M and 
24M rats 
Fish oil or control 1 M Morris 
water 
maze 
No effect on 
acquisition 
or retention 
Calon et 
al., 2004 
Tg2576 
APP and 
NT mice 
n-3 deficient  supplemented 
with DHA 17M 
to 22M 
Visible 
platform 
No effect  
    Morris 
water 
maze 
Tg+ DHA 
improved 
acquisition; 
no effect on 
retention 
Carrie et 
al., 2000 
Mice Sardine oil or 
Palm oil 2 
generations 
Young (2-3M) 
Mature (9-10M) 
Old (17-19M) 
Open 
Field 
Young 
sardine 
increased 
activity 
    Active 
Avoidan
ce 
No effect 
    Morris 
water 
maze 
Mature 
sardine  
increased 
time in 
former 
platform 
quadrant 
above 
chance 
Chalon 
et al., 
1998 
Wistar 
rats  
Fish oil or control 
2 generations 
2M Open 
Field 
Fish oil  
decreased 
ambulation 
    Elevated 
plus 
maze 
No effect 
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Table 1 (Continued). 
Study Animal Model 
Dietary 
Supplementation 
Duration of 
Supplementation Task Results 
De 
Wilde et 
al., 2002 
Bilateral 
carotid 
occlusio
n in 4M 
rats 
n-3 PUFAs or 
control 
1M to 7M Elevated 
plus 
maze at 
5M 
No effect 
    Active 
avoidan
ce at 5M 
No effect 
    Morris 
water 
maze at 
7M 
No effect on 
acquisition 
or retention 
Gamoh 
et al., 
2001 
Wistar 
rats 
Fish oil deficient 
for 3 generations 
DHA supplement 
from 24M to 
26½M 
8-arm 
radial 
maze at 
25½M 
No effect 
Hashim
oto et 
al., 2005 
Aβ1-40 
infused 
rats 
Fish oil-deficient 
for 3 generations 
DHA supplement 
from 8½-12M  
8-arm 
radial 
maze at 
10½M 
DHA had 
increased 
reference & 
working 
memory 
Hashim
oto et 
al., 2002 
Aβ1-40 
infused 
rats 
Fish oil-deficient 
3 generations 
DHA supplement 
from 6M to 9M 
Shuttle 
avoidan
ce at 9M 
DHA had 
increased 
avoidance 
learning 
Ikemoto 
et al., 
2001 
Donryu 
rats 
Safflower oil or 
Perilla oil (high 
n-3) 2 generations 
1M to 3M 
supplemented 
safflower diet 
with DHA  
Brightne
ss 
discrimi
nation  
No effect 
Jensen 
et al., 
1996 
Wistar 
rats 
Seal oil; fish oil; 
vegetable oil; 
control for 4 
generations 
3M Morris 
water 
maze 
No effect on 
acquisition 
or retention 
Lim & 
Suzuki, 
1999 
Young 
mice 
(1M); 
Aged 
mice 
(14M) 
DHA or palm oil 5 months 
supplementation 
Maze 
learning
-3 trials 
DHA 
decreased 
errors & 
latency for 
selected 
trials 
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Table 1 (Continued). 
Study Animal Model 
Dietary 
Supplementation 
Duration of 
Supplementation Task Results 
Lim & 
Suzuki, 
2000 
Mice DHA or palm oil 
Beginning at 3M 
for ¼, ½, 1 or 3M Maze 
learning
-3 trials 
DHA 
decreased 
errors & 
latency for 
selected 
trials 
Minami 
et al., 
1997 
SHRSP 
rats 
0, 1, 5%DHA 1½  M to 5M Passive 
avoidan
ce 
SHRSP+DH
A had 
increased 
avoidance 
learning 
Sugimot
o et al., 
2002 
Mice DHA or control 9M to 11M 8-arm 
radial 
maze 
DHA 
increased 
working 
memory 
Suzuki 
et al., 
1998 
mice Sardine oil or 
palm oil 
Beginning at ¾M 
for 12M 
Maze 
learning
-3 trials 
Sardine oil 
decreased 
errors/latenc
y for initial 
trials 
Wainwri
ght et 
al., 1999 
Artificia
lly 
reared 
rats 
0-2.5% DHA/AA 
combinations 
Postnatal day 5 to 
1½M 
Morris 
water 
maze 
No effect on 
acquisition 
or retention 
Abbreviations: M, month; NT, non-transgenic mouse; Tg+, APP transgenic mouse; 
DHA, docosahexaenoic acid; PUFAs, polyunsaturated fatty acids; SHRSP, stroke-prone 
spontaneously hypertensive rats; AA, arachidonic acid. 
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Aside from avoidance tasks, spatial maze learning is a good indicator of both 
reference and working memory.  Sugimoto et al. (2002) found a decrease in working 
memory errors in the eight-arm radial maze for adult (9 months) mice supplemented with 
a DHA-rich diet for 2 months compared to unsupplemented control mice; there was, 
however, no difference in reference memory errors.  Gamoh et al. (2001) showed no 
overall improvement in performance in the same task with aged rats administered DHA 
from 24 months to 26½ months of age after two generations on a fish oil-deficient diet.  
Eight-arm radial maze learning, assessed by 3 trials per day for 3 separate days, 
beginning around 25 months of age for 5 weeks showed no difference in working or 
reference memory with DHA supplementation compared to rats without this supplement 
(Gamoh et al., 2001).  More recently, Hashimoto et al. (2005) fed a fish oil-deficient diet 
to rats for 3 generations.  At 5 months of age, the F3 generation rats were either infused 
through osmotic minipumps with Aβ1-40 or vehicle alone for 5 weeks.  Subsequently, rats 
from each group were administered either oral DHA or vehicle for 7 weeks and then 
tested in the eight-arm radial maze for 5 weeks.  Overall, DHA administration improved 
reference and working memory in both vehicle and Aβ-infused groups (Hashimoto et al., 
2005). 
Utilizing a different task involving maze learning, Suzuki et al. (1998) 
supplemented 3-week old mice for 12 months with sardine oil.  Maze learning was 
assessed by 3 trials administered 4 days apart using a simple maze construction with one 
entry/exit and many blind alleys.  Suzuki et al. (1998) found decreased latency and errors 
for trials 1 and 2; by trial 3 the palm oil fed mice exhibited a similar performance.   A 
similar study by Lim and Suzuki (1999) fed DHA-enriched or palm oil-enriched diets to 
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3-month old and 14-month old mice for 5 months, followed by 3 trials of maze learning 
with the same protocol used by Suzuki et al. (1998).  The young mice supplemented with 
DHA showed decreased latency and errors only on trial 2, whereas the aged mice 
supplemented with DHA showed decreased latency and errors on trials 2 and 3 (Lim & 
Suzuki, 1999).  Similar to the above maze studies, young mice (3 months old) were fed 
DHA enriched diet or palm oil enriched diet for 1 week, 2 weeks, 1 month, or 3 months 
then tested for the same maze learning as previously discussed (Lim & Suzuki, 2000).  
The mice fed the DHA enriched diet for 1 and 3 months had decreased errors and latency 
only in trial 3 compared to palm oil enriched mice (Lim & Suzuki, 2000).  The above 
results, performed with DHA administration for different durations, suggest that n-3 
enrichment can improve cognitive performance at any age, although the data are far from 
conclusive.   
A major task used to evaluate spatial learning/ memory among rodents is the 
Morris water maze.  This task provides measures for reference learning during 
acquisition and memory retention during the probe trial.  Jensen et al. (1996) showed that 
rats fed fish, seal, or vegetable oil-rich diets for 4 generations had a trend toward 
improved performance in the Morris water maze versus rats fed a control diet; however 
there were no differences between the groups in cognitive performance.  The fish oil 
group had an insignificant decrease in acquisition latency at 3 months of age during the 
9-day task with no overall difference within any of the groups (Jensen et al., 1996).  In 
conjunction with the lack of effect from fish oil supplementation by Jensen et al. (1996), 
Barcelo-Coblijn et al. (2003) found that 3-month old rats that had been fed a diet enriched 
with fish oil for 1 month showed no overall differences in Morris water maze 
 112 
performance (acquisition or retention) between the enriched versus control groups.  
Within the same study, there was also no difference in Morris maze acquisition or 
retention performance in 24 month old rats fed a fish oil supplement for 1 month versus 
control fed rats (Barcelo-Coblijn et al., 2003).   
In another study, artificially reared rats were fed milk supplements with 0 to 2.5% 
DHA and/or AA in combination from postnatal day 5 to postnatal day 18 (Wainwright et 
al., 1999).  After postnatal day 18, rats were weaned onto diets that contained identical 
amounts of DHA and AA compared to the milk substitutes.  At 1½ months of age, rats 
supplemented with DHA and/or AA showed similar latencies to controls during Morris 
water maze acquisition and retention testing; thus, no effect of DHA and/or AA was 
observed (Wainwright et al., 1999).  In addition to open field and active avoidance, 
Carrie et al. (2000) used the Morris water maze to evaluate cognition in young (2-3 
months), mature (9-10 months) or old (17-19 months) mice administered fish oil 
supplementation (sardine oil) or a palm oil enriched diet over two generations.  This 
study found no difference in acquisition between any of the groups; however, only 
mature mice fed the sardine oil diet showed significant memory retention during the 
probe trial, as indicated by their spending more time than chance in the former platform-
containing quadrant (Carrie et al., 2000).   
Clearly, Morris water maze acquisition and retention cognitive performance does 
not seem be strongly affected by generations of fatty acid-supplemented diets in non-
transgenic mice.  Likewise, 17-month old Tg2576 APP transgenic and non-transgenic 
mice fed an n-3 deficient diet with or without DHA enrichment for ~3½ months showed 
no differences in latency in visible platform testing (Calon et al., 2004).  Within the first 
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3 blocks of visible platform testing, the non-transgenic mice supplemented with DHA 
showed improved performance, as exhibited by a decreased latency compared to the non-
transgenic mice on a low DHA diet.  During Morris water maze testing, in the same 
study, APP mice fed the n-3 deficient diet showed impaired spatial learning only over the 
last two blocks of testing, days 7-9 and 10-12, compared to APP mice supplemented with 
DHA and non-transgenic mice with or without DHA enrichment.  Although there was no 
overall effect of DHA supplementation on spatial learning, the authors conclude that 
DHA supplementation to the n-3 deficient APP mice corrected the learning impairment 
caused by n-3 deficiency.  However, the probe trial measuring memory retention showed 
a lack of retention by all groups except the non-transgenic group supplemented with 
DHA that exhibited a partial quadrant preference.  This group spent significantly more 
time in the quadrant that formerly contained the platform versus the opposite quadrant.  
No other group showed this preference, indicating that DHA supplementation could not 
correct the spatial memory deficits by the APP mice fed the n-3 deficient diet (Calon et 
al., 2004).  Overall, n-3 supplementation appeared to impact avoidance learning more 
than spatial memory tasks such as the Morris water maze, possibly due to a difference in 
cognitive domains used between the tasks.  
In conclusion, omega-3 fatty acids have been shown to have some beneficial 
affects on membrane lipid composition, inflammation, the cholinergic system and LTP.  
Also described were improvements of cognition in some human trials and animal studies.  
However, there are some drawbacks to the prior behavioral studies involving n-3 and n-6 
fatty acids in human and animal studies.  To date, there have been no human studies done 
that have used DHA and EPA in combination to analyze effects on AD as treatment or 
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prevention.  Yehuda et al. (1996) did test the behavioral effects of LA and ALA together 
in AD patients over a short one-month treatment period; however, only about 15% of 
ALA is converted to DHA for use in the body.  No other study has followed a treatment-
based approach using fatty acids or fish oil to reverse cognitive decline due to 
Alzheimer’s disease.  However, essentially all of the “protection-based” human studies 
have been epidemiologic, retrospective studies which are often inaccurate and unable to 
control for many other factors that could affect cognition later in life.  Additionally, there 
are no longitudinal studies that have administered or retrospectively looked at n-3 fatty 
acids or fish oil supplements to determine any beneficial behavioral affect.   Aside from 
human studies, there are no animal studies involving an AD transgenic mouse model 
which utilized DHA and EPA as prevention therapy.  Calon et al. (2004) used APP 
transgenic mice on an n-3 deficient diet supplemented with only DHA as treatment for 
AD.  This approach was also used many times in non-transgenic rodent studies, as 
previously discussed, and is not a realistic approach to human dietary intervention.  A 
more realistic approach would be a supplementation with an appropriate ratio of n-6 and 
n-3 fatty acids (composed primarily of DHA and EPA) that could be duplicated for 
human dietary prevention of AD.  The majority of control diets that were used in animal 
studies were n-3 deficient, having only ALA as the primary n-3 fatty acid, and had no 
DHA or EPA.  Also, the experimental diets used for comparison to the control diets do 
not incorporate both DHA and EPA specifically; instead they used an ethyl ester form of 
DHA or a complete fish oil supplement which adds additional n-3 fatty acids.  Neither of 
these diet compositions accurately displays a sufficient human dietary intervention that 
would incorporate amounts of n-3 fatty acids present in foods.  In addition, most of the 
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animal studies used only one behavioral task, either active avoidance or Morris water 
maze, to evaluate the behavioral affects of n-3 administration.  Such behavioral analyses 
do not provide a complete assessment of cognitive changes that could occur from a 
dietary intervention study.  Instead, a more complete behavioral analysis should include 
tasks that test multiple sensorimotor and cognitive domains.   
 
 
XI.  Statement of Purpose 
As detailed in the Background section, two potential therapeutics against AD are 
Aβ-based immunotherapy and n-3 fatty acid administration.  This proposal will involve 
studies that directly test the ability of these two therapies to protect against AD-like 
behavioral impairment and pathology in a transgenic mouse model for AD —  the 
APP+PS1 mouse.   
Regarding Aβ immunotherapy, to date there have been no studies that show life-
long or longitudinal behavioral benefits of Aβ vaccinations.  Also, no studies have 
evaluated the same vaccinated transgenic animals in an extensive behavioral battery that 
incorporates multiple sensorimotor and cognitive domains at several time points during 
the vaccination period.  Therefore, this proposal involves long-term prevention-based Aβ 
immunotherapy to APP+PS1 mice that will: 
• longitudinally evaluate cognitive function in at two separate time points 
during aging in an extensive behavioral battery. 
• determine extent of Aβ pathology at the latter time point and correlate 
with behavior.   
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Regarding n-3 fatty acid administration, there have been no clinical studies 
performed to determine the protective or treatment effects of DHA+EPA supplementation 
against AD.  Also, there have been no animal studies that have used a comprehensive 
behavioral batter to assess the effects of n-3 fatty acids, specifically DHA and EPA, on 
behavior in non-transgenic or AD transgenic animal models.  Therefore, this proposal 
will administer to APP+PS1 mice a prevention-based high n-3 fatty acid supplement, rich 
in DHA and EPA.  This diet is modeled to mimic a twice-weekly dietary intake of fish 
for humans.  In addition, a high n-6 fatty acid diet, rich in LA, will be given to other 
APP+PS1 mice.  This n-6 diet is modeled to mimic a typical (bad) Western diet.  To 
compare the dietary effects of a high n-3 fatty acid diet versus a high n-6 fatty acid diet in 
APP+PS1 mice and non-transgenic mice, this proposal will:  
• evaluate cognitive function in an extensive behavioral battery at 4 to 5½ 
months into dietary treatment.  
• examine fatty acid levels in multiple tissues including brain, liver and 
plasma to note differential incorporation rates into membranes, which may 
potentially affect intracellular signaling.  
• analyze markers that could impact AD progression and be affected by n-3/ 
n-6 dietary manipulation, such as Aβ pathology, oxidative damage and 
inflammatory proteins, which correlation to behavior. 
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Materials and Methods 
 
I.  Life-long Vaccination Study 
 
 Animals.  Double transgenic APP + PS1 mice were derived from a cross of the 
mutant APPK670N,M671L transgenic line with the mutant PS1 transgenic line 5.1.  APP mice 
had a C57B6/SJL X C57B6 background and PS1-5.1 mice had a Swiss Webster/B6D2F1 
X B6D2F1 background, providing progeny with a mixed background.  Non-transgenic 
littermates were used as controls, with all mice being from the eighth or ninth generation 
following the initial cross.  After weaning, mice were genotyped and group housed until 
the start of vaccinations at two months of age. All mice were maintained on a 12 hour 
light-dark cycle, with free access to rodent chow and water. Behavioral testing was 
performed in the light period and in the same room where animals are being housed. 
 
 General Protocol.  The general protocol for this study is temporally depicted in 
Fig. 3.  Beginning at 2 months of age, APP+PS1 mice were injected monthly with the 
Aβ1-42 peptide (n=8) or phosphate-buffered saline (PBS) with adjuvant (n=6).  Control 
non-transgenic littermates (n=9) received monthly injections of PBS with adjuvant.  All 
mice were tested in a 6-week behavioral battery at 4½-6 months of age (2½-4 months 
into immunotherapy), then again in the same test battery at 15-16½ months of age (13-
14½ months into immunotherapy).  The test battery consisted of three sensorimotor-
based, one anxiety-based, and five cognitive-based tasks, that were performed in the 
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following order: open field activity, balance beam, string agility, Y-maze, elevated plus 
maze, Morris water maze, circular platform, platform recognition, and radial arm water 
maze.   
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 Fig. 3.  General protocol time line for life-long vaccination study.   
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Following completion of the test battery at 16½ months of age, all animals were 
euthanitized, their brain removed and processed for Aβ histopathology.  Using DNA 
extracted from tail samples, PCR genotyping of animals for mutant APP and PS1 genes 
was performed at weaning, and again (for confirmation) on the day of euthanitization.  
Procedures for all of the above were reviewed and approved by the USF Institutional 
Animal Care and Use Committee (IACUC). 
 
 Vaccination protocol.  The human Aβ42 peptide (Bachem) was first suspended in 
pyrogen-free Type I water at 2.2 mg ml-1 and then mixed with 10X PBS in order to yield 
1X PBS.  This solution was then incubated overnight at 37°C, then mixed with Freund’s 
complete adjuvant at 1:1; 100 µg of the Aβ vaccination mix was injected subcutaneously 
into APP+PS1 mice.  Each boost vaccination at monthly intervals was prepared fresh 
with incomplete Freund’s.  Injections for control APP+PS1 and non-transgenic mice 
consisted of PBS plus adjuvant prepared in the same way.  The experimenter that 
performed these injections had no role in the behavioral testing of mice. 
 
 Histopathology and Image Analysis.  Following completion of behavioral 
testing, mice were overdosed with pentobarbital (100 mg/kg i.p.) and perfused 
transcardially with 25ml of normal saline (0.9%).   Brains were removed and immersion 
fixed in a fresh solution of 4% paraformaldehyde (pH 7.4) for 24 hours; they were then 
cryoprotected in a series of sucrose solutions, frozen and sectioned in the horizontal plane 
at 25 µm using a microtome.  Brain sections were stored at 4°C in Dulbecco’s PBS for 
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Aβ immunocytochemistry (total Aβ = both Aβ1-40 & Aβ1-42) and Congo red (Aβ1-40) 
histologic staining for compact deposition as described in a latter section. 
  
II.  Omega-3 Fatty Acid Study- Survival Analysis 
 Animals.  All APP/PS1 and PS1 transgenic mice were obtained from a cross 
between heterozygous male mice carrying the mutant APPK670N,M671L gene and 
homozygous female mice with the mutant PS1transgenic line 6.2.  All of the offspring 
contained a mixed background of 37.5% C57, 25% B6, 12.5% SJL and 25% Swiss 
Webster.  The non-transgenic and APP single transgenic mice were obtained from a cross 
of the F1 PS1 female mice with P (parental generation) heterozygous APP male mice to 
obtain APP+PS1, APP, PS1 and non-transgenic (Tg-) offspring with a 56.25% C57, 
12.5% B6, 18.75% SJL and 12.5% Swiss Webster mixed background.  The mice were 
genotyped and singly housed after weaning.   
 
 General Protocol.  Thirty-eight F1 APP+PS1 and twenty-seven F2 Tg- mice 
were started on either a low omega-3, omega-3-deficient diet (omega-6 only), or standard 
rodent chow at an average of 6 weeks of age (range = 4-8 weeks) (Fig. 4).  The low 
omega-3 diet contained 13 APP/PS1 and 9 Tg- mice; there were 15 APP/PS1 mice and 9 
Tg- mice in the omega-6 only diet group and the standard diet included 10 APP/PS1 and 
9 Tg- mice.  There was a 100% mortality rate for both Tg+ and Tg- mice on the omega-3 
deficient diet, with most Tg+ mice dying between 20-25 days after diet initiation and all 
Tg- mice dying within 2-8 days of diet initiation.  Because of the longer survival of the 
Tg+ mice on the omega-3 deficient diet, Study 1 has been designed to investigate the 
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potential role of APPsw and/or PS1 transgenes in protecting against early mortality that 
otherwise occurred in Tg- mice.  Thus, 7 APPsw and 7 PS1 transgenic mice will be 
started on the omega-3 deficient diet at 2 months of age, with daily monitoring for 
mortality.  To determine the effects of age on the mortality of APPsw+PS1 mice resulting 
from the omega-3 deficient diet, 2-3 APPsw+PS1 mice will be started on the omega-3 
deficient diet at 2, 3 and 4 months of age.  Daily monitoring for mortality will occur.  
Figure 2 indicates a timeline of when all Tg+ and Tg- mice were or will be started on the 
omega-3 deficient diet.  Table 1 gives all of the major fatty acids present within the three 
diets.  None of these animals will be behaviorally tested; they will only be monitored for 
health problems and rate of mortality once they are started on their respective diets. 
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Fig. 4.  General protocol time line for omega-3 fatty acid study-Survival Analysis.  
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 Fatty Acid Diets.  Both experimental diets were obtained from Purina Mills Test 
Diets (Lafayette, IN) and lipid profiles were performed by Barrow-Agee Laboratories to 
confirm the fatty acid content for each diet.  The 2018 Teklad Global 18% Protein Rodent 
Diet standard diet used was obtained from Harlan.  The low omega-3 fatty acid diet 
included 8.55% fat with the majority of fat from oleic acid and palmitic acid (Table 2).  
The n-6/n-3 ratio for this diet was 6.3 to 1.  The omega-3-deficient diet included 6.72% 
fat with the majority of fat also from oleic acid and palmitic acid (Table 2).  This diet 
contained an n-6/n-3 ratio which could not be determined because it contained no 
detectable amounts of any n-3 fatty acids.  There were no detectable amounts of DHA or 
EPA in any of the three diets presented in Table 1.  There were similar amounts of n-6 
fatty acids present in both diets.  The major fatty acids present in each diet are presented 
in Table 2.      
 125 
Table 2.  Percent fatty acid composition of total fat for three diets. 
  Standard 
Diet 
Low Omega-3 
Diet 
Omega-3-
Deficient 
Diet 
% Total Fat  5.00 8.55 6.72 
Total Saturated Fats  9.59 42.07 30.23 
Total Monounsaturated 
Fats  
  12.84 32.30 28.46 
Total Polyunsaturated  
Fats 
 34.11 8.42 4.64 
Saturated Fats 
Butyric C4:0 0.00 0.00 0.00 
Caproic C6:0 0.00 0.00 0.00 
Caprylic C8:0 0.00 0.34 1.16 
Capric C10:0 0.00 0.00 0.00 
Lauric C12:0 0.26 0.19 0.00 
Myristic C14:0 0.06 8.19 1.99 
Pentadecanoic C15:0 0.00 0.69 0.22 
Palmitic C16:0 7.64 25.40 19.03 
Magaric  C17:0 0.00 0.67 0.00 
Stearic C18:0 1.50 5.80 6.61 
Arachidic C20:0 0.01 0.48 0.73 
Behenic C22:0 0.03 0.316 0.50 
Lignoceric C24:0 0.00 0.00 0.00 
Monounsaturated Fats 
Palmitoleic C16:1n-7 0.07 6.99 1.39 
Heptadecenoic C17:1n-8 0.00 0.39 0.00 
Oleic C18:1n-9c 12.59 19.61 24.77 
Gadoleic C20:1n-9 0.17 0.00 0.00 
Erucic C22:1n-9 0.01 0.00 0.00 
Polyunsaturated Fats 
Linoleic C18:2n-6c 31.35 7.27 4.64 
α-Linolenic C18:3n-3c 2.76 0.00 0.00 
γ-Linoleic C18:3n-6c 0.00 0.00 0.00 
Octadecatetraenoic C18:4n-3 0.00 0.00 0.00 
Eicosadienoic C20:2n-6 0.00 0.00 0.00 
Homo-γ Linolenic C20:3n-6c 0.00 0.00 0.00 
Arachidonic C20:4n-6c 0.00 0.00 0.00 
Eicosapentaenoic C20:5n-3c 0.00 0.00 0.00 
Docosapentaenoic C22:5n-3 0.00 1.15 0.00 
Docosahexaenoic C22:6n-3c 0.00 0.00 0.00 
Total n-3 Fats  2.76 1.15 0.00 
Total n-6 Fats  31.35 7.27 4.64 
n-6/n-3 ratio  11.4 to 1 6.3 to 1 ∞ 
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II.  Omega-3 Fatty Acid Study- Behavioral, Pathologic and Neurochemical Assessments 
 Animals.  All mice were obtained from a second generation cross between 
heterozygous APPK670N,M671L and heterozygous PS1transgenic line 6.2.  The backgrounds 
of all offspring were a mix of C57/B6/SJL/Swiss Webster.  The mice were genotyped and 
singly housed after weaning and a confirmatory genotyping was performed 1 month prior 
to behavioral testing.  All mice were maintained on a 14 hour light and 10 hour dark 
cycle for the duration of the study; all behavioral testing was performed during the light 
cycle. 
 
 General Protocol.  A total of 16 double transgenic APP+PS1 mice, 7 APP mice 
and 24 non-transgenic (NT) littermates were randomly divided into one of three diet 
groups.  Beginning at 2 months of age, NT and transgenic (Tg+) mice were divided into 
three separate diet groups: high omega-3, high omega-6, and standard diets (Fig. 5).  
Because of the oxidative properties of omega-3 fatty acids the diets were stored at -20ºC 
in 4-7 day supply aliquots.  Mice fed the high omega-3 diet consisted of 7 APP+PS1 mice 
and 2 APP mice and 8 NT mice; the standard diet fed mice included 9 APP+PS1 and 1 
APP mouse and 9 NT mice; the high omega-6 fatty acid diet group consisted of 1 
APP+PS1 mouse and 4 APP mice and 7 NT.  At 6 months of age, the NT groups were 
behaviorally tested in a 6-week battery that included three sensorimotor-based, one 
anxiety-based, and five cognitive-based tasks, performed in the following order: open 
field activity, balance beam, string agility, Y-maze, elevated plus maze, Morris water 
maze, circular platform, platform recognition, and radial arm water maze.  At 7.5 months 
of age, Tg+ mice were examined in the same 6-week battery of tasks (Fig. 5).  NT and 
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Tg+ mice could not be tested concurrently because of the large total number of animals 
involved (e.g., 47 mice).  Immediately following behavioral testing all mice were 
euthanitized; brains were then  removed for Aβ histological and fatty acid analyses. 
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Fig. 5.  General protocol time line for omega-3 fatty acid study II-Behavioral, 
Pathologic and Neurochemical Assessments  
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 Fatty Acid Diets.  Fatty acid diets were obtained from Purina Mills Test Diets 
(Lafayette, IN).  Lipid profiles were performed by Barrow-Agee Laboratories for each 
diet prior to administration to the mice to confirm their fatty acid content.  Each of the 
experimental diets contained 10% fat.  The high omega-3 diet included 6% safflower oil 
and 4% menhaden fish oil with an n-6:n-3 ratio of 3.8 to 1; the high omega-6 diet 
included 9.5% safflower oil and only 0.5% menhaden fish oil resulting in an n-6:n-3 ratio 
of 32.8 to 1.  The standard diet was the 2018 Teklad Global 18% Protein Rodent Diet 
received from Harlan, which was normally given to all mice within our mating colonies 
who were not on a special diet.  As indicated in Table 3, this Harlan diet had only half the 
fat as the other two diets.  The exact lipid composition for the major fatty acids present in 
each diet is indicated in Table 3. 
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Table 3.  Percent fatty acid composition of total fat for three diets. 
  Standard 
Diet 
High Omega-3 
Diet  
High Omega-6 
Diet 
% Total Fat  5.00 10.44 9.99 
Total Saturated Fats  9.59 20.04 10.79 
Total 
Monounsaturated 
Fats 
 
12.84 19.73 14.59 
Total Polyunsaturated 
Fats  
 34.11 64.22 74.27 
Saturated Fats 
Butyric  C4:0 0.00 0.00 0.00 
Caproic C6:0 0.00 0.00 0.00 
Caprylic C8:0 0.00 0.00 0.00 
Capric C10:0 0.00 0.00 0.00 
Lauric C12:0 0.26 0.06 0.00 
Myristic C14:0 0.06 3.37 0.58 
Pentadecanoic C15:0 0.00 0.28 0.06 
Palmitic C16:0 7.64 11.88 7.54 
Magaric  C17:0 0.00 0.29 0.07 
Stearic C18:0 1.50 2.84 2.16 
Arachidic C20:0 0.010 0.28 0.33 
Behenic C22:0 0.03 0.00 0.00 
Lignoceric C24:0 0.00 0.09 0.11 
Monounsaturated Fats 
Palmitoleic C16:1n-7 0.07 4.03 0.60 
Heptadecenoic C17:1n-8 0.00 0.29 0.08 
Oleic C18:1n-9c 12.59 11.94 13.03 
Gadoleic C20:1n-9 0.17 0.094 0.24 
Erucic C22:1n-9 0.01 0.07 0.00 
Polyunsaturated Fats 
Linoleic C18:2n-6c 31.35 49.99 71.99 
α-Linolenic C18:3n-3c 2.76 0.70 0.13 
γ-Linoleic C18:3n-6c 0.00 0.26 0.00 
Octadecatetraenoic C18:4n-3 0.00 1.39 0.22 
Eicosadienoic C20:2n-6 0.00 0.22 0.04 
Homo-γ Linolenic C20:3n-6c 0.00 0.07 0.00 
Arachidonic C20:4n-6c 0.00 0.28 0.04 
Eicosapentaenoic C20:5n-3c 0.00 4.74 0.85 
Docosapentaenoic C22:5n-3 0.00 0.87 0.11 
Docosahexaenoic C22:6n-3c 0.00 5.71 0.89 
Total n-3 Fats  2.76 13.40 2.20 
Total n-6 Fats  31.35 50.82 72.07 
n-6/n-3 ratio  11.4 to 1 3.8 to 1 32.8 to 1 
 131 
 Brain Collection and Dissection.  Immediately following behavioral testing mice 
were euthanitized with an overdose of pentobarbital (100mg/kg), blood and liver sections 
were collected and the brain were removed and bisected sagittally.  Blood (0.2 ml) was 
drawn directly from the heart prior to saline perfusion (100 ml).  The blood mixed with 
0.5M EDTA was immediately centrifuged to separate plasma from red blood cells.  Both 
portions were stored and frozen at -80ºC for lipid analysis.  After saline perfusion a 
similar portion from each animal’s liver was removed and stored in a 1.5 ml tube at -80ºC 
for lipid analyses.  For the brain, the left half was stored overnight in a 4% 
paraformaldehyde solution for immunohistochemistry.  The left half was then transferred 
to a graded series of sucrose solutions at 4ºC ending at 30% sucrose for storage until 
sectioning with a sliding microtome into 25µm coronal sections for Aβ 
immunocytochemistry and histology as described in a latter section.  The right half of 
each brain was momentarily placed in a cold saline solution, and then dissected into brain 
stem, cerebellum, posterior cortex, anterior cortex, striatum and hippocampus; each brain 
region was transferred to a separate pre-labeled 1.5 ml tube and stored at -80ºC for 
neurochemical analysis of protein carbonyls, lipid peroxidation and cytokines as 
described below. 
 
Extraction of Brain Protein for Sandwich Enzyme-Linked Immunosorbent 
Assay (ELISA).  A 5% sucrose homogenate (wet weight of tissue/ volume) from frozen 
mouse hippocampus was prepared and extracted as described by Schmidt et al. (2004).  
Each hippocampal tissue was individually weighed, and then combined with tissue 
homogenization buffer (THB) at 2 ml per 100 mg of tissue.  In addition to the THB, a 
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protease inhibitor cocktail was also added at 20% of the wet tissue weight to prevent 
against degradation of the proteins within the tissue samples.  On ice, each of the samples 
were combined with the calculated amounts of THB + inhibitors and fully homogenized.  
After homogenization, the samples were frozen and stored at -80ºC until diethylamine 
(DEA) and formic acid (FA) extractions. 
DEA extraction was used to separate soluble Aβ from the tissue homogenate.  
First, 100 µl of 5% homogenate was mixed with a 0.4% DEA solution (diluted in 100mM 
NaCl) over ice.  This mixture was then transferred into a thick-walled polycarbonate tube 
and centrifuged at 100,000 x g for 1 hour at 4ºC.  Following centrifugation, 170 µl of 
supernatant was removed and added to a microcentrifuge tube containing 17 µl of 0.5M 
Tris Base, pH 6.8 (1 µl per 10 µl of supernatant) and vortexed briefly.  These samples 
were then frozen on dry ice and stored at -80ºC for later analysis by the ELISA kits.   
FA extraction was used to isolate insoluble Aβ from tissue homogenate.  For this 
extraction 100 µl of THB was added to the pellet from the initial polycarbonate tube to 
return the mixture to the original volume.  Following the addition of 220 µl of 95% FA, 
pellets were sonicated for 1 minute on ice.  This mixture was then centrifuged at 100,000 
x g for 1 hour at 4ºC.  After centrifugation, 52.5 µl of the intermediate phase of the FA 
extracted mixture was added to 1 ml of FA neutralization solution.  Samples were 
vortexed, immediately frozen on dry ice, and then stored at -80ºC for later analysis by the 
ELISA kits. 
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Aβ Brain Deposition.  Sandwich ELISA kits for Aβ1-40 and Aβ1-42 analyses were 
purchased from Signet Laboratories.  Briefly, the standard curve for Aβ1-40 was generated 
with the maximum value at 2000 ng/ml and the minimum value at 0 ng/ml.  Each well of 
the 96-well plate was loaded in duplicate with either standard curve samples or diluted 
tissue samples.  For the formic acid (FA) extracted tissue, the homogenate was diluted 
with wash/sample diluent (provided) to a ratio of 1:500 of homogenate to diluent; for the 
diethylamine (DEA) extracted tissue, the homogenate was diluted with wash/sample 
diluent to a ratio of 1:400.  Once loaded into the plate, the standard curve and tissue 
samples incubated overnight at 4ºC.  Following this incubation, the plate was washed, 
diluted primary antibody was added, and the plate was incubated for 2 hours at room 
temperature.    The plate was washed again, and then incubated for 2 hours with 
secondary antibody-HRP complex.  Following another wash, o-Phenylenediamine 
dihydrochloride (OPD) substrate was added, and incubated in a dark room for 45 
minutes.  Stop solution (3N H2SO4) was added to each well and the optical density was 
read at 490 nm.  All of the above steps were repeated to measure for Aβ1-42, except that 
the tissue samples were diluted to 1:100 for the DEA extracted samples, while the same 
1:500 dilution was used for the FA extracted samples.  The standard curve was generated 
so that the lowest point on the curve was used to correct all of the tissue samples to 
account for the background interference.  The optical densities were then used to 
calculate wet brain protein concentrations (pmol/g) for either Aβ1-40 or Aβ1-42.   
  
 Fatty Acid Extraction, Transesterification and Fast Gas Chromatography.  
The extraction was performed on frontal cortex according to the method of Folch et al. 
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(1957).  Briefly, individual samples were thawed and homogenized in 20 volumes of 
chloroform-methanol (2:1, v/v).  The homogenate was partitioned with an aqueous salt 
solution and a small aliquot of the lower phase (total lipid extract) was used for the fatty 
acid analysis. 
 Transesterification was performed according to Lepage and Roy (1986).  Briefly, 
an internal standard solution (providing 10µg of 23:0 methyl ester) was combined with an 
aliquot of the lipid extract and a mixture of methanol-hexane (4:1; v/v) into a borosilicate 
glass tube.  Samples were vortexed and placed on ice; subsequently acetyl chloride was 
added.  The tubes were then capped, placed under nitrogen, and transferred to a heating 
block at 100ºC for 10 minutes, the tubes again vortexed and the caps retightened.  
Following an additional 50 minutes on the heating block, samples were placed on ice, 
uncapped and neutralized by addition of K2CO3.  The samples were then centrifuged to 
remove emulsion and to separate the mixture into two phases.  The upper phase was 
collected and evaporated under a stream of dry nitrogen to a volume of 60µl.  This 
solution was transferred to a gas chromatography (GC) vial for fast GC analysis. 
 A fused silica capillary column (DB-FFAP) of 0.1 mm ID x 15 m length with a 
film thickness of 0.1 µm was used for the fast GC analysis.  The following temperature 
program was used: initial, 150ºC with a 0.25 minute hold; ramp: 35ºC/minute to 200ºC, 
8C/minute to 225ºC with a 3.2 minute hold, and then 80ºC/minute to 245ºC with a 2.75 
minute hold.  The following instrumental conditions were used: carrier gas was H2 at a 
flow rate of 56 cm/s and a constant head pressure of 344.7 kPa; FID set at 250ºC; air and 
nitrogen make-up gas flow rates at 450 ml/min and 10 ml/min, respectively; split ratio of 
50:1; sampling frequency of 50 Hz; autosampler injections of 2µl volume.  Individual 
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fatty acids were identified by comparison with retention times of internal standards and 
calculated as mean percentage of total frontal cortex fatty acids. 
 
Cytokines.  Transgenic AD mice produce pro-inflammatory cytokines that might 
play a role in the AD-like pathology exhibited by these mice.  Therefore, to elucidate the 
role of fatty acid dietary incorporation on inflammation, pro-inflammatory cytokines (IL-
1α, IL-1β, IL-2, IL-6, IL-12p70, TNF-α, IFNγ, and GM-CSF) and anti-inflammatory 
cytokines (IL-4, IL-10) were determined using the RayBiotech Custom Mouse Cytokine 
Antibody Array within plasma.  Briefly, membranes containing the antibodies to the 
previously mentioned 10 cytokines were blocked against unspecific binding and 
subsequently incubated for one hour with 1:10 diluted plasma samples from each 
APP/PS1 and NT mouse.  One NT mouse was deleted due to limited space requirements 
for the kit.  The same NT mouse was also deleted from RAWM analysis due to non-
performance.  The membranes were then incubated with 1x secondary biotinylated 
antibodies for one hour, followed by incubation with HRP-conjugated streptavidin 
overnight at 4ºC.  Between each of the incubations, the membranes were washed with 
provided washing buffer solutions.  Detection of cytokine expression was determined 
with a two-minute incubation of provided detection buffers and using Fujifilm AR x-ray 
film that was allowed to develop for 7 seconds.  A Kodak DC290 digital camera was 
used to take back-lit photographs of the AR film.  The mean intensity of each signal was 
determined by densitometry and quantified by the Kodak ID Imaging Analysis Software.  
Each of the signals were standardized to a zero to one scale based on minimum and 
maximum mean intensity readings for each cytokine.  This was necessary due to the 
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naturally occurring variability (100x-1000x) in expression levels among the various 
cytokines.  Relative cytokine expression levels among the four groups were compared 
using the standardized mean signal intensities. 
 
IV.  Behavioral Testing Procedures 
Open Field.  Open field measured exploratory behavior and general activity.  
Mice were individually placed into an open black box 81 x 81 cm with 28.5 cm high 
walls.  This area was divided by white lines into 16 squares measuring 20 x 20 cm.  Lines 
crossed were counted for each mouse over a five-minute period.   
Balance Beam.  This task measured balance and general motor function.  The 
mice were placed on a 1.1 cm wide beam 50.8 cm long suspended 46 cm above a padded 
surface by two identical columns.  Attached at each end of the beam was a 14 x 10.2 cm 
escape platform.  Mice were placed on the beam in a perpendicular orientation and were 
monitored for a maximum of 60 seconds.  The time spent by each mouse on the beam 
before falling or reaching one of the platforms was recorded for each of 3 successive 
trials.  If a mouse reached one of the escape platforms, a time of 60 seconds was assigned 
for that trial.  The average of all three trials was calculated and recorded. 
String Agility.  To assess forepaw grip capacity and agility, mice were placed in 
the center of a taut cotton string suspended 33 cm above a padded surface between the 
same two columns as in the balance beam task.  Mice were allowed to grip the string with 
only their forepaws and then released for a maximum of 60 seconds.  A rating system, 
ranging between 0 and 5, was employed to assess string agility for a single 60-second 
trial.  A string agility score was given to each mouse based on the following scale:  “0” 
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was awarded for mice that were unable to hang for even a short period of time, “1” if the 
mouse hung by both forepaws for 60 seconds without escape, “2” was given if the mouse 
hung with both forepaws plus one hind limb, “3” if the mouse hung with all four paws 
around the string with no escape, “4” if the mouse had all four paws plus tail around the 
string, and “5” was given if the mouse escaped to one of the vertical support columns.   
Y-maze.  To measure general activity and basic memory function, mice were 
allowed 5 minutes to explore a black Y-maze with 3 arms.  Each arm measured 21 x 4 cm 
with 40 cm high walls.  Mice were placed in the center of the maze facing the center area 
and allowed to explore for 5 minutes, with the number and sequence of arm choices being 
recorded.  General activity was measured as the total number of arm entries, while basic 
mnemonic function was measured as a percent spontaneous alternation (the ratio of arm 
choices differing from the previous two choices divided by the total number of entries).  
For example, the sequence of arm entries (2,3,1,3,2,1,2,3) has six alternation 
opportunities (total entries minus two) and the percent alternation would be 67%. 
Elevated Plus Maze.  To measure anxiety/emotionality, mice were placed in the 
center of an elevated plus maze 82 cm above the floor. The maze consisted of two 
opposite “open” and two opposite “closed” arms, each 30 x 5 cm; 15 cm high black 
aluminum walls surrounded the closed arms.  The mice were placed in the 5 x 5 cm maze 
center, facing a closed arm, and were allowed to explore for 5 minutes.  The total number 
of closed arm entries, open arm entries and total time (seconds) spent in the open arms 
was recorded. 
Morris Water Maze.  To measure reference learning (acquisition) and memory 
retention, mice were placed in a 100 cm pool that was divided into 4 equal quadrants by 
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black lines drawn on the floor of the pool.  A transparent 9 cm platform was placed 1.5 
cm below the surface of the water in the center of quadrant two.  An assortment of visual 
cues surrounded the pool.  For each of four successive one-minute trials per day, mice 
were started from a different quadrant; the same quadrant start pattern was used across 10 
days of acquisition.  Latency to find the platform (maximum of 60 seconds) was recorded 
for each trial and the four daily trials were averaged for statistical analysis.  Once a 
mouse found the platform, it was allowed to stay on it for 30 seconds; if a mouse did not 
find the platform, it was gently guided to the platform and given the 30 second stay.  
Animals that did not find the platform were given a latency of 60 seconds.  On the day 
following acquisition testing (day 11), a memory retention (probe) trial was done.  For 
this 60-second trial, the platform was removed and the mouse was started in the quadrant 
opposite the platform-containing quadrant.  Percent time spent in each quadrant, annulus 
crossings, and average swim speed was determined from videotape recordings of this 
probe trial. 
Circular Platform.  As a test of spatial (reference) learning and memory, mice 
were placed in a 69 cm circular platform with 16 equally-spaced holes on the periphery 
of the platform.  Underneath only one of the 16 holes was a box filled with bedding to 
allow the mouse escape from aversive stimuli.  The aversive stimuli included two 150-
watt flood lamps hung 76 cm above the platform and one high-speed fan 15 cm above the 
platform.  Each mouse was given one 5-minute trial per day to explore the area.  Between 
each animal’s daily trial, the box position was changed to a different one of three possible 
escape holes and the platform was cleaned with a dilute vinegar solution to control for 
olfactory cues.  The box position was changed between mice so that different mice had 
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different escape holes, but any given mouse maintained the same escape hole across all 
days of testing.  Prior to day 1 of testing, two consecutive “shaping” trials were 
performed wherein mice were placed in the center of the platform and gently guided to 
their escape location.  For the single trial administered on each of 8 test days, mice were 
placed in the center of the platform facing away from their escape hole and given 5 
minutes to explore.  Escape latency was measured (maximum of 300 seconds), as was the 
total number of errors (e.g., the number of head pokes into non-escape holes).   
Platform Recognition.  This task measured the ability to search for and 
identify/recognize a variably-placed visible platform.  Although this task requires good 
vision, it is a cognitive-based task because: 1) it necessitates animals to change from the 
Morris maze’s spatial strategy to a recognition/identification strategy, and 2) it requires 
animals to ignore the spatial cues present around the pool, which was the same pool used  
in earlier Morris water maze testing.  The platform recognition task employed a 9-cm 
circular platform raised 0.8 cm above the surface of the water, with a prominent 10 x 40 
cm black ensign attached.  Mice were started from the same location in the pool for four 
60-second maximum trials per day for 4 days.  For each trial, the platform location was 
changed to a different one of the four quadrants. Mice were allowed a maximum of 60 
seconds to search/identify and ascend the platform, with a 30-second stay if they located 
the platform.  Mice that did not find the platform within 60 seconds were gently guided to 
the platform by the experimenter and allowed to stay for 30 seconds.  For statistical 
analysis, escape latencies for all four daily trials were averaged.   
Radial Arm Water Maze.  Working (short-term) memory was evaluated in the 
radial arm water maze (RAWM) task, using the same pool that was involved in both 
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Morris water maze and platform recognition testing.  This task also used the same clear 
platform and visual cues as in Morris maze testing.  For RAWM testing, however, an 
aluminum insert was placed in the pool to create 6 radially distributed swim arms 30.5 
cm in length and 19 cm wide emanating from a central circular swim area 40 cm in 
diameter.  The insert extended 5 cm above the surface of the water.  The last of four 
consecutive acquisition trials (T4) and a 30-minute delayed retention trial (T5) were 
indices of working memory.  On any given day of testing, the submerged clear platform 
was placed at the end of one of the six swim arms.  The platform location was changed 
daily to a different arm in a semi-random pattern.  For both studies (I and IIB), mice were 
tested for 9-12 days.  On each day, different start arms for each of the 5 daily trials were 
selected from the remaining 5 swim arms in a semi-random sequence that involved all 5 
arms.  For any given trial, the mouse was placed into that trial’s start arm facing the 
center swim area and given 60 seconds to find the platform with a 30 second stay.    Each 
time the mouse entered a non-platform containing arm it was gently pulled back into the 
start arm and an error was recorded.  An error was also recorded if the mouse failed to 
enter any arm within 20 seconds (in which case it was returned to that trial’s start arm) or 
if a mouse entered the platform-containing arm but did not find the platform.  If the 
mouse did not find the platform within a 60-second trial, it was guided by the 
experimenter to the platform, allowed to stay for 30 seconds, and was assigned a latency 
of 60 seconds. An error was assigned to any animal that, for any one minute trial, did not 
find the goal arm and refused to make at least 3 choices on their own during that trial.  
This number was calculated by averaging errors for all animals that did not locate the 
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platform for Block 1 (day 1 through day 3) on trial 1.  Both the number of errors 
(incorrect arm choices) and escape latency were recorded for each daily trial. 
 
V.  Brain Aβ Deposition Determinations 
Aβ Immunostaining.  The “total Aβ” primary antiserum was raised against Aβ40 
in rabbits and recognized Aβ40 and Aβ42 via ELISA assays.  Antiserum selective for both 
Aβ1-40 and Aβ1-42 was purchased from Quality Controlled Biochemical (Hopkinton, 
MA).  Confirmation of selectivity was provided by preabsorption experiments, which 
blocked all punctuate staining.  Brain sections were incubated with the primary antibody 
overnight at 4°C.  The sections were then incubated in biotinylated secondary antibody 
for two hours followed by streptavidin-peroxidase.  The peroxidase reaction consisted of 
a solution of 1.4mM diaminobenxidine and 0.03% hydrogen peroxide in PBS for five 
minutes. 
Congo Red Staining.  Congo red staining for compact Aβ deposition was 
performed on slide-mounted sections that were dried for at least 12 hours and then 
rehydrated for approximately 30 seconds prior to staining.  The hydrated slides were 
incubated in a freshly prepared alkaline alcoholic saturated chloride solution consisting of 
2.5mM NaOH in 80% reagent alcohol (95% ethanol and 5% isopropanol) for 20 minutes.  
The sections were then incubated in 0.2% Congo red in a freshly prepared and filtered 
alkaline alcoholic saturated sodium chloride for 30 minutes.  The slides were rinsed with 
three rapid changes of 100% ethanol, cleared through three rapid changes of xylene, and 
finally cover slipped with Permount. 
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Quantification of Aβ deposition.  The Oncor V150 image analysis system was 
used to quantify stained brain sections.  This software used hue, saturation and intensity 
(HIS) to segment objects within the image field.  Standard slides were used, which 
contain extremes of staining intensities, to establish thresholds for object segmentation.  
The operator for image analysis remained blind with respect to genotype or behavioral 
assessment.  For each animal, frontal cortex and hippocampus was quantified from four 
horizontal sections spaced 600µm apart beginning at 2000µm ventral to bregma.  The 
frontal cortex measurement used an 80x field with one limit as the edge of the cortex and 
the other limit as the midline in the most anterior position possible.  The total cortical 
measurement area consisted of a rectangular 850,000µm2.  This area was primarily 
comprised of the middle two-thirds of the cortical mantle (e.g., cortical layers 1 and 6 are 
excluded).  The hippocampal analyses involved three sub-areas: CA1, CA3, and dentate 
gyrus.  The areas measured were comprised of 6-8 horizontal sections equally spaced 
within each region of CA1, CA3 and dentate gyrus.  Region CA1 was defined as the 
pyramidal cells on the opposite side of the hippocampal fissure from the dentate gyrus.  
The pyramidal cell region adjacent to the dentate gyrus, not including the granule cell 
layers, encompassed region CA3.  The objective was positioned so that the hilus of the 
dentate gyrus was in the center for analysis of this region.  “Aβ load” referred to the 
percent area within the measurement field occupied by the reaction product, while 
“Congo red staining” referred to the percent area stained with Congo red.  All values for 
a given mouse and given brain area were averaged to represent a single value for that 
animal that was used in the statistical analysis. 
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VI.  Statistical Analysis 
A total of 19 behavioral measures were obtained from the 9-behavioral task 
battery previously described.  The tasks were divided into single day tasks and tasks that 
involved multiple test days.  All of the single day tasks (open field, balance beam, Y-
maze and elevated plus maze) except string agility were analyzed using one-way 
ANOVA.  String agility was analyzed using the Kruskal-Wallis non-parametric test and 
post hoc Mann-Whitney U test.  For multi-day tasks (Morris water maze, circular 
platform, platform recognition and radial arm water maze) both one-way ANOVAs and 
two-way repeated measure ANOVAs were employed.  Prior to statistical analysis of 
multi-day measures, data was grouped into 2-5 day blocks (except for platform 
recognition) to facilitate analysis and presentation.  Following ANOVA analysis, post-
hoc pair-by-pair differences between groups (planned comparisons) was resolved using 
the Fisher LSD test.  Swim speed from the Morris water maze retention trial was 
calculated using the Mouse Clocker software and analyzed by one-way ANOVA; annulus 
crossings during this trial were analyzed by Mann-Whitney U-tests.  All group 
comparisons were considered significance at p<0.05.  Any non-performers (e.g. repeated 
circulars, consistent floaters, etc.) in a particular task were eliminated from statistical 
analysis in that task. 
To group behavioral and/or pathologic measures based on their common factors, 
Factor Analysis (FA) was performed using Systat software.  FA used all collected data, 
regardless of genotype or treatment, to relate measures into individual factors.  Each 
factor measured a different component of behavior or cognition (i.e. reference memory, 
sensorimotor function, etc.).  In this way, behavioral measures related to one another 
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could be determined, as well as how performance in one task might be predictive of 
performance in another task (see Leighty et al., 2004 for more detailed explanation of 
FA).   
For Study I (Life-long Vaccination Study), an FA was performed using all 19 
behavioral measures collected at both the 4½-6 month and 15-16½ month time points.  
An additional DFA was carried out at the 15-16½ month time point that included 8 Aβ 
pathologic measures in addition to the 19 behavioral measures.  The 8 pathology 
measures included 4 measures for total Aβ burden (diffuse + compact) within 3 
hippocampal areas (CA1, CA3 & dentate gyrus) and frontal cortex (CX), and 4 measures 
for Congo red staining (compact Aβ only) within the same brain areas. 
To determine if the three experimental groups (NT, Tg+/Con and Tg+/Aβ) were 
distinguishable behaviorally from one another, discriminant function analysis (DFA) was 
performed using all 19 behavioral measures for both the 4½-6 month and 15-16½ month 
time points.  For the 4½-6 month time point, DFA was carried out with only the 7 
measures (all cognitive-based) that loaded within Factor 1.  Similarly, the 15-16½ month 
time point DFA was also performed with only the 9 measures (all cognitive-based) that 
loaded within Factor 1.  All DFA analyses were performed using the Systat software with 
two different DFA methods — direct entry and stepwise-forward.  The direct entry 
method used all behavior measures available, while the stepwise-forward method 
selected measures based on their variance contribution to best discriminate between the 
three groups (see Leighty et al., 2004 for more detailed information on DFA 
methodology. 
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For Study II, Part B (Omega-3 Behavioral Study), statistical analysis of behavior 
was similar to Study I, as just described.  In addition, separate behavioral analyses 
including only APP/PS1 and NT mice on either the standard or high n-3 fatty acid diets 
were evaluated and included after the initial Omega-3 Fatty Acid Study – Part BI section  
and entitled Omega-3 Fatty Acid Study – Part BII. 
For the Omega-3 Fatty Acid Study II neurochemical and histological analyses, 
groups were compared using one-way ANOVAs, with post-hoc Fisher’s test to determine 
significance and included only the NT and APP/PS1 mice on any of the three 
experimental diets. 
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Results 
I.  Life-long Vaccination Study 
 Significant differences of transgenic and Aβ immunotherapy effects are 
summarized in Table 4. 
 
 
 
Table 4.  A summary of transgenic and immunotherapy at both 4½-6 and 15-16½ month 
test points.  
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Sensorimotor- and Anxiety-based Tasks. 
 Open Field and Y-maze Entries.  At 4½-6 months of age, both Tg+/Con and 
Tg+/Aβ exhibited increased open field activity (Fig. 6a) compared to NT control mice 
(P< 0.02).  However, at the later time point, 15-16½ months of age, there were no 
differences between the groups.  Within the Y-maze task for activity/exploration, arm 
entries of the Tg+/Aβ group were elevated at both early (P< 0.01) and late (P< 0.05) test 
points compared to both Tg+/Con and NT groups (Fig. 8a).  
 Balance Beam.  In the balance beam task (Fig. 6b), 4½-6 month old Tg+/Aβ 
exhibited poorer performance than the NT mice; the Tg+/Con group showed an 
intermediate balance ability.  However, at 15-16½ months, all three groups exhibited 
poor balance ability as indicated by short trial times prior to falling from the beam. 
 String Agility.  Despite differences in activity (from open field or Y-maze 
entries) and balance performance, there were no differences at either test point in string 
agility (Fig. 6c).  This shows that any age- and genotype/treatment-related deficits 
exhibited in sensorimotor tasks are task-specific and did not deleteriously affect 
performance in cognitive-based tasks. 
 Elevated Plus-Maze.  In the elevated plus-maze task for anxiety and/or 
emotionality at 4½-6 months of age, an increased number of both open and closed arms 
entries was exhibited by Tg+/Aβ mice, but not the Tg+/Con mice, compared with NT 
control mice (Fig. 7b and c).   This is more reflective of an increase in activity level (in 
open field and Y-maze entries) and less of a decrease in anxiety.  This is especially 
evident since arm entries in elevated plus-maze generally load with other activity 
measures in Factor Analysis (see below).  Despite the increased number of entries, there 
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were no differences seen between all three groups in the percent time spent in the open 
arms at the younger test age (Fig. 7a).  However, at the aged test point, Tg+/Con mice 
exhibited less anxiety by spending an increased percent time in the open arms compared 
to NT controls (P< 0.02).  Though there were no group differences in the number of 
entries into either closed or open arms at this age (Fig. 7b and c). 
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Fig, 6.  Comparison of sensorimotor function in NT, Tg+/Con, and Tg+/Aβ mice at 4½ -
6 and 15-16½ behavioral test points.  Data represent the mean ±S.E.M. (a)  Open field 
activity, determined by open field line crossings, was increased in young adult Tg+/Con 
and Tg+/Aβ mice (b)  Equilibrium/agility, as measured by time on a balance beam, was 
impaired in young Tg+/Aβ mice.  (c)  String agility, as measured by forepaw grip 
suspension.  *Significantly different from NT at the age indicated, with P< 0.05 or higher 
level of significance. 
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Fig. 7.  Anxiety/emotionality, as determined in the elevated plus-maze by percent time in 
open arms and arm entries.  NT, Tg+/Con, and Tg+/Aβ mice were evaluated at adult 
(4½-6 month) and aged (15-16½ month) test points.  (a)  Aged Tg+/Con mice spent an 
increased percent time in open arms compared with NT controls.  (b)  The number of 
open arm entries was elevated in adult Tg+/Aβ mice in comparison to both NT and 
Tg+/Con mice.  (c)  Adult Tg+/Aβ mice also had an increased number of closed arm 
entries.  Data represent the means ±S.E.M.  *Significantly different from NT mice at 
P<0.05, **significantly different from adult NT and Tg+/Con mice at P<0.05. 
 151 
Cognitive-based Tasks 
 
Y-maze Alternation.  There was no transgenic effect at either test point for 
percent alternation within the Y-maze task (Fig. 8b), thus no protective effect of Aβ 
vaccination could be observed for this task. 
Morris Water Maze Acquisition.  To facilitate presentation and statistical 
analysis, the Morris maze acquisition data was evaluated as two 5-day blocks (Fig. 9).  At 
the adult test point, there was an overall groups effect across both blocks [F(2,19)=7.37; 
P< 0.005], with the Tg+/Con exhibiting impairment compared to the two remaining 
groups.  Also across both blocks, the Tg+/Con were found to have significantly higher 
escape latency, compared to both NT (P<0.005) and Tg+/Aβ (P<0.02) mice; the latter 
two groups did not differ in their acquisition performance.  At the aged test point, 15-16½ 
months, there was nearly an overall groups effect [F(2,15)=3.28; P=0.07).  Planned 
comparisons revealed a significant impairment across both blocks for Tg+/Con mice 
compared with NT controls (P<0.05).  In contrast, the performance of Tg+/Aβ mice was 
no different from that of NT control mice.  Additionally, across both blocks at both the 
young and aged test point, the Tg+/Aβ were no different from the NT controls.  Overall, 
Aβ immunotherapy protected APP/PS1 transgenic mice against memory impairment that 
was present in control Tg+ mice at an adult age and this protection was preserved into old 
age.  
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Fig. 8.  Y-maze arm entries (a)  and percent spontaneous alternation (b) for adult and 
aged NT, Tg+/Con, and Tg+/Aβ mice.  Data represent the mean ±S.E.M.  (a)  Tg+/Aβ 
mice had significantly more arm entries (e.g. increased activity) compared with both NT 
and Tg+/Con mice at the 4½ -6 month adult test point.  At the 15-16½ month aged test 
point, Tg+/Aβ mice continued to exhibit an increased number of arm entries compared 
with NT controls.  (b)  There were no group differences at either age for percent 
spontaneous alternation.  *Significantly different from NT and Tg+/Con at P<0.05, or 
higher level of significance. 
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Fig. 9.  Morris water maze acquisition at adult (4½-6 months) and aged (15-16½ months) 
time points for NT, Tg+/Con, and Tg+/Aβ mice.  The 10 days of acquisition, as measured 
by latency to find a submerged stationary platform, are presented in two 5-day blocks.  
For both blocks and at both test points, Tg+/Con mice were significantly impaired, while 
performance of Tg+/Aβ mice was no different than NT mice.  **Significantly different 
from both other groups at P<0.02 or higher level of significance, *significantly different 
from NT group at P<0.05. 
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 Morris Water Maze Retention.  The Morris water maze probe trial is presented 
below in Fig. 10  for both adult (4½-6 months) and aged (15-16½ months) test points.  
Both adult NT and Tg+/Aβ groups showed an exclusive preference for the quadrant that 
formerly contained the submerged platform (Q2).  In contrast, the adult Tg+/Con mice 
showed no quadrant preference as seen by their having similar percent time spent in each 
quadrant.  Also, the Tg+/Con mice had significantly fewer annulus crossings compared to 
the NT mice (P<0.05), while the Tg+/Aβ mice had similar annulus crossings to the NT 
group.  This shows that at the adult test point, Aβ immunotherapy protects against 
cognitive impairment of memory retention that was present in Tg+/Con mice.  At the 
aged test point, similar to the adult mice, the NT group showed an exclusive quadrant 
preference for the former platform-containing quadrant (Q2).  However, neither group of 
Tg+ mice showed such a preference.  In addition, at the aged test point, there were no 
group differences in annulus crossings; neither were there any group differences in swim 
speed at either test point exhibited during this probe trial. 
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Fig. 10.  Probe trial testing for reference memory retention, assessed on the day following 
the completion of water maze acquisition.  A single 1-minute trial was done, with the 
percent of time spent in the quadrant formerly containing the submerged platform (Q2) 
and the number of annulus crossings determined.  At the 4½-6 month test point, NT and 
Tg+/Aβ mice showed an exclusive quadrant preference for Q2 compared with all other 
quadrants, while Tg+/Con mice exhibited no quadrant preference.  *Significantly higher 
than all other quadrants at P<0.0001 (NT group) or P<0.01 (Tg+/Aβ group).  Tg+/Con 
mice also had significantly fewer annulus crossings compared with NT mice (P<0.05), 
while there was no difference between the other two groups.  At 15-16½ months of age, 
only NT mice showed a quadrant preference for Q2 (*significantly higher than all other 
quadrants at P<0.0001).  There were no group differences in annulus crossings at this 
age.  
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Circular Platform.    There were no impairments in latency to find the escape 
hole (Fig. 11a and b)  or number of head pokes/errors  into non-escape holes (Fig. 12a 
and b) for Tg+/Con mice at either test point in the circular platform task for spatial 
learning/memory.  Therefore, no protective effect of Aβ immunotherapy could be 
observed in this task.  In addition there were no differences at either the adult or aged test 
points between any of the groups; however, strong overall effects of learning across days 
were present at both adult [F(7, 133)=10.75; P<0.0001] and aged [F(7,112)=7.24; 
P<0.0001] test point in circular platform latency. 
 
 157 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 11.  Spatial learning/memory, as determined by the circular platform task latency to 
find the escape hole across 4 blocks consisting of 2 days each.  NT, Tg+/Con, and 
Tg+/Aβ were behaviorally evaluated at both adult (4½-6 months) and aged (15-16½ 
month) test points.   There were no group differences at either adult (a) or aged (b) test 
points.  However, there was a strong overall effect of learning across days at both adult 
and aged test points. 
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Fig. 12.  Spatial learning/memory, as determined by the circular platform task the number 
of errors, indexed as the number of head pokes into holes which did not contain the 
escape hole, across four 2-day blocks.  NT, Tg+/Con, and Tg+/Aβ were behaviorally 
evaluated at both adult (4½-6 months) and aged (15-16½ month) test points.   There were 
no group differences at either adult (a) or aged (b) test points.   
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 Platform Recognition.  At the 4½-6 month test point, all groups collectively 
exhibited a strong learning effect across days [F(3. 54)=20.91; P<0.0001], and there were 
no overall group differences across the 4 days of testing (Fig. 13).  Contrary, there was an 
overall groups effect over all 4 days of testing at the 15-16½ month time point 
[F(2,15)=3.97; P<0.05].  At this age, the Tg+/Con mice were impaired overall versus NT 
controls (P<0.02) and specifically on days 1 and 3 compared to the NT mice.  In contrast 
to the impaired performance of the Tg+/Con mice, the aged Tg+/Aβ mice performed 
similar to NT controls overall and for each of the 4 test days (Fig. 13).  However, by the 
last day of testing, there were no group differences in escape latency.  This indicates that 
the Tg+/Con were eventually able to reduce their latencies comparable to the remaining 
two groups.  In a comparison across both test points, the NT and Tg+/Aβ mice showed 
similar latencies indicating that their performance did not decline with increased age.  In 
contrast, the escape latency of the Tg+/Con mice was significantly higher at the aged test 
point compared to the adult test point (P<0.05).  This indicates that Aβ immunotherapy 
protected Tg+ mice from an age-dependent impairment in switching from the spatial 
strategy of Morris maze to the recognition/ identification strategy of platform recognition. 
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Fig. 13.  Platform recognition testing for the ability to search/ identify a variably-placed 
and conspicuously marked platform over 4 days of testing, with latency to swim to the 
platform being measured.  At the 4½-6 month test point, there were no differences 
between NT, Tg+/Con, and Tg+/Aβ mice to find the variably placed platform, with all 
groups reducing their escape latency over days.  At the 15-16½ month test point, 
however, aged Tg+/Con mice were impaired overall, as well as during days 1 and 3 of 
testing.  By contrast, Tg+/Aβ mice performed identically to NT mice.  *Significantly 
different from NT mice at P<0.005, **significantly different from both NT and Tg+/Aβ 
mice at P<0.025 or higher level of significance. 
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Radial Arm Water Maze.  The number of errors at the 4½-6 month test point in 
the Radial Arm Water Maze (RAWM) task is shown in Fig. 14 below.  At this age, the 
data were collected across three 3-day blocks for T1(randomized initial trial), T4 (final 
acquisition trial), and T5 (delayed retention trial).  For block 1 (B1), both groups of Tg+ 
mice showed memory impairment in the final acquisition trial in addition to the delayed 
retention trial compared to the NT group, which was effective in lowering their errors by 
T4 and T5.   In contrast, by block 2, the Tg+/Aβ mice had similar performance to the NT 
mice on T5, whereas the Tg+/Con mice remained impaired compared to the NT controls.  
By block 3, the Tg+/Aβ group performed similar to the NT control mice on both T4 and 
T5 trials of working memory; in sharp contrast the Tg+/Con exhibited marked memory 
impairment on both T4 and T5 compared to the NT mice.  Over all three blocks of 
testing, there was a significant effect of groups for both T4 [F(2,18)=11.30; P<0.001] and 
T5 [F(2,18)=9.28; P<0.005] in that both Tg+ groups were impaired compared to the NT 
controls overall for both T4 and T5 (P<0.02 or higher level of significance).  This overall 
impairment of Tg+/Aβ mice reflects the fact that it required them several blocks of 
testing to reduce their T4 and T5 errors to the level of the NT controls.  Fig. 15 below 
illustrates the latency in seconds across three 3-day blocks of RAWM behavioral testing 
at the adult test point.  Initially within B1, Tg+/Aβ mice had significantly higher latencies 
on T4 and T5 compared to the NT mice.  However, by the remaining blocks, they had 
similar latencies/working memory to the NT control group.  Although also not 
statistically different from NT controls or Tg+/Aβ mice, Tg+/Con mice exhibited 
consistently higher latencies than those two groups for T4 and T5 within the last two 
blocks of testing. 
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Fig. 14.  Working memory in the RAWM task at the 4½-6 month test point, with errors 
being evaluated for T1, T4, and T5 over three 3-day blocks.  T4 and T5 are indices of 
working memory.  By the last block of testing, Tg+/Aβ mice were no different than NT 
mice in working memory performance, while Tg+/Con mice consistently performed 
poorly over all three blocks in being unable to reduce their number of errors by T4 and 
T5 in any block.  All data are means (±S.E.M.).  *NT group significantly better than both 
Tg+/Con and Tg+/Aβ groups at P<0.05 or higher level of significance, †NT group 
significantly better than Tg+/Con group at P<0.05 or higher level of significance.  
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Fig. 15.  Working memory in the RAWM task at the 4½-6 month test point, with latency 
to find the hidden platform being evaluated for T1, T4, and T5 over three 3-day blocks.  
Within the first block of testing (B1), the NT mice performed significantly better than the 
Tg+/Aβ mice on T4 and T5, with the Tg+/Con mice having intermediate performance.  
However, by the last two blocks of testing, Tg+/Aβ mice were no different than NT mice 
in working memory performance.  Although not statistically different from NT controls, 
Tg+/Con mice consistently had higher latencies and were unable to reduce their latencies 
by T4 and T5 in any block.  All data are means (±S.E.M.).  *NT group significantly 
better than Tg+/Aβ group at P<0.05 or higher level of significance.  
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The number of errors at the 15-16½ month test point in the RAWM task is shown 
in Fig. 16 below using errors for T1, T4, and T5.  Comparisons between the two test 
points for RAWM can not be made because prior to the aged test point, the walls at the 
end of each swim arm of the RAWM aluminum insert were painted black.  For the first 
three blocks of behavioral testing, all groups performed similarly with the NT controls 
having consistently fewer errors than the two Tg+ groups.  By block 4, however, the 
Tg+/Con mice exhibited significantly more errors compared to the NT controls for T4 
(P<0.01) and T5 (P<0.01), while the Tg+/Aβ mice reduced their errors similar to that of 
the NT mice.  In addition, Tg+/Con mice were significantly impaired by having a higher 
number of errors in overall T5 performance (P<0.05), in contrast to the performance of 
Tg+/Aβ mice which was identical to that of NT mice.  The protective effect of Aβ 
immunotherapy to Tg+ mice is underscored by RAWM escape latency (Fig. 17), 
particularly during the last block.  During trial 4 of block 4, Tg+/Aβ mice performed 
identical to NT mice, while Tg+/Con were impaired compared to both Tg+/Aβ and NT 
mice.  Likewise, during T5, the Tg+/Aβ mice had similar latencies to the NT mice, while 
the Tg+/Con mice were significantly impaired compared to the NT mice.  In addition, 
Tg+/Con mice were impaired by having substantially higher latencies in overall T4 
(P<0.02) and overall T5 (P<0.02) across all four blocks in contrast to Tg+/Aβ which 
performed similar to NT mice in those trials. 
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Fig. 16.  RAWM testing for working memory at the 15-16½ month test point, with 
number of errors indicated for T1, T4, and T5 over four 3-day blocks of testing.  For the 
first three blocks of testing, all groups performed similarly.  By the final block, however, 
Tg+/Aβ mice reduced their T4 and T5 errors down to the level of NT controls, while 
Tg+/Con mice made significantly higher numbers of errors compared with NT mice.  
†Tg+/Aβ group significantly different from NT group at P<0.05, *Tg+/Con group 
significantly different from NT group at P<0.05.  All data are means (±S.E.M.).  
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Fig. 17.  RAWM testing for working memory at the 15-16½ month test point, as indexed 
by escape latency, across four 3-day blocks of testing.   For the first three blocks of 
testing, all groups performed similarly except that both Tg+ groups had higher latencies 
within the first block, T5.  Also, the Tg+/Con showed significantly higher latencies 
compared to NT mice on T4 in blocks 2 and 3, while Tg+/Aβ mice performed similar to 
the NT mice.  From T1 to T4, within the final block, Tg+/Aβ mice performed identical to 
NT controls and were significantly better than Tg+/Con mice on T4.  On T5, Tg+/Aβ 
mice were again no different in performance vs. NT controls, while Tg+/Con mice were 
substantially impaired (high latencies).  †NT mice significantly lower latency compared 
to both Tg+/Con and Tg+/Aβ groups at P<0.05 or higher level of significance, *Tg+/Con 
group significantly worse than NT group at P<0.05.  **Tg+/Con significantly worse than 
both NT and Tg+/Aβ groups at P<0.05 or higher level of significance.  All data are 
means (±S.E.M.).  
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Aβ Histopathology 
 At around 15 months into Aβ immunotherapy (and at 17 months of age), Aβ 
immunostaining and Congo Red staining were performed on brain sections from the 
frontal cortex, dentate gyrus and both CA1 and CA3 regions of the hippocampus in Tg+ 
mice.  The results shown in Table 5 illustrate that long-term Aβ immunotherapy did not 
alter total or compact Aβ deposition in any of the brain regions analyzed.  However, one 
of the four Tg+/Aβ mice did have appreciable reductions in mean Aβ levels ranging from 
76 to 86% compared to Tg+/Con mice. 
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Table 5.  Total Aβ (diffuse and compact) and compact Aβ (Congo Red) for Tg+/Con 
(n=4) and Tg+/Aβ (n=4) at 17 months of age within frontal cortex and hippocampus 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. 
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FA and Correlation Analyses 
 Table 6  shows the factor analysis of behavioral measures with and without Aβ 
histopathologic measures in order to determine the underlying relationships between such 
behavioral measures and Aβ deposition.  At the adult (4½-6 months) test point, of the 19 
behavioral measures analyzed, 15 measures loaded on three principle factors which 
together account for more than 70% of the total variance.  All measures of RAWM and 
Morris Water maze loaded heavily under factor 1, which was clearly cognitively-based 
and accounted for more variance (32.5%) than either of the other two factors.  In contrast, 
factor 2 was strongly sensorimotor/anxiety based, including activity/exploratory, elevated 
plus maze and string agility measures.  At the aged (15-16½ month) test point, many of 
the above 19 behavioral measures loaded into five principle factors (Table 6).  Similar to 
the adult test point, factor one was largely cognitively based and factor 2 was primarily 
sensorimotor/anxiety based.  Factor 1 again included all measures of RAWM and Morris 
water maze in addition to both measures of platform recognition; this factor, therefore, 
encompassed working memory, reference learning/memory and recognition/ 
identification.  Also, both measures of platform recognition loaded separately into factor 
3.   Sensorimotor/ anxiety-based factor 2 retained three measures present at the earlier 
time point and gained an additional elevated plus-maze measure (number of closed arm 
entries).  Two other measures (time in plus-maze open arms and string agility) which 
previously loaded together in factor 2 at the adult test point, loaded separately into factors 
4 and 5, respectively.  Inclusion of the eight histopathologic measures at the aged test 
point resulted in five of these measures loading into factor 1 with essentially all of the 
RAWM and Morris water maze measures.  The five histopathologic measures in factor 1 
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included all four brain areas stained for “total” Aβ and one area that was stained for 
compact Aβ deposition.  Compact Aβ deposition in region CA3 of the hippocampus 
loaded with various sensorimotor and cognitive-based measures in factor 2.  Factor 3 was 
largely activity/exploratory-based, while factor 4 included only Congo Red staining in the 
cortex and dentate gyrus.  Lastly, factor 5 solely contained the time in plus-maze open 
arms.  Therefore, similar factor loadings were seen with and without Aβ histopathology, 
although the pathologic measures did modify the behavioral loadings somewhat. 
 At the aged test point, correlation analyses were performed between the nine 
cognitive-based measures from factor 1 and all eight of the Aβ histopathologic measures.  
This analysis involved all Tg+ mice (4 Tg+/Aβ mice and 4 Tg+/Con mice).  Of a total of 
72 total correlations that were done, there were no significant correlations found. 
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Table 6.  Factor Loadings of behavioral measures, with and without pathologic measures. 
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DFA 
 Discriminant function analysis (DFA) was used in order to determine if the 
behavioral performance of each of the three groups (NT, Tg+/Con and Tg+/Aβ) could be 
distinguished from each other at both 4½-6 month and 15-16½ month test points.  Table 
1.4 shows a summary of two DFA methods including the “direct entry” method 
(including all behavioral measures) and the “step-wise forward” method (selects 
behavioral measures from all the measures based on their contribution to the variance) at 
both test points.  The direct entry DFA could not distinguish the three groups at either test 
point based on their behavioral performance.  However, at the 4½-6 month test point, the 
step-wise forward DFA could completely distinguish between all three groups such that 
their rank order of performance was as follows: NT>Tg+/Aβ>Tg+/Con.  Additionally, at 
the 15-16½ test point, the step-wise forward DFA successfully distinguished between the 
two Tg+ groups, even with the lesser number of animals.  At both test points a 
sensorimotor measure (Y-maze entries) and a cognitive-based measure (either RAWM 
trial 5 on last block or platform recognition averaged latency) were retained as providing 
the maximal discriminability. 
 Additional DFAs were performed utilizing only the cognitive-based measures that 
loaded on factor 1 in FA (see Table 1.3).  The direct entry DFA at the adult test point 
resulted in significant discrimination between the NT group and both Tg+ groups using 
all seven cognitive measures in factor 1.  In contrast, direct entry DFA at the aged test 
point was unable to successfully distinguish between any of the three groups using the 
nine behavioral measures from the factor 1.  However, all three groups were completely 
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distinguished from each other at the adult test point by step-wise forward DFA (rank 
order by performance was NT>Tg+/Aβ>Tg+/Con).  The measures retained as providing 
maximal discrimination were cognitive-based, including measures from RAWM and 
Morris water maze.  Similar to the adult test point, step-wise forward DFA at the aged 
test point could successfully discriminate the NT group from the Tg+/Con group.  More 
importantly, step-wise forward DFA could not distinguish the NT group from the 
Tg+/Aβ group based on their behavioral performance.  Three measures, including two 
from RAWM and one from platform recognition, were retained as providing maximum 
discrimination between the NT group and the Tg+/Con group. 
Fig. 18 shows canonical scores plot of both the seven- and nine-measure step-
wise forward DFAs at 4½-6 month and 15-16½ test points, respectively.  The measures 
that provided the maximal discrimination between groups were RAWM trial 5 
performance overall and RAWM trial 5 performance on the last block of testing (Table 
7).  Between 85-88% of the mice at the adult test point and 69-75% of the mice at the 
aged test point were correctly classified by the step-wise forward DFA.   
 
 
 
 
 
 
 
 
 174 
 
 
Table 7.  Summary of discriminant function analyses. 
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Fig. 18.  Canonical score plots of step-wise forward discriminant function analyses used 
to compare the “overall” cognitive performance of NT, Tg+/Con, and Tg+/Aβ groups.  
Each symbol represents the cognitive performance of one animal graphed from the two 
linear functions derived in the DFA.  At the 4½-6 month test point involving all seven 
cognitive measures from factor 1 (upper), all groups could be distinguished from one 
another in cognitive performance (rank order: NT>Tg+/Aβ>Tg+/Con).  At the 15-16½ 
month test point involving all nine cognitive measures from factor 1 (lower), the 
performance of the NT and Tg+/Aβ mice could not be distinguished from one another, 
while NT mice were clearly distinguishable (better than) Tg+/Con mice.  
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II.  Omega-3 Fatty Acid Study- Survival Analyses 
 
 Fig. 19 shows profound differences in the survivability of F1 generation APP/PS1 
(n=13) and PS1 (n=7) mice that were fed the omega-3-deficient (omega-6 only) diet 
beginning at 6 weeks of age.  All of the PS1 mice survived on this diet for 120 days, at 
which time the mice were euthanitized.  In sharp contrast, the APP/PS1 mice experienced 
100% mortality, mostly within 20 days of beginning the diet.  This resulted in a highly 
significant difference in the cumulative proportion surviving, as determined by the Cox-
Mantel test (P < 0.0001). 
 In addition to the survival analysis within the F1 generation, F2 generation APP 
(n=7), PS1 (n=9) and NT (n=9) were started on the omega-3-deficient diet at an average 
of 6 weeks of age.  As shown in Fig. 20, all genotypes showed similar survival on the 
experimental diet (P > 0.05), with the majority of the mortality occurring between 5 and 
10 days after beginning the diet.  
 By comparing survivability within the PS1 transgenic groups for F1 versus F2, it 
is evident that it is a combination of the interaction between the PS1 transgene and the 
background strain that determines survival on the omega-3-deficient diet (Fig. 21).  There 
is a significant difference in the cumulative proportion surviving (P < 0.0001), with the 
F1 PS1 mice having complete survival in contrast to the 100% mortality seen in the F2 
generation of PS1 mice.  In reference to the difference in the background between 
generations, the F1 generation was composed of a higher amount of B6 with a lesser 
amount of C57 present as compared to the F2 generation mice.  This suggests that the 
interaction between the B6 background and the PS1 transgene provided limited 
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protection against a diet that completely lacks omega-3 fatty acids.
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Fig. 19.  Survivability analysis showing days on the omega-3-deficient diet wherein the 
F1 PS1 mice had no mortality through 3 months after starting on the experimental diet.  
However, the F1 APP/PS1 mice had no survival on the omega-3-deficient diet. 
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Fig. 20.  Survivability analysis showing days on the omega-3-deficient diet.  All 3 groups 
of the F2 mice had similar mortality after starting on the experimental diet.  
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Fig. 21.  Survivability analysis comparing F1 PS1 mice to F2 PS1 mice, showing a 
significant difference in survival between the two generation within the same genotype.  
As shown, the PS1 transgene is not completely protective against mortality on a diet that 
is devoid of omega-3 fatty acids. 
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III.  Omega-3 Fatty Acid Study: Behavioral, Pathologic, and Neurochemical Assessments 
 Following a pre-diet baseline determination of body weight, all mice were 
weighed weekly throughout the 5½-7 month duration of the study.  Averaging all weekly 
weight determinations, no overall differences were found between any of the six groups 
of mice, nor were there any differences in final weights at the end of the study (data not 
shown). 
Significant differences in behavioral performance due to transgenicity (standard  
diet NT vs. standard diet Tg+) or diet are summarized in Table 8.  Table 9 presents 
differences in behavioral performance due to transgenicity or diet (standard vs. high n-3) 
for only APP/PS1 and NT mice; all APP mice and also all high n-6 diet groups were 
excluded. 
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Table 8.  A summary of transgenic and dietary behavioral effects (high n-3 and high n-6) 
in NT and Tg+ mice. 
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Table 9.  A summary of transgenic and dietary behavioral effects (high n-3 vs. standard 
diet) in NT and APP/PS1 mice.   
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Sensorimotor- and Anxiety-Based Tasks 
 
 For all sensorimotor- and anxiety-based tasks, there were no effect of high n-3 or 
high n-6 diets on performance of NT mice (Figs. 22-24).  Thus, neither diet affected 
sensorimotor abilities or level of anxiety in NT mice.  Some effects of transgenicity and 
diet were, however, evident for Tg+ mice, as indicated below.  
 Open Field and Y-maze Entries.  The Tg+ high n-3 mice had increased open 
field activity (Fig. 22a) compared to all NT groups (P<0.01) and Tg+ standard mice 
(P<0.05).  Similarly, within the Y-maze task for activity/exploration, arm entries of the 
Tg+ high n-3 group were elevated compared to all NT groups (P<0.01) and Tg+ standard 
mice (P<0.02) (Fig. 24a).  Thus, a high n-3 diet increased activity/exploration in Tg+ 
mice. 
 Balance Beam.  In the balance beam task (Fig. 22b), all three groups of Tg+ mice 
exhibited equally poor balance ability compared to NT standard-fed mice, as indicated by 
short trial times prior to falling from the beam.  A strong overall effect of transgenicity 
was present [F(1,47)=22.47; p<0.0001].  These results indicate there was no beneficial 
effect on balance for either high n-3 or n-6 diets in Tg+ mice. 
 String Agility.  Although a significant overall effect of transgenicity was evident 
(p<0.002, Mann-Whitney U test], neither of the Tg+ groups fed the high n-3 or high n-6 
diets exhibited deficits in string agility compared to NT standard-fed mice (Fig. 22c).  In 
contrast, the standard Tg+ mice did show a deficit in string agility compared to standard 
NT mice (P<0.05).  Nonetheless, all 3 Tg+ groups showed the same level of agility. 
Elevated Plus-Maze.  In the elevated plus-maze task, there were no significant 
differences in either the percent of time spent in the open arms or the number of open arm 
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entries between any of the Tg+ and NT groups (Fig. 23a and b).  As well, there were no 
overall effects of transgenicity for either of these measures.  Despite the lack of 
difference in open arm entries, both the high n-3 and high n-6 had increased closed arm 
entries compared to the standard Tg+ mice, but not vs. NT standard-fed mice (Fig. 23c).  
Within the NT mice, there was no difference in closed arm entries between any of the 
diet groups. 
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Fig, 22.  Comparison of sensorimotor function in NT and Tg+ mice fed either standard, 
high n-3 or high n-6 diets. Data represent the mean ±S.E.M. (a) Open field activity, 
determined by open field line crossings, was increased in high n-3 Tg+ mice. (b) 
Equilibrium/agility, as measured by time on a balance beam, was impaired in all three 
Tg+ diet groups.  (c) String agility, as measured by forepaw grip suspension was 
impaired only in Tg+ standard mice, although there was no difference in agility between 
Tg+ groups.  *Significantly different from NT standard group, with P< 0.05 or higher 
level of significance.  †Significantly different from all NT mice and standard Tg+ mice. 
a) 
b) 
c) 
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Fig. 23.  Anxiety/emotionality, as determined in the Elevated Plus-maze by percent time 
in open arms and arm entries.  No differences were evident in either percent time in open 
arms (a) or number of open arm entries (b) within any of the NT and Tg+ groups.  
However, both high n-3 and high n-6 Tg+ mice had an increased number of closed arm 
entries vs. standard Tg+ mice.  Data represents the mean ±S.E.M.  * Significantly 
different from standard Tg+ mice at P< 0.05. 
 
a) 
c) 
b) 
 188 
Cognitive-based Tasks 
 As shown in Figures 24 – 37, there was no effect of a high n-3 diet on 
performance of NT mice in any of the cognitive-based tasks.  This was also the case for 
NT mice on a high n-6 diet, with the exception of n-6 induced deleterious effects on 
Morris maze retention and circular platform errors.  Thus, these diets had minimal impact 
on cognitive performance in normal mice.  For Tg+ mice, however, there were some 
effects of diet on cognitive performance.  These effects were largely only seen in 
comparison to standard NT mice, but not standard Tg+ mice. 
 Y-Maze Alternation.  In Y-maze testing for spontaneous alternation, there was 
no overall effect of transgenicity, nor were there any differences among the NT and Tg+ 
groups (Fig. 24b). 
Morris Water Maze Acquisition.  In addition to the lack of impairment of Tg+ 
mice in Y-maze spontaneous alternation, there also was no transgenic impairment in 
Morris water maze acquisition over 10 days of testing.  For both 5-day blocks, all NT 
groups and all Tg+ groups performed similarly to each other (Fig. 25).  Even on the final 
day of testing, there were no group differences in acquisition (data not shown). 
Morris Water Maze Retention.  Within the NT group, the standard and high n-3 
diet mice, but not the high n-6 mice, showed an exclusive quadrant preference; 
nonetheless, all three NT groups had a similar number of annulus crossings.  Despite no 
impairment in Morris maze acquisition, standard Tg+ mice showed reference memory 
impairment compared to standard NT mice in both time spent in the former platform-
containing quadrant and annulus crossings (Fig. 26).  Surprisingly within the Tg+ groups, 
only the high n-6 Tg+ mice had an exclusive quadrant preference, whereas the high n-3 
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Tg+ mice only showed a partial quadrant preference for Q2 versus Q1.  Similarly, both 
the standard and high n-3 Tg+ mice exhibited a lower number of annulus crossings 
during the memory retention trial compared to the standard NT mice.  However, there 
were no differences in annulus crossing when the 3 Tg+ groups were compared directly.   
With inclusion of only APP/PS1 mice in both standard and high n-3 groups (Fig. 
27), only the standard Tg+ group remained completely impaired in memory retention 
versus standard NT mice – this, for both quadrant preference and annulus crossings.  In 
contrast, the high n-3 APP/PS1 mice showed a partial quadrant preference for Q2 
compared to Q1 and Q4.  Consistent with this modestly improved retention of n-3 
APP/PS1 mice, they also exhibited a similar number of annulus crossings compared to 
standard NT mice (Fig. 27).  By contrast, standard APP+PS1 mice exhibited a lower 
number of annulus crossings vs. standard NT mice.  The only modest benefit of a high n-
3 diet in APP+PS1 mice is underscored by the fact that there was no difference in annulus 
crossings between APP+PS1 mice on the high n-3 diet vs. those on a standard diet.  
Consistent with their lack of quadrant preference, APP/PS1 standard mice exhibited a 
lower number of annulus crossings vs. standard NT mice. 
The Morris maze retention data suggest that both n-3 and n-6 fatty acid 
supplementation can partially correct memory retention deficits that are otherwise present 
in standard-fed Tg+ mice, although the high n-6 diet was actually deleterious in NT mice.  
During the probe trial, there were no differences in swim speed among the Tg- and Tg+ 
groups. 
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Fig. 24.  Y-maze arm entries (a) and percent spontaneous alternation (b) for standard, 
high n-3 and high n-6 diet groups within NT and Tg+ mice.  Data represents the mean 
±S.E.M.  (a)  High n3 Tg+ mice had significantly more arm entries (e.g., increased 
activity) compared to all three NT groups and standard Tg+ mice.  (b) There were no 
group differences for either NT or Tg+ groups in percent spontaneous alternation.  
*Significantly different from standard-fed Tg+ mice at P< 0.02. 
a) 
b) 
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Fig. 25.  Morris water maze acquisition for standard, high n-3 and high n-6 diet groups of 
NT and Tg+ mice.  The 10 days of acquisition, as measured by latency to find a 
submerged stationary platform, are presented in two 5-day blocks.  For both blocks and 
for all three NT and three Tg+ groups, there were no differences in acquisition. 
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Fig. 26.  Probe trial testing for reference memory retention, assessed on the day following 
the completion of water maze acquisition.  A single 1-min trial was done, with the 
percent of time spent in the quadrant formerly containing the submerged platform (Q2) 
and the number of annulus crossings determined.  Within the NT groups, both the 
standard-fed and high n-3 mice showed an exclusive quadrant preference for Q2 
compared to all other quadrants.  In sharp contrast, the high n-6 NT mice showed no 
quadrant preference.  Within the Tg+ mice, the standard-fed mice showed no quadrant 
preference, while the high n-3 mice showed a partial quadrant preference for Q2 
compared to Q1  († = significantly higher than Q1 at P<0.05).  Also, the high n-6 Tg+ 
mice showed a significant exclusive quadrant preference for Q2 versus all other 
quadrants.  (* = significantly higher than all other quadrants at P<0.05 or higher level of 
significance).  No differences were seen in number of annulus crossings within the NT 
mice, however the standard and high n-3 Tg+ had significantly fewer annulus crossing 
compared to standard NT mice (# significantly different from standard NT at P<0.05), 
although there were no differences in annulus crossings among the 3 Tg+ groups. 
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Fig. 27.  Probe trial testing for reference memory retention, assessed on the day following 
the completion of water maze acquisition, including only NT and APP/PS1 groups.  
Within the NT groups, both the standard-fed and high n-3 mice showed an exclusive 
quadrant preference for Q2 compared to all other quadrants (* significantly higher than 
all other quadrants at p<0.05 or higher level of significance).  Within the APP/PS1 mice, 
the standard-fed mice showed no quadrant preference, while the high n-3 mice showed a 
partial quadrant preference for Q2 compared to Q1 and Q4  († = significantly higher than 
Q1 and Q4 at P<0.05 and P<0.02, respectively).  No differences were seen in number of 
annulus crossings within the NT mice, however the standard APP/PS1 mice had 
significantly fewer annulus crossing compared to standard NT mice (# significantly 
different from standard NT at P<0.02), while there was no difference between the high n-
3 APP/PS1 mice and standard NT mice.   
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Circular Platform.  Assessment of spatial learning/memory in the circular 
platform task showed marked differences between the diet groups on the last day of this 
8-day task.  Although there was no transgenic effect in either number of head 
pokes/errors into non-escape holes or latency to find the escape hole, there were dietary 
differences within the NT and Tg+ groups.  Fig 28 shows that the high n-6 NT mice had 
impaired spatial learning/memory, as evidenced by increased errors compared to both 
standard NT mice and high n-3 NT mice.  However, there were no differences within the 
NT groups in latency.  Within the Tg+ groups, the high n-6 mice were also impaired in 
errors (vs. standard Tg+ mice) and latency (vs. standard NT mice) to find the escape hole.    
For both NT and Tg+ genotypes, high n-3 mice performed similar to standard fed mice.  
Since there were no differences in performance between genotypic groups for any diet, 
the two genotypes were combined.  Fig 29 shows the resultant strong effect of diet in the 
circular platform task.  Together, NT and Tg+ mice fed the high n-6 diet had increased 
errors compared to both standard and high n-3 diet groups.  Similarly, the combined high 
n-6 diet group had increased latency compared to the combined standard diet group. 
These data indicate that a diet high in n-6 fatty acids induces impairment in spatial 
reference learning/memory, while a diet high in n-3 fatty acids does not induce such an 
impairment.  
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Fig. 28.  Spatial learning/memory, as determined by the circular platform task by number 
of head pokes/ errors (a) into non-escape holes and latency (b) to find the escape hole 
across 8 days of testing, with the last day of testing shown above.  (a)  High n-6 NT mice 
showed impairment by an increase of errors compared to both standard and high n-3 mice 
(** significantly different from standard and high n-3 NT mice at P<0.02).  Similarly, 
high n-6 Tg+ mice had increased errors compared to standard Tg+ (*p<0.05), with the 
high n-3 Tg+ mice having similar performance to the standard Tg+ group.  (b)  Despite a 
difference in errors, there were no differences between the NT mice with respect to 
latency to find the escape hole.  However, the high n-6 Tg+ were impaired in latency 
compared to the standard NT mice († significantly different from standard NT mice at 
P≤0.05). 
a) 
b) 
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Fig 29.  The last day of circular platform shows a strong effect of diet by combining both 
genotypes.  Together, NT and Tg+ mice on the high n-6 diet were impaired, as shown by 
a high number of errors into non-escape holes versus both standard and high n-3 groups 
(** = P<0.01 or higher level of significance).  Also, the high n-6 mice had increased 
latency to find the escape hole compared to the standard diet group (* = P<0.05). 
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 Platform Recognition.  Within the NT groups, all mice collectively showed a 
strong learning effect across the four days of testing, with no differences between the diet 
groups overall or at individual days (Fig. 30a).  In contrast, the standard Tg+ mice were 
impaired overall versus the standard NT mice (Fig. 30b; p<0.05).  Even in comparison to 
the standard Tg+ group’s poor performance, high n-6 Tg+ were significantly worse than 
all five other groups, including both standard and high n-3 Tg+ mice.  In contrast to the 
impaired high n-6 Tg+ performance, the high n-3 Tg+ group performed significantly 
better overall (p<0.005).  Although performance of high n-3 Tg+ mice was no different 
from standard NT mice overall, their performance still was not improved enough to be 
significantly better than standard Tg+ mice.  High n-3 Tg+ mice did have significantly 
lower latencies on days 2, 3, and 4 versus high n-6 Tg+ mice.  The platform recognition  
data indicate that a diet high in n-3 fatty acids protects AD transgenic mice from 
impairment in recognition/identification.  In addition, a diet with a high amount of n-6 
fatty acids induces an impairment in recognition/identification that is even greater than 
that normally present in Tg+ on a standard diet.   
 Inclusion of only APP/PS1 mice for both standard and high n-3 Tg+ groups 
revealed marked differences in recognition/identification within this task.  Standard 
APP/PS1 mice were impaired overall (p<0.02) and specifically on days 3 and 4 versus 
the standard NT mice (Fig. 31b; p<0.02).  In sharp contrast to the impaired standard 
APP/PS1 performance, the high n-3 APP/PS1 group performance was no different from 
the standard NT mice on all days and over all 4 days of testing.  Moreover, by day 4 of 
the task, the high n-3 APP/PS1 mice performed significantly better (had lower latency) 
than the standard APP/PS1 and were no different from standard NT mice.  These data 
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indicate that a diet high in n-3 fatty acids protects AD transgenic mice from impairment 
in recognition/identification and by the end of the task fully reversed the transgenic 
impairment present in standard-fed mice.   
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Fig. 30.  Platform recognition testing for the ability to search/ identify a variably-placed 
and conspicuously marked platform over 4 days of testing, with latency to swim to the 
platform being measured.  (a) There were no differences in latency between the diet 
groups of the NT mice, with all groups reducing their latency over days.  (b) The Tg+ 
standard-fed mice, however, were impaired overall  vs. NT standard-fed mice.  In 
addition, the high n-6 Tg+ mice were significantly more impaired compared to the 
standard Tg+ mice.  In sharp contrast, the high n-3 Tg+ mice performed significantly 
better compared to the high n-6 Tg+ groups overall and specifically during days 2 
through 4 of testing, although their performance was not statistically better than that of 
standard Tg+ mice.  † Significantly different from standard NT mice overall at P<0.05, * 
significantly different from high n-3 Tg+ mice at P<0.02 or higher level of significance, 
**significantly different from all other groups in overall performance at P<0.05 or higher 
level of significance.   
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Fig. 31.  Platform recognition, as assessed within NT and APP/PS1 standard and high n-3 
diet groups.  (a) There were no differences in latency between the diet groups of the NT 
mice, with both groups reducing their latency over days.  (b) The Tg+ standard-fed mice, 
however, were impaired overall compared to standard NT mice.  In sharp contrast, the 
high n-3 Tg+ mice performed significantly better compared to the standard APP/PS1 
mice by day 4 of testing.  † Significantly different from high n-3 APP/PS1 mice at 
P<0.05, * significantly different from standard NT mice at P<0.05 or higher level of 
significance, **significantly different from standard NT overall at P<0.02. 
a) b)
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 Radial Arm Water Maze.  RAWM data are presented in terms of errors (Figures 
32-34) and latency (Figures 35-37) to find the goal arm.  All of the NT groups performed 
similar to each other across all three blocks (Fig. 32a) exhibiting no differences due to 
dietary intervention.  In addition, all NT groups showed learning by exhibiting a 
significant reduction of errors from T1 to T4 and retaining that low number during T5 for 
both blocks 2 and 3 as well as overall three blocks.  In contrast, the standard-fed Tg+ 
mice (Fig. 32b) had significantly more errors (were impaired) as compared to the 
standard-fed NT mice for T4 and T5 during block 2, and during T5 for the last block of 
testing.  Within the Tg+ groups, there was no significant benefit of either experimental 
diet.  However, the Tg+n-3 did make significantly more errors on block 1 T5 as 
compared to the standard Tg+ mice.  With that exception, there were no other group 
differences within the Tg+ groups.  
There were no differences in overall T4 or T5 errors within the NT groups (Fig. 
33).  Regarding Tg+ mice, only the standard Tg+ mice were impaired overall on T4 
compared to the standard NT mice, while the high n-3 and high n-6 Tg+ performed 
similar to standard NT mice (Fig. 33a).  More importantly, however, the overall 
performance of high n-3 and high n-6 Tg+ mice was not significantly better than standard 
Tg+ mice.  Moreover, all 3 groups of Tg+ mice were equally impaired in overall T5 
errors versus standard NT mice (Fig. 33b).   
Comparison between only the standard and high n-3 dietary groups including only 
NT and APP/PS1 mice is presented as overall T4 and T5 errors in Figure 34.  Regarding 
the NT mice, both groups performed similar to each other for both T4 and T5.  Analysis 
pertaining solely to APP/PS1 mice showed that for both T4 and T5 overall errors, only 
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the standard APP/PS1 mice were impaired compared to the standard NT mice; 
performance of the high n-3 APP/PS1 mice was statistically not different from the same 
standard NT mice (Fig. 34).  As was the case for all mice included (Figure 33), however, 
a high n-3 diet did not affect working memory (T4 and T5) performance of APP+PS1 
mice compared to standard APP+PS1 mice.  These data involving RAWM errors indicate 
that a diet high in n-3 and/or n-6 fatty acids has very minimal to no effect on working 
memory in Alzheimer’s transgenic mice.   
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Fig 32.  Working memory in the RAWM task in NT (a) and Tg+ (b) mice being 
evaluated for T1, T4 and T5 errors over three 3-day blocks.  T4 and T5 are indices of 
working memory.  All three NT groups performed similarly in being able to reduce their 
number of T4 and T5 errors across blocks.  By contrast, standard Tg+ were impaired 
versus standard NT mice for T4 and T5 during block 2 and T5 only during block 3.  
Within the Tg+ groups, the n-3 mice were impaired as compared to standard Tg+ mice 
for T5 within block 1.  Otherwise there were no differences due to diet within the Tg+ 
mice.  *Standard Tg+ mice significantly different from standard NT mice at P<0.05 or 
higher level of significance.  † High n-3 Tg+ significantly different from standard Tg+ 
mice at P<0.05. 
a) 
b) 
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Fig 33.  RAWM errors in overall T4 (a) and T5 (b) for both NT and Tg+ groups.  All NT 
groups had similar overall performance in both T4 and T5.  Although the standard Tg+ 
mice had increased errors in overall T4 compared to standard-fed NT mice, there were no 
differences in T4 performance between the three Tg+ groups.  In overall T5 errors, all 
three Tg+ groups displayed similar working memory impairment in making an increased 
number of errors versus standard NT mice.  *Significantly different from standard NT at 
P<0.05. 
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Fig 34.  RAWM errors in overall T4 and T5 for both NT groups and APP/PS1 groups.  
All NT groups had similar overall performance in both T4 and T5.  The standard 
APP/PS1 mice (but not the high n-3 mice) had increased T4 and T5 overall errors 
compared to standard-fed NT mice.  However, the high n-3 diet had no effect on T4 and 
T5 working memory when the two APP+PS1 groups were compared directly to one 
another.  *Significantly different from standard NT at P<0.05. 
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Latencies to find the hidden platform for T1, T4 and T5 across the three 3-day 
blocks of the RAWM task are graphed for both NT (Fig. 35a) and Tg+ (Fig. 35b) mice.  
Across all nine days of RAWM testing, there were no differences between any of the NT 
groups with respect to latency to find the hidden platform.  As was the case for RAWM 
errors, by the final two blocks of testing (B2 and B3), all three NT groups showed 
excellent working memory, as evidenced by their low T4 and T5 latencies.  By contrast, 
all three Tg+ groups had increased latencies for both working memory trials (T4 and T5) 
in blocks 1 and 2 compared to standard NT mice.  This impairment in T4 and T5 
performance continued into the final block for standard Tg+ mice vs. standard NT mice.  
Compared to standard Tg+ mice, high n-3 and high n-6 Tg+ mice had slightly lower T4 
and T5 latencies in Block 3 (Fig. 35b), which resulted in both of these groups not being 
different from standard NT controls on those trials.  However, in the more important 
direct comparison between the three Tg+ groups, no significant differences were noted in 
T4 and T5 performance during block 3 (or any other block).  Underscoring the lack of a 
robust effect of high n-3 or high n-6 diets in Tg+ mice are results of overall T4 and T5 
performance (Fig. 36).  All three NT groups performed similar in showing excellent 
overall T4 and T5 performance (e.g., low latencies), while all three Tg+ groups showed 
similar overall T4 and T5 impairment compared to standard NT controls.  Despite the 
somewhat improved performance of the high n-3 and high n-6 Tg+ groups by the last 
block, neither of these groups performed significantly better than standard-fed Tg+ 
controls for any RAWM latency measure and both groups were impaired by having 
higher overall latencies in T4 (Fig. 36a) and T5 (Fig. 36b) overall.   
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To determine any effects a high n-3 diet might have specifically on APP+PS1 
mice, RAWM performance of only APP/PS1 mice was compared to NT controls in the 
last block of testing (Fig. 37).   As with all other indexes of RAWM performance, a high 
n-3 diet did not improve the already excellent working memory performance of NT mice 
during this final block.  However, standard Tg+ mice were unable to improve their 
performance between T1 and T4/5 while high n-3 mice were able to do so.  Because of 
this better performance by high n-3 Tg+ mice, they were no different in T4 or T5 
latencies compared to standard NT mice, while standard Tg+ mice were impaired on both 
T4 and T5 (Fig. 37).  By T5 of the last block, there was a strong trend for the high n-3 
APP/PS1 mice to have improved performance compared to the impairment of the 
standard APP/PS1 group (P=0.06).  As with RAWM errors, the RAWM latency analysis 
suggests that dietary supplementation with n-3 or n-6 fatty acids results in slight or no 
improvement in working memory performance. 
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Fig 35.  Working memory in the RAWM task in NT (a) and Tg+ (b) mice being 
evaluated as latency to find the platform for T1, T4 and T5 over three 3-day blocks.  
There were no differences in latency between any of the NT groups across all days of 
RAWM testing or at individual blocks.  In block 1 and block 2, all three Tg+ groups had 
increased latencies in both T4 and T5 compared to standard-fed NT mice († = all Tg+ 
groups significantly different from standard NT at P<0.05 or higher level of 
significance).  However, by block 3 both high n-3 and high n-6 Tg+ mice performed 
somewhat better, such that their performance was not different from standard NT mice, 
whereas the standard Tg+ group remained impaired. * Standard Tg+ group significantly 
different from standard NT group at P<0.05. 
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Fig 36.  RAWM latency to find the hidden platform in overall T4 (a) and T5 (b) for both 
NT and Tg+ groups.  All NT groups had similar overall performance in both T4 and T5, 
however, all three Tg+ groups had increased latencies in both T4 and T5 compared to the 
standard-fed NT mice. *Significantly different from standard NT at P<0.02 or higher 
level of significance. 
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Fig 37.  RAWM latency to find the hidden platform within the last block of testing for 
both NT and APP/PS1 on either the standard or high n-3 fatty acid diets.  Both NT groups 
performed similar to each other and exhibited excellent learning by a decrease in latency 
from T1 to T4/T5.  Likewise, the high n-3 APP/PS1 showed this learning effect, whereas 
the standard APP/PS1 could not improve their performance between T1 and T4/5.  Also, 
the standard APP/PS1 had increased latencies versus standard NT mice for T4 and T5 (* 
P<0.05 or greater level of significance vs. standard NT controls) 
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Cytokine Levels   
 At 7½-9 months of age (5½ -7 months into dietary treatments), pro-inflammatory 
and anti-inflammatory cytokines from plasma were measured in both NT (Fig. 38a) and 
APP/PS1 (Fig. 38b) mice from both the high n-3 and high n-6 diet groups.  For NT mice, 
there were no differences in plasma levels of any cytokine for high n-3 vs. high n-6 diet 
groups (Fig. 38a).  Among APP/PS1 mice, there was a consistent trend for high n-6 mice 
to have reduced levels of both pro- and anti-inflammatory cytokines compared to high n-
3 mice (Fig. 38b).  However, only levels of IL-1β and IFN-γ were significantly reduced 
by a high n-6 diet vs. a high n-3 diet.  Because there were no significant differences 
between the two genotypes for any cytokine irrespective of diet, cytokine levels from 
both genotypes were combined.  As shown in Figure 39, the high n-6 diet mice (NT & 
APP/PS1) had consistently lower levels of all cytokines measured compared to all mice 
on the high n-3 diet.  However, the only measure that was significantly reduced by the 
high n-6 diet was IL-1β.  Surprisingly, the anti-inflammatory cytokines, IL-4 and IL-10 
were also slightly, but not significantly, lower in the high n-6 group.  For both NT and 
APP/PS1 mice, these results indicate that the plasma cytokine profile is similar following 
a lengthy period of a high n-3 vs. a high n-6 diet. 
 
Hippocampal Aβ levels 
   As measured by ELISA, there were no differences in levels of either soluble or 
insoluble Aβ within hippocampal tissue between any of the three APP/PS1 dietary groups 
(Fig. 40).  Thus, neither a high n-3 or a high n-6 diet, administered over 5½ months, 
affected brain Aβ levels.  There was however, a strong trend for the high n-6 APP/PS1 
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group to have a lower level of insoluble Aβ42 compared to both standard and high n-3 
diet groups. 
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Fig. 38.  Standardized mean signal intensity of plasma cytokines in both NT (a) and 
APP/PS1 (b) mice on either the high n-3 or high n-6 fatty acid diets.  No differences were 
seen in any of the cytokine levels between the two NT groups for either pro- or anti-
inflammatory cytokines.  However, within the APP/PS1 groups, the high n-6 mice 
expressed lower levels of IL-1β and IFN-γ compared to high n-3 APP/PS1 mice.  Also, 
the high n-6 group had reduced expression of TNF-α compared to both NT groups.         
* Significantly different compared to high n-3 APP/PS1 mice at P<0.05. 
a) 
b) 
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Fig. 39.  Standardized mean signal intensity of plasma cytokines for all mice on either the 
high n-3 or high n-6 fatty acid diets irrespective of genotype.  Although the high n-6 diet 
group had consistently lower levels across all cytokines, IL-1β in high n-6 diet mice was 
the only cytokine that was significantly reduced vs. high n-3 mice.  *Significantly 
different from high n-3 group at P<0.05. 
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Fig. 40.  Hippocampal Aβ levels (pmol/g), as measured by ELISA, of insoluble and 
soluble Aβ1-40 (a, b) as well as insoluble and soluble Aβ1-42 (c, d).  No differences were 
found between any of the dietary groups for any Aβ marker.  
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Fatty Acid Brain Tissue Levels   
 Saturated and Mono-unsaturated Fatty Acids.  Fatty acid levels including 
saturated, mono-unsaturated and polyunsaturated fatty acids were measured from frontal 
cortex and expressed as mean percentage of the total fatty acids.  There were no 
differences in any of the saturated or mono-unsaturated fatty acids between any of the 
three NT groups (data not shown).  Figure 41 illustrates that there were no differences in 
either total saturated (Fig. 41a) or total mono-unsaturated (Fig. 41b) fatty acids between 
the NT groups.  Similarly, there were no differences in any of the saturated fatty acids 
within the three APP/PS1 groups or in their total saturated fatty acid level (Fig. 41a).  
There was also no difference in total mono-unsaturated fatty acids between any of the 
APP/PS1 groups (Fig. 41b). 
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Fig. 41.   Cortical levels of total saturated (a) and mono-unsaturated (b) fatty acid levels 
of standard, high n-3 and high n-6-fed NT and APP/PS1 mice.  No differences were 
found between any of the groups for saturated or mono-unsaturated fatty acids.  Values 
expressed as mean percentage of total fatty acids ±SEM. 
a) 
b) 
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 Omega-6 and Omega-3 Fatty Acids.  As seen in Figure 42a for NT mice, the 
high n-6 group had elevated cortical levels of 18:2n-6 and 20:2n-6 as compared to both 
other groups.  Likewise, the high n-3 mice had reduced levels of 20:4n-6 and 22:4n-6 as 
compared to both standard and high n-6 mice.  Surprisingly, however, the high n-3 mice 
showed an elevation of one n-6 fatty acid, 20:3n-6.  Despite this elevation, the high n-3 
mice had reduced total n-6 fatty acids compared to both standard and high n-6 NT mice 
(Fig. 43a).  Therefore, in the important direct comparison of the high n-3 diet versus the 
high n-6 diet, the high n-6-fed NT mice had increased levels of four of seven omega-6 
fatty acids.  Of the four different n-3’s that were measured, 20:5n-3 and 22:5n-3 were 
both significantly elevated in the high n-3 NT mice compared to both other groups (Fig. 
42a).   Likewise, total n-3 fatty acids were higher in the n-3 fed NT group as compared to 
the standard-fed and high n-6 fed mice (Fig. 43b).  Thus, in a direct comparison between 
the two experimental diets, the high n-3 diet resulted in increased omega-3 fatty acids 
within the frontal cortex in the NT mice. 
 Within the dietary groups of APP/PS1 mice, the results were less consistent.  
Figure 42b shows that only 22:5n-6 was significantly increased in the n-6 fed mice 
compared to the n-3 fed mice.  However, reductions in 3 of the seven n-6 fatty acids 
(18:2n-6, 20:2n-6 and 20:3n-6) were found in the standard-fed mice compared to both 
experimental diet groups.  As Figure 45a shows, there were no differences in total 
omega-6 fatty acids between any of the diet groups within the APP/PS1 mice.  There 
were also no differences in any of the n-3 fatty acids measured in the APP/PS1 mice (Fig. 
42b).  Thus, the total n-3 fatty acids were similar between the three APP/PS1 diet groups, 
as seen in figure 43b. 
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 Comparisons were also made within the individual diet groups to determine the 
effect of genotype on the fatty acid content in the frontal cortex (data not shown).  For the 
standard-fed mice, there were no significant differences between any of the fatty acids 
measured for NT vs. APP/PS1 mice, except for elevations in both 22:5n-6 and 22:5n-3 in 
APP/PS1 mice. However, for the high n-3 diet mice, 5 of the seven n-6 fatty acids were 
elevated in APP/PS1 mice compared to NT mice (exceptions were 18:3n-6 and 20:3n-6), 
resulting in significantly higher total n-6 fatty acid levels in cortex of APP/PS1 mice vs. 
NT controls.  In addition, 20:5n-3 and 22:5n-3 were reduced in the APP/PS1 mice versus 
NT mice on the high n-3 diet.  The reduction in these two n-3 fatty acids resulted in a 
significant reduction in total n-3 fatty acids in the APP/PS1 mice.  Lastly, for mice fed 
the high n-6 diet, only 20:2n-6 was elevated in APP/PS1 mice compared to NT mice.  
Thus, for mice fed the high n-6 diet, there were no genotypic differences in any of the 
other six n-6 fatty acids, or any genotypic differences for any of the n-3 fatty acids.   
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Fig. 42.  Cortical levels of n-6 and n-3 fatty acids for standard, high n-3 and high n-6 NT 
(a) and APP/PS1 (b) mice.  Within the NT mice, the high n-6 diet group showed 
increases in four of seven n-6 fatty acids compared to the high n-3 diet group.  
Conversely, high n-3 diet mice had elevations in two of four omega-3 fatty acids, 20:5n-3 
and 22:5n-3, as compared to both other NT groups.  Within the APP/PS1 mice, the high 
n-6 group had elevations in only one n-6 fatty acid (22:5n-6) versus the high n-3 mice.  
However, the standard-fed mice had lower levels of three n-6 fatty acids compared to 
both other groups.  There were no differences in omega-3 fatty acids between any of the 
three APP/PS1 groups.  Values expressed as mean percentage of total fatty acids ±SEM.  
*Significantly different from both other diet groups within that genotype at P<0.05 or 
greater level of significance.  # Significantly different from standard-fed group within 
that genotype at P<0.05 or higher level of significance. 
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Fig. 43.  Total n-6 (a) and total n-3 (b) fatty acid levels in standard, high n-3 and high n-6 
NT and APP/PS1 mice.  High n-3 NT mice had significantly lower total n-6 as compared 
to both other NT groups.  Similarly, high n-3 NT mice had significantly elevated n-3 as 
compared to both standard and high n-6-fed mice.  There were no differences between 
the APP/PS1 groups for either total n-6 or n-3 fatty acid levels in frontal cortex.  Values 
expressed as mean percentage of total fatty acids ±SEM.  * Significantly different from 
both standard-fed and high n-6-fed NT groups at P<0.05 or higher level of significance. 
a) 
b) 
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Correlations and Multimetric Analyses 
 Correlations were performed involving both NT and APP/PS1 mice for behavioral 
measures versus fatty acid levels (saturated, mono-unsaturated and poly-unsaturated) 
from the frontal cortex, plasma cytokines, and hippocampal Aβ levels.  First, behavioral 
measures of NT mice, combining all three diet groups, were correlated with cortical fatty 
acid levels.  Then, NT mice from only the high n-3 and high n-6 groups were used to 
correlate behavior with both fatty acid levels and plasma cytokines.  Because all 
pathology factors were only measured in APP/PS1 mice, a final two sets of correlations 
excluded all APP mice and therefore also excluded behavioral measures from the high n-
6 mice.  Therefore, correlations were performed between standard and high n-3 APP/PS1 
mice behavioral measures and both cortical fatty acids and hippocampal Aβ levels.  
Lastly, Aβ levels, cytokines and fatty acid levels were correlated within the high n-3 and 
high n-6 APP/PS1mice. 
 Correlations involving all NT groups.  Significant correlations involving all NT 
mice combined from the three diet groups revealed associations between n-6 or n-3 fatty 
acids in the frontal cortex with cognitive impairment (Table 10).  More specifically, 
20:2n-6 (di-homo linoleic acid) was negatively correlated with Morris water maze 
retention, such that an increased amount of this fatty acid in the brain was associated with 
less time spent in the former platform-containing quadrant during the probe trial.  In 
addition, levels of this same fatty acid as well as 22:5n-6 (docosapentaenoic acid) were 
correlated with increased latency to find the hidden platform in RAWM.  Surprisingly, 
22:6n-3 (DHA) and total N-3 PUFAs were positively correlated to impairment in both 
Morris water maze acquisition and RAWM.   
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 Correlations involving high n-3 and high n-6 NT groups.  Additional 
correlations, including only the high n-3 and high n-6 fatty acid diets were also 
performed with the NT mice involving behavioral performance, brain fatty acid levels, 
and plasma cytokines (Table 10).  Many significant correlations arose between 
impairment in platform recognition and all seven n-6 fatty acids, as well as 2 of 4 n-3 
fatty acids, indicating a clear association between high brain lipid levels and impaired 
search/recognition and identification learning.  Despite no differences between the n-3 
and n-6 NT dietary groups  in saturated or mono-unsaturated fatty acid levels, there were 
significant and consistent associations between high levels of eight out of ten saturated 
fatty acids and impairment in the platform recognition task for both NT groups combined.  
Also, six out of ten mono-unsaturated fatty acid levels were significantly correlated to 
impairment in the same task for both n-3 and n-6 NT groups combined.  In addition, all 
n-6 fatty acids measured and two of four n-3 fatty acids were significantly correlated with 
impairment in the platform recognition task for both n-3 and n-6 NT groups combined.  
There were essentially no correlations between plasma cytokine levels and cognitive 
performance for the combined high n-3 and high n-6 NT diet groups. 
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Table 10.  Correlations for all NT mice combined between cortical fatty acid levels and 
behavioral measures or for only high n-3 and high n-6 NT mice between fatty acid levels, 
plasma cytokines and behavioral performance.  All abbreviations defined below in Table 
12. 
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 Correlations involving standard and high n-3 APP/PS1 groups.  Significant 
correlations were found between combined standard-fed and high n-3-fed APP/PS1 
groups versus behavioral measures, brain fatty acid, and Aβ levels (Table 11).   Most 
notably, elevated hippocampal soluble Aβ40 was significantly associated with Morris 
water maze acquisition and retention impairment, in addition to increased latencies for 
platform recognition and RAWM.  As well, insoluble Aβ40 also significantly correlated 
with impairments in Morris water maze and platform recognition.  Soluble and insoluble 
Aβ42 were not as well correlated with cognitive measures, although high levels of Aβ42 
were associated with poorer RAWM performance.   
 In addition to Aβ levels, increased levels of several cortical n-6 fatty acids also 
correlated with cognitive deficits in Morris water maze acquisition and retention, as well 
as cognitive impairment in RAWM.  Surprisingly, cortical levels of n-3 fatty acids were 
essentially not associated with improvement in any of the cognitive-based measures.   
 Correlations involving high n-3 and high n-6 APP/PS1 groups.  Significant 
correlations were found between hippocampal Aβ levels, plasma cytokines and cortical 
fatty acid levels in high n-3 and high n-6 APP/PS1 mice (Table 11).  There were 
significant positive correlations between insoluble Aβ42 and plasma cytokines, IFN-γ 
and IL-10, indicating both pro-inflammatory and anti-inflammatory associations with Aβ.  
However, 20:2n-6, 20:4n-6 and 22:5n-6 all negatively correlated with pro-inflammatory 
cytokines such as IFN-γ, TNF-α, IL-2 or IL-6.  In addition, the n-3 fatty acid, 18:3n-3 
(ALA) also negatively correlated with many of the pro-inflammatory cytokines as well as 
with the anti-inflammatory cytokine, IL-10.  Together, these correlations indicate that 
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increased cortical levels of n-6 and n-3 fatty acids are associated with an overall anti-
inflammatory effect. 
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Table 11.  Correlations for combined standard and high n-3 APP/PS1 mice between 
behavioral measures, cortical fatty acid levels and hippocampal Aβ levels or for 
combined high n-3 and high n-6 APP/PS1 mice between hippocampal Aβ levels, plasma 
cytokines and brain fatty acid levels.  * InsolAβ42 = insoluble Aβ42 within 
hippocampus; all other abbreviations defined below in Table12. 
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 Table 12 shows the factor analysis of behavioral measures including all animals in 
all 6 treatment/genotype groups on a standard, high n-3 or high n-6 fatty acid diet.  The 
table also includes a factor analysis for only the NT and APP/PS1 mice on either the 
standard or high n-3 diet, with and without pathologic measures.  Including all 6 
experimental groups, 16 of the 19 behavioral measures analyzed loaded on four principle 
factors, which together account for more than 65% of the total variance.  All measures of 
RAWM errors and platform recognition, plus two measures of Morris water maze, loaded 
heavily in Factor 1, which was clearly cognitively-based and accounted for 33% of the 
total variance.  In contrast, Factor 2 was strongly sensorimotor/anxiety based, including 
both elevated plus maze and balance beam measures.  Factor 3 included both circular 
platform measures as well as Y-maze activity, while Factor 4 contained a single measure 
- the number of closed arm choices in elevated plus maze testing.  Utilizing only two diet 
groups (standard and high n-3) and including only NT and APP/PS1 animals, many of the 
above 19 behavioral measures loaded similarly in Factors 1 and 2 (Table 10).  Factor 1 
was again cognitively- based in loading all measures of RAWM errors, platform 
recognition, and all three measures of Morris water maze.  This factor, therefore, 
encompassed working memory, reference learning/ memory and recognition/ 
identification.  Factor 2 was anxiety-based in loading only measures of elevated plus 
maze, while Factor 3 loaded two measures of activity/exploratory behavior.   
 Including neurochemical measures of cortical fatty acids (total saturated, total 
mono-unsaturated, total n-3, total n-6, and individual n-3 and n-6 fatty acids), as well as 
hippocampal soluble and insoluble Aβ levels to the behavioral measures for the NT and 
APP/PS1 groups is also reported in Table 12.  Loading on Factor 1 were 10 cognitive 
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measures, soluble Aβ40 and Aβ42, and four n-6 fatty acid measures (including total n-6 
fatty acid levels).  Factor 1 contributed over 31% to the total variance.  Factor 2 contained 
only fatty acid measures - two individual n-6 fatty acids and three individual n-3 fatty 
acids.  Factor 3 contained the same measures of elevated plus maze as Factor 2 without 
the pathology measures.  In addition, string agility and two measures of n-3 fatty acids 
also loaded on Factor 2.  Lastly, total mono-unsaturated fatty acids loaded separately on 
Factor 4.  In summary, factor loadings with and without pathologic measures were 
similar for Factor 1, though clearly there was an association between these measures and 
both Aβ pathology and cortical fatty acid levels. 
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Table 12.  Factor loadings of behavioral measures, with and without pathologic 
measures.  
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 Discriminant function analysis (DFA) was used in order to determine if the 
overall behavioral performance of each of the three diet groups (standard, high n-3 and 
high n-6) could be distinguished from each other for both NT and Tg+ groups.  Table 11 
shows a summary of two DFA methods: the “direct entry” method (which included all  
19 behavioral measures) and the “step-wise forward” method (which selected behavioral 
measures from all the measures based on their contribution to the variance).  The direct 
entry DFA could not distinguish between the three groups for either NT or Tg+ mice 
based on their overall behavioral performance.  However, the step-wise forward DFA, 
iteratively selecting from the 19 behavioral measures, could distinguish between the NT 
high n-6 group and both other NT groups.  This discrimination was based on a single 
behavioral measure - circular platform errors on the final day of testing, wherein high n-6 
NT mice were markedly impaired vs. the other two groups. 
Within the Tg+ groups, the step-wise forward DFA was successful in 
distinguishing between all three diet groups so that the percent of animals correctly 
classified was 100% according to the classification matrix.  Nine of the 19 behavioral 
measures were retained as providing the highest level of discriminability within the Tg+ 
groups: 8 cognitive measures and 1 anxiety/activity measure.  A Canonical plot of these 
stepwise-forward DFA results involving Tg+ mice is presented in Figure 44.  Similar 
discrimination was seen when including only APP/PS1 mice and comparing standard and 
high n-3 dietary groups (Table 12).  A step-wise forward DFA using all behavioral 
measures could successfully discriminate between both standard and high n-3 APP/PS1 
groups.  Similar to the DFA that utilized all three Tg+ groups, the percent of animals 
correctly classified by the step-wise forward DFA including only APP/PS1 animals was 
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100%.  Although both step-wise forward DFA’s did provide discrimination between Tg+ 
groups behaviorally, no group was clearly superior across all of the behavioral measures 
iteratively selected therein.  Moreover, direct entry DFA’s were completely unsuccessful 
in distinguishing overall behavioral performance of the three Tg+ groups.  Thus, there 
was no overall benefit or impairment provided by either the n-3 or n-6 diets in Tg+ mice.  
Four additional DFAs were performed, which included only the eight cognitive-
based measures that loaded into Factor 1 from Table 10.  For the NT mice, neither the 
direct entry nor stepwise-forward DFAs could distinguish between any of the three 
dietary groups (Fig. 45a).  Likewise, the direct entry DFA method could not discriminate 
between any of the Tg+ groups (Fig. 45b).  However, a stepwise-forward DFA, selecting 
from the 8 cognitive-based measures from Factor 1 revealed discrimination between Tg+ 
high n-6 mice and both Tg+ standard and Tg+ high n-3 mice.  The measures retained as 
providing maximal discrimination were platform recognition on the last day of testing (a 
search recognition/identification-based measure) and T5 latency during the last block of 
RAWM testing.  When repeating the above DFA’s for only APP/PS1 mice and only for 
standard diet vs. high n-3 diet, the two APP/PS1 groups could be distinguished when a 
stepwise-forward DFA was utilized and only Factor 1 cognitive-based measures were 
included.  The two measures retained as providing this discrimination were RAWM last 
block T5 and RAWM overall T5 latency.  For both of these cognitive measures, high n-3 
mice had better performance.  The percent of animals correctly classified by the step-wise 
forward DFA for Factor 1 for all Tg+ animals and only APP/PS1 animals was 72% and 
90%, respectively.  Nonetheless, for all three other DFA’s that were done involving 
APP/PS1 mice alone, there was no discrimination between high n-3 and standard diet 
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groups, again underscoring that a high n-3 diet did not provide substantially better overall 
performance across a variety of tasks. 
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Fig. 44.   Canonical scores plot of stepwise-forward DFA using all 19 behavioral 
measures for the three Tg+ groups.  Each symbol represents the cognitive performance of 
one animal as graphed from the two linear functions derived in the DFA.  For the Tg+ 
animals, all groups could be distinguished from one another in cognitive performance.  
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Fig. 45.  Canonical scores plots of direct entry DFA’s for the three groups of NT mice (a) 
and the three groups of Tg+ mice (b).  The eight cognitive-based  measures that loaded 
on Factor 1 of Factor Analysis were utilized.  The DFA could not successfully 
discriminate between any of the three dietary groups within the NT animals.  Similarly, 
none of the three Tg+ groups could be discriminated from the others based on their 
overall cognitive performance across the 8 cognitive measures utilized. 
a) 
b)
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Table 13.  Summary of discriminant function analyses including NT and Tg+ mice. 
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Table 14.  Summary of discriminant function analyses including NT and APP/PS1 mice 
for the standard and high n-3 groups. 
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Discussion 
 
 In the present work, we evaluated the behavioral and pathological effects of active 
Aβ immunotherapy and dietary administration of omega-3 and omega-6 fatty acids in 
APP/PS1 and NT mice.  Previous work has shown the significance of using transgenic 
animals to test various therapeutics for AD, such as environmental enrichment, dietary 
supplementations or vaccination protocols.  Within the present work, there was a greater 
cognitive benefit from Aβ vaccination as compared to omega-3 dietary intervention.  
However, neither study resulted in any significant alteration of Aβ levels, indicating that 
any cognitive benefits observed through either Aβ immunotherapy or dietary fatty acid 
administration were Aβ independent.  
 
I.  Aβ Vaccination Discussion 
 
 Immunotherapeutic approaches to AD first began in the 1996 with in vitro work 
using monoclonal antibodies against Aβ (Solomon et al., 1996).  It wasn’t until 1999, 
however, that the first study was performed on an AD transgenic mouse model (Schenk 
et al., 1999).  Within the last 6 years, many studies have focused on the use of either 
active or passive vaccinations in transgenic mice; however, few have behaviorally 
assessed the efficacy of such immunotherapy.  The current study tested the effects of life-
long active Aβ vaccination on behavioral and Aβ deposition measures in AD transgenic 
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mice.  Following initiation of immunotherapy at 2 months of age, these mice were 
behaviorally evaluated at an early time point (4½-6 months) and a late time point (15-
16½months) in an extensive battery that analyzed multiple sensorimotor and cognitive 
domains.  Thus Tg+ were vaccinated over a 14½ month period (essentially most of their 
adult life) to determine if life-long vaccinations protect against cognitive impairment in 
both adulthood and old age.  This study represents the longest period of time any AD 
vaccination protocol has utilized in any species.  Briefly, this protracted protocol of 
immunotherapy protected AD transgenic mice from impairment in a variety of cognitive 
measures that were otherwise present at both test points.  This improvement in cognition, 
however, occurred without any change in compact Aβ deposition within the brains of 
these mice.  Nevertheless, factor analysis revealed an underlying relationship between 
compact Aβ and multiple cognitive measures, indicating an interaction between brain Aβ 
and cognitive performance. 
 
Behavioral Effects - Sensorimotor and Anxiety-based Tasks 
 Within this study, at the early time point, the Tg+/Aβ group exhibited increased 
activity over multiple measures.  The increased activity could be due to higher levels of 
soluble Aβ or an interaction of the Aβ/antibody complex within the hippocampus, which 
has been shown to be influential on locomotor activity (Laghmouch et al., 1997).  
Alternatively, the increased activity could be due to glutamate activation by Aβ1-42, 
resulting in over-activation of NMDA receptors (Brunskill et al., 2005).  Over activation 
of NMDA receptors in the hippocampus has previously been shown to result in increased 
motor activity (Rogers et al., 1989).   
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 Subjects with AD have been shown to exhibit reduced anxiety levels (Gauthier, 
1998; Stout et al., 2003), as did the Tg+/C mice at the late test point.  However, because 
the Tg+/Aβ mice had corrected their level of anxiety to the level of the NT mice, the Aβ 
vaccination corrected their disinhibition.  Comparable to findings by Arendash et al. 
(2001), the Tg+/C group at either test point had similar overall activity to the NT mice.  
In addition, both balance beam and string agility tasks did not result in any difference 
between the Tg+/C mice and the NT mice.  This indicates that any cognitive impairment 
in the Tg+/C mice was not due to sensorimotor impairments.  
 
Behavioral Effects - Cognitive-based Tasks 
 Similar to the balance beam and string agility tasks, both Y-maze and circular 
platform tasks did not reveal any difference in performance between the Tg+/Con and NT 
groups at either test point.  Therefore, there was no potential for the immunotherapy to 
correct the performance within these tasks.  These findings are similar to those by 
Arendash et al. (2001a) and King and Arendash (2002) that found no change in 
performance between NT and APP Tg+ mice at similar ages for the Y-maze task.  
Importantly, measures from both Y-maze and circular platform tasks loaded independent 
from other cognitive-based measures in the factor analysis, as our laboratory has 
previously reported (Leighty et al., 2004).  This implies that these two tasks measure 
separate cognitive domains as compared to the water-based memory tasks.  
 Most active vaccination studies that reported behavioral findings only used single 
tasks to identify any cognitive improvement.  Janus et al. (2000) reported that 17 weeks 
of Aβ1-42 injections to 15 week old TgCRND8 mice resulted in improved spatial 
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reference learning, compared to control mice.  Similarly, the present study also found a 
significant improvement at a young age in AD transgenic mice due to repeated 
vaccinations (see below).  However at the aged test point, the results were less 
impressive, possibly due to the loss of  Tg+ mice between the two test points, resulting in 
lower group size and consequently less power for statistical analysis.  It is noteworthy 
that the survival rate of APP/PS1 mice in the present study was comparable to the 
survival rate of APP mice reported by King and Arendash (2002).  Nevertheless, at both 
test points, Tg+/Con mice were impaired versus NT mice in spatial reference learning 
during Morris maze testing.  In contrast, Arendash et al. (2001a) found that young adult 
APP/PS1 mice were not impaired in spatial reference learning in Morris water maze.  A 
possible explanation for the discrepancy could be the slight alteration in Aβ 
processing/aggregation after generations of crossbreeding, thereby making the APP 
transgene more sensitive to the cognitive domain required for Morris water maze 
acquisition.  At both young and aged timepoints, Aβ immunotherapy was effective at 
protecting against reference learning impairment, particularly at the earlier test point, as 
evidenced by Morris water maze acquisition results.  Similar to Morris water maze 
acquisition, Aβ immunotherapy protected against the memory retention deficit otherwise 
present at the young time point, as shown in the Morris water maze probe trial.  However, 
by the late time point, the immunotherapy was unable to protect against the continued 
memory impairment exhibited by these same mice.  The lack of effect of the vaccination 
could be partially due to the reduced number of animals in both Tg+ control and 
treatment groups.  Alternatively, it may be due to the high plaque load these animals have 
accumulated by 16 months of age, which was not prevented by Aβ immunotherapy and 
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that adversely affected their memory retention.  In contrast, Kotilinek et al. (2002) 
reported an improvement in both Morris water maze acquisition and retention memory in 
adult Tg2576 mice following 1 week of passive immunization.  However, the results 
indicated a significant treatment effect only for  pre-treatment versus post-treatment 
testing of the Tg+ mice and not for a direct comparison of post-treatment performance of 
Tg+ controls vs. Tg+/Aβ treated mice. 
 The platform recognition task, performed immediately following Morris water 
maze, measured the animals’ ability to switch strategies.  During Morris water maze, the 
mice were required to use a spatial strategy to find a submerged platform; however, the 
platform recognition task required the animals to use a different strategy - 
identification/recognition learning.  At the early time point, no effect of the Aβ 
immunotherapy could be seen because all groups performed well.  At the aged test point, 
however, the performance of Tg+/C mice was impaired vs. NT controls.  However, the 
performance of Aβ-treated Tg+ mice was no different from the NT mice or from any of 
the groups at the early test point, indicating that Aβ immunotherapy protected these mice 
from impairment in switching strategies.  This immunization-induced protection is 
especially relevant to patients with AD, who commonly have deficits in attention-shifting 
tasks (Amieva et al., 2004; Tales et al., 2004; Dorion et al., 2002).  Deficits in attention-
shifting tasks have been shown to be regionalized in the parietal cortex (Buck et al., 
1997).  Adult Tg+ mice show Aβ plaques in the cortex (Dodart et al., 2000b), which 
could contribute to the impairment in strategy-switching of the Tg+/C mice.  Therefore, it 
is evident that Aβ immunotherapy administered early in life and continued as a 
prophylactic can protect AD Tg+ mice from impairment in strategy switching. 
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 Previously, the radial arm water maze (RAWM) task has been shown to be 
sensitive to working memory impairment and Aβ deposition (Arendash et al., 2001a; 
Gordon et al., 2001; Nilsson et al., 2004; Leighty et al., 2004).  By the last block of the 
task, and for both time points, the present study’s Tg+/C mice exhibited poor 
performance.  This is in conjunction with short-term memory impairments, which 
progress throughout the disease process in patients with  AD.  In contrast, Aβ 
immunotherapy improved the performance of Tg+ at both ages such that the Tg+/Aβ 
mice were no different from NT mice by the last block of testing.  Morgan et al. (2000) 
had similar results after 8 months of Aβ1-42 injections, such that Aβ-treated mice 
performed significantly better than control Tg+ mice and no different from NT mice.  
Likewise, Sigurdsson et al. (2003) injected 6-8 month old Tg2576 mice with Aβ1-30 for 
13 months and found an overall significant improvement in working memory 
performance in an 8-arm radial maze.  However, the use of Aβ immunotherapy in aged 
APP/PS1 mice did not reverse any of the working memory impairments exhibited in 
RAWM testing, as reported by Austin et al. (2003).  In that later study, the lack of a 
treatment effect could be due to the much shorter period of vaccination and/or the much 
greater Aβ burdens that the “aged” APP/PS1 had when Aβ immunotherapy was begun. 
Results from the present study indicate that long-term Aβ immunotherapy is effective at 
protecting against working memory impairments in AD Tg+ mice if implemented at a 
young or adult age.  Summarizing the behavioral data in this study, Aβ immunotherapy 
administered for 15 months effectively protected AD Tg+ mice against cognitive deficits 
 244 
in spatial learning/reference memory (Morris water maze), strategy switching/recognition 
(platform recognition), and working memory (RAWM). 
 
Aβ Histopathology   
 Surprisingly, all of the cognitive improvements previously reported occurred 
without any change in compact Aβ deposition.  Therefore, all of the cognitive benefits 
from life-long Aβ immunotherapy were independent of alterations of Aβ deposition.  
Several prior vaccination studies have also shown cognitive benefits of immunotherapy 
in behavioral tasks without concurrent changes in Aβ measures.  Morgan et al. (2000) 
only found a reduction in Aβ in the cortex, not hippocampus, despite significant 
improvements in working memory.  In addition, passive immunotherapy has been 
reported to result in improvements in cognition with no alterations in amyloid deposition.  
Regarding the latter, Dodart et al. (2002) found that administration of m266 (specific to 
Aβ13-28) improved object recognition memory after a single injection, with no concurrent 
change in Aβ deposition.  The authors suggested that the behavioral benefit from the 
vaccination is more likely due to peripheral clearance or sequestration of soluble Aβ, and 
not by altering deposited forms of Aβ within the brain.  In effect, the present study and 
others suggest that behavioral improvements resulting from Aβ immunotherapy are 
possibly due to neutralization of soluble Aβ oligomers from the brain.  This effect occurs 
early in Aβ aggregation, prior to manifest Aβ fibrillar formation, such that improvements 
in cognition could occur at an early age, prior to overt Aβ deposition, as was seen the 
present study for the early time point. 
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Correlations and Multimetric Analyses 
 Previous work has demonstrated significant correlations between cognitive 
measures and Aβ deposition; however, the present study found no such correlations.  
Most notably this could be due to the lack of change in Aβ deposition between the 
transgenic groups, despite the improved cognitive performance of Tg+/Aβ mice.  Also, 
because previous work from the same mouse line (Arendash et al., 2001; Gordon et al., 
2001) found significant correlations between cognitive performance and Aβ pathology 
measures, generations of crossbreeding for the present study could have affected the 
behavioral phenotype of the transgenic mice, as well as the fact that the present study 
involved a full test battery (run twice).  Despite the lack of correlations, FA analysis 
revealed significant underlying relationships between multiple cognitive measures and 
Aβ deposition.  In prior work from our laboratory, factor analysis has been successfully 
used in transgenic AD mouse models to identify underlying relationships between 
cognitive and pathological measures (Leighty et al., 2004).  Studies that employ a 
comprehensive test battery that encompasses multiple cognitive and sensorimotor 
domains have the advantage of utilizing multimetric analyses, such as FA and DFA, in 
order to characterize and distinguish between different treatment groups based on their 
performances.  Leighty et al. (2004) demonstrated significant associations between 
cognitive performance and Aβ deposition measures within four separate PDAPP mouse 
lines.  At both the early and late test point the current study found one primary factor 
(factor 1) that was largely cognitively based and one factor (factor 2) that loaded mainly 
sensorimotor measures.  At the late test point, both with and without Aβ pathologic 
measure, one measure of elevated plus maze (EP-TO) loaded separately in its own factor.  
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While the remaining two factors (EP-#C and EP-#O) loaded with activity or exploratory 
measures, the “percent time in open arms” clearly measures more of a true anxiety 
component.  Also at the late test point, Aβ pathologic measures loaded primarily within 
factor 1, which remained cognitively-based.    However, the findings from factor 2 
associated cognitive and sensorimotor components in addition to one measure of Aβ; 
whereas without pathologic measures, factor 2 did not include any cognitive measures.  
This indicates that Aβ interacts with measures of activity in addition to measures of 
cognition.  
 In addition to FA, discriminant function analysis (DFA) has also been used 
successfully in transgenic mouse models studies.  This analysis attempts to discriminate 
between groups of mice based on their performance.  Within the present study, although 
the “direct entry” method was relatively ineffective in discriminating between the 3 
groups, the DFA step-wise forward method was very effective at distinguishing between 
the NT and Tg+ groups.  At the later test point, starting with all 19 behavioral measures, 
this DFA was able to discriminate between the Tg+ groups.  This indicates that even after  
15 months of active Aβ immunizations, Aβ vaccinated Tg+ were still clearly 
distinguishable from Tg+ controls based on their sensorimotor measures and cognitive 
performance.  In addition, a stepwise forward DFA using only the top cognitive measures 
from factor 1 significantly separated the NT and Tg+/Con groups, but could not 
distinguish cognitive performance of the NT and Tg+/Aβ groups.  The measures retained 
for providing the discrimination between NT and Tg+/Con mice included two measures 
of RAWM, and one from platform recognition, indicating that the transgenic behavioral 
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effect at 15-16½ months is largely based on working memory and recognition/ 
identification.  
 In summary, life-long active Aβ immunotherapy was effective at protecting AD 
Tg+ mice from impairment in a variety of cognitive domains .  This protection provided 
to Tg+ mice extended across all of the water-based cognitive tasks and well into older 
age.  Since this cognitive protection occurred without a decrease in Aβ deposition, the 
mostly likely mechanism of Aβ immunotherapy’s action involves neutralization/removal 
of small Aβ oligomers from the brain. 
 Because of the effectiveness of several Aβ immunotherapy studies in AD 
transgenic models of Alzheimer’s disease, clinical trials were performed.  A Zurich 
cohort of AD subjects that had received active vaccinations of Aβ1-42 showed 
stabilization of memory and preserved hippocampal function in conjunction with the 
production of antibodies (Hock, 2003).  Also, antibodies from these inoculated AD 
subjects were reactive to Aβ plaques from AD Tg+ mouse brains and Aβ from human 
brains (Hock, 2002).  However, 5 % of a separate cohort of AD subjects that were 
injected with Aβ1-42 developed a severe inflammatory response (e.g., 
meningoencephalitis) to the vaccine or to the vaccine’s adjuvant.  Therefore, these trials 
were halted and less risky approaches for AD immunotherapy are currently being 
explored.  Alternative vaccination therapies which might offer less negative side effects 
include passive vaccinations, immunization with partial Aβ fragments, or injection of T-
cells.   
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II.  Omega-3 Discussion   
Numerous epidemiologic studies suggest that a higher intake of fish oils is 
associated with a reduced risk of dementia later in life (Kalmijn et al., 1997a; Kalmijn et 
al., 1997b, Kalmijn et al., 2004).  This reduced risk is thought to be more specifically 
contributed by the n-3 fatty acids, DHA and/or EPA, which are highly concentrated in 
fish (Kalmijn et al., 1997a; Kalmijn et al., 1997b).  Despite this notion, there have been 
no long-term clinical studies that have administered either DHA or EPA to subjects with 
dementia as a treatment, or prior to onset of cognitive impairment in the form of a 
prevention-based study.  In addition, the majority of rodent studies that have utilized fish 
oils or DHA supplementation have largely first involved DHA or n-3 depletion prior to 
supplementation (Gamoh et al., 2001; Ikemoto et al., 2001; Calon et al., 2004; Hashimoto 
et al., 2005).  In non-transgenic rodents, there was no cognitive benefit to 
supplementation with DHA after multiple generations of n-3 deficiency (Gamoh et al., 
2001; Ikemoto et al., 2001).  Likewise, Calon et al. (2004) found no benefit of 
recognition/identification memory or memory retention in either non-transgenic or APP 
transgenic mice supplemented with DHA.  However, APP mice enriched with DHA 
showed an improvement in memory acquisition in the Morris water maze (Calon et al., 
2004).  In addition, Hashimoto et al. (2005) showed an improvement in working and 
reference memory in rats supplemented with DHA, after being fed a fish oil deficient diet 
for 3 generations and infused with Aβ1-40.  Thus, the effects of n-3 fatty acid 
supplementation in rodents is equivocal, with the later two studies related to Alzheimer’s 
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disease not designed to address the central question of whether n-3 fatty acids are 
cognitively protective against AD.  
The major aims of the present study were to: 1) determine the cognitive effects of 
a high n-3 diet in both NT and AD transgenic mice, 2) determine the cognitive effects of 
a typical American diet (high in n-6 and low in n-3 fatty acids) in both NT and AD 
transgenic mice, and 3) determine the effects of these two diets on blood cytokine levels, 
brain fatty acid levels, and brain Aβ levels (Tg+ mice only).  The high n-3 diet mimicked 
humans having fish twice weekly, with a dietary n-6/n-3 ratio of 4/1.  In essence, this 
study investigated whether an n-3 enriched diet, begun in young adulthood, can protect 
against inevitable cognitive impairment in AD transgenic mice and whether a high n-6 
enriched diet with an n-6/n-3 ratio of 50/1 can contribute to greater cognitive impairment 
in AD transgenic mice.  Moreover, since both diets were also given to non-transgenic 
mice, cognitive effects in normal animals could also be tested.  
 
Survival Analysis. 
 Prior to an assessment of the behavioral impact of a high n-3 or high n-6 diet in 
Tg+ mice (see below), a study was performed to determine the effects of an n-3 deficient 
diet on survivability.  Briefly, this study found that an interaction between the 
background and transgene profile determined the survivability of mice that were fed an n-
3 deficient diet.  F1 generation PS1 mice had increased survival on an n-3 deficient diet 
as compared to F1 APP mice and F2 generation APP, PS1 and NT mice.  The F1 
generation had a relatively high amount of B6 background (25%), which primarily 
contributed to the increased survival of the PS1 mice.  Mice with 100% B6 background 
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have been shown to be less sensitive to dietary alterations in fat, and have minimal 
changes in metabolism when shifting between high fat to low fat diets (Biddinger et al., 
2005).  In addition, mice with a high B6 background also have elevated expression of 
fatty acid synthase (FAS), malic enzyme and δ-5 desaturase, - all of which convert 
available fatty acids into long-chain fatty acids (Coleman, 1992; Biddinger et al., 2005).  
FAS is critical in de novo lipogenesis to ultimately contribute to the production of 
palmitate.  Palmitate is a precursor to downstream production of long-chain fatty acids.  
Malic enzyme also contributes to the de novo production of palmitate.  Thus, the B6 
background appears to have contributed to increased lipid metabolism in order to 
compensate for the n-3 deficiency and reduced n-6 dietary content.  A combination of the 
increased expression of FAS, malic enzyme and δ-5 desaturase due to the increased B6 
background from the F1 versus the F2 generation clearly contributed to the increased 
survivability of PS1 mice on a diet devoid of n-3 fatty acids. 
As to why the PS1 transgene contributed to survival whereas the APPsw 
transgene did not, there is no clear association between either of these transgenes and 
lipid metabolism.  Previous work has shown that the presence of a mutant APP transgene 
in mice leads to increased inflammation, oxidative damage and dystrophic neurites 
(Irizzary et al., 1997; Benzing et al., 1999; Melhorn et al., 2000; Pratico et al., 2001).  
These factors alone are not detrimental to the survival of APP mice at their young age.  
However, the combination of the severe reduction in n-6 fatty acids, the lack of n-3 fatty 
acids in the omega-3 deficient diet, and the presence of mutant APP could account for 
their low survival.  In the present study, the F2 generation mice had a reduced percentage 
of B6 background (12.5%), which was insufficient to contribute to survival irrespective 
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of genotype.  In summary, the higher B6 background and PS1 genotype of F1 generation 
mice was able to compensate for the a diet low in n-6 and deficient in n-3 fatty acids. 
 
Behavioral, Pathologic and Neurochemical Assessments. 
 Briefly, this study determined that in NT mice, long-term n-3 supplementation did 
not provide any cognitive benefits.  Similarly, in Tg+ mice, n-3 supplementation largely 
resulted in cognitive performance that was no better than that of mice fed a standard diet 
or a diet high in n-6 fatty acids.  For both NT and Tg+ mice, the high n-6 diet did not 
result in an overall worse cognitive performance as compared to the standard-fed mice.  
These results suggest that DHA and EPA supplementation may only provide limited, or 
no cognitive protection against AD.  It is possible, however, that dietary fish contains 
additional beneficial nutrients, besides DHA and EPA, that could offer protection against 
development of AD in humans.  Additionally, there were no major diet-induced changes 
in plasma cytokine levels or brain Aβ deposition (the later for Tg+ mice).  However NT 
mice did show some marked diet-induced changes in cortical fatty acids levels.  Within 
the high n-6 fed NT mice, most of the n-6 fatty acids were elevated as compared to the 
high n-3 fed NT mice.  Similarly, half of the n-3 fatty acids were elevated in the high n-3 
fed NT mice as compared to the high n-6 fed NT mice.  However, in the APP/PS1 mice, 
there were minimal diet-induced changes in cortical fatty acid levels with either a high n-
3 or high n-6 diet.  Additionally, there were no diet-induced changes in soluble or 
insoluble hippocampal Aβ or plasma cytokines between any of the three APP/PS1 
groups.  Despite the minimal changes in cognitive and pathologic measures, multimetric 
analyses revealed significant separations between the dietary groups of the Tg+  and 
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more specifically between the standard and high n-3 APP/PS1 mice.  However, within 
the NT mice, only the high n-6 fed mice were discriminated from both the standard and 
high n-3 NT mice.  
  
Behavioral Effects - Sensorimotor and Anxiety-based Tasks 
 Prior rodent studies that have evaluated sensorimotor and anxiety effects from 
fish oil supplementation found both an increase (Carrie et al., 2000) and decrease (Chalon 
et al., 1998) in locomotor activity; however no significant changes in anxiety-based tasks 
(Chalon et al., 1998; de Wilde et al., 2002).  The present study did not reveal any 
differences in sensorimotor/anxiety measures among the three dietary groups of NT mice.  
Thus, no effects of high n-3 or high n-6 diets were evident on sensorimotor function and 
anxiety level in normal mice.  These results are in contrast to several prior reports 
involving normal rodents.  Carrie et al. (2000) showed increased locomotor activity in 
mice that were supplemented with fish oil.  However, Chalon et al. (1998) found reduced 
activity in young rats that had been supplemented with fish oil for two generations.  
Chalon et al. (1998) also measured anxiety in the elevated plus maze task and found no 
effect with fish oil supplementation.  In conjunction with this, de Wilde et al. (2002) also 
found no difference in elevated plus maze measures with n-3 PUFA enrichment in rats. 
The results from prior studies are therefore inconsistent, perhaps reflecting different 
methodologies.  In contrast to the lack of dietary effects on sensorimotor function/anxiety 
in the present study’s NT mice, Tg+ mice given n-3 supplementation had increased 
activity in two separate tasks (open field and Y-maze).  The reason(s) for why an 
 253 
increased level of activity results from n-3 supplementation in Tg+ mice, but not NT 
mice, are unknown and would be based on conjecture without further study.  
 No previous studies have evaluated the effects of n-3 or n-6 supplementation on 
balance beam or string agility in either normal or Alzheimer’s transgenic mice.  For both 
NT and Tg+ mice of the present study, there were no effects of either the n-3 or the n-6 
diet on either of these tasks.  These results underscore that neither diet had deleterious 
effects on sensorimotor function and that any dietary effects on cognitive-based tasks 
within the NT or Tg+ groups could not be attributable to sensorimotor impairment.   
  
Behavioral Effects - Cognitive-based Tasks 
 Previous work involving alterations of dietary n-3 or n-6 fatty acids evaluated 
cognitive performance primarily in the Morris water maze task (Jensen et al., 1996; 
Wainwright et al., 1999; Carrie et al., 2000;  de Wilde et al., 2002; Barcelo-Coblijn et al., 
2003; Calon et al., 2004).  A few studies (all from the same group) have reported 
enhanced performance with n-3 supplementation in maze learning using a simple maze 
construction with only one entry/exit and many blind alleys  (Suzuki et al., 1998; Lim & 
Suzuki, 1999; Lim & Suzuki, 2000).  One study that utilized the Tg2576 APP transgenic 
mouse model found marginal improvement in spatial memory learning from Morris water 
maze acquisition with DHA enrichment (Calon et al., 2004).  It is important to 
underscore, however, that the Calon et al. (2004) study involved DHA supplementation 
to Tg2576 mice that were previously on a DHA-deficient diet.  As mentioned earlier, this 
experimental model has marginal relevance to human-related studies.  Within the present 
study there were minimal effects of either diet across a variety of cognitive measures in 
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NT or Tg+ mice. The few effects of high n-3 or high n-6 diets can primarily be 
summarized as follows:  n-6 enrichment in Tg+ and NT mice resulted in impaired spatial 
learning/memory in the circular platform task as compared to standard-fed groups within 
their genotypes,  n-6 supplementation in Tg+ mice resulted in improved memory 
retention as seen in the Morris water maze, and n-3 supplementation in APP/PS1 mice 
resulted in improvement in recognition/identification in the platform recognition task, as 
compared to the standard-fed APP/PS1 mice.    
 Because there was no difference in Y-maze percent alternation between the 
standard Tg+ mice and the standard NT mice, no improvement due to fatty acid 
administration could be seen in the Tg+ mice.  Also, in the NT mice, supplementation of 
n-3 fatty acids did not result in any improvement in alternation performance; as well, 
supplementation of n-6 fatty acids did not result in a lower percent alternation in either 
Tg+ or NT mice.  Even though no other previous work has evaluated the effects of n-3 or 
n-6 fatty acid supplementation on spatial learning/memory in the circular platform task, 
the present study showed that dietary enrichment of either NT or Tg+ mice with n-6 fatty 
acids resulted in cognitive impairment in this task.  Although the circular platform task 
measures spatial reference learning and memory similar to Morris water maze, circular 
platform measures loaded on factors independent of other cognitive measures in factor 
analysis, indicating a separate cognitive domain used in this task as compared to Morris 
maze and water-based cognitive tasks in general.  Clearly, circular platform uses unique 
cognitive domains that were sensitive to n-6 supplementation in both Tg+ and NT mice. 
 Likewise to the above-mentioned tasks, the standard-fed Tg+ mice performed 
similar to the standard-fed NT mice in Morris water maze.  Despite this lack of a 
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transgenic impairment, there was ample opportunity for the n-3 supplementation to 
improve upon Morris maze performance in Tg+ mice, and yet no such improvement 
occurred with n-3 supplementation.  The lack of a transgenic impairment in Morris 
acquisition is in opposition to the impairment seen in 5½ month old APP mice (Arendash 
et al., 2004) and 4½-6 month old APP/PS1 mice previously reported in this dissertation 
(Jensen et al., 2005).  The lack of an improvement or impairment in Morris maze 
acquisition with either n-3 or n-6 dietary intervention in NT mice is consistent with all 
other NT rodent studies that have used Morris water maze to evaluate cognitive effects of 
fatty acid supplementation.  Jensen et al. (1996) found no improvement in spatial 
learning/memory after 4 generations of fish oil supplementation in either acquisition or 
retention memory.  Additional work involving supplementation of young rats with DHA 
or fish oil did not result in improved spatial memory (Wainwright et al., 1999; Barcelo-
Coblijn et al., 2003).  Also, de Wilde et al. (2002) showed that adult rats did not 
behaviorally benefit from n-3 supplementation in Morris water maze acquisition or 
retention.  Thus, the present study’s lack of any n-3 dietary effect on Morris maze 
acquisition in normal rodents is consistent with the prior literature.   
 Within Tg2576 APP mice Calon et al (2004) reported that DHA enrichment to an 
n-3 deficient diet resulted in improved acquisition in Morris water maze.  However, the 
improvement in acquisition was only noted in the latter phase of Morris maze acquisition.  
Thus, there was no effect overall of transgenicity, DHA enrichment or low dietary DHA.  
The design of the Calon study done in AD Tg+ mice and the present study’s design are 
not comparable.  Nonetheless, both studies found no effects of a high n-3 diet on Morris 
maze retention – this is, if all 6 groups of the present study are included in the analysis.  
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If only APP/PS1 mice are compared for a high n-3 vs. standard diet, however, the present 
study found that n-3 supplemented Tg+ mice showed a partial improvement in memory 
retention.  Surprisingly, the high n-6 Tg+ mice showed a complete restoration in memory 
retention to the same level as the NT mice.  Within the NT mice, opposite results were 
seen, such that the high n-6 mice showed impairment in memory retention.  Thus, the 
same diet involving high n-6 fatty acids had opposite effects in NT and Tg+ mice.  
Several previous studies have shown that NT mice supplemented with n-3 fatty acids 
show no benefit in Morris water maze acquisition or retention (Jensen et al., 1996; 
Wainwright et al., 1999; Carrie et al., 2000), while NT mice fed low dietary n-3 fatty 
acids are not impaired in Morris water maze (Calon et al., 2004).  Since no prior Morris 
maze studies involved administration of a high n-6 diet to AD Tg+ mice, there is a lack of 
information in the available literature that could account for the discrepancy between the 
response of NT and Tg+ to a high n-6 diet.  
 The platform recognition task requires that mice switch strategies from the spatial 
memory of Morris water maze to a search/identification strategy.  Calon et al. (2004) 
found no effect of dietary DHA in NT mice in this task, similar to the results from the 
present study.  However, Calon et al. (2004) also found no difference overall between 
APP and NT mice, nor with the addition of DHA to either genotype.  However, the 
present study found a clear impairment of Tg+ mice fed a high n-6 diet as compared to 
mice fed a high n-3 fatty acids.  Although, n-3 fatty acids have been shown to be 
important in visual development (Marin et al., 2000), this is most likely not the reason for 
the impairment of high n-6 Tg+ mice.  All Tg+ and NT groups performed similar in 
MWM acquisition in which they were required to use spatial cues, illustrating that all 
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groups had similar visual abilities.  Thus, there was a clear cognitive protection offered 
by n-3 fatty acids to AD Tg+ mice compared to the impairment otherwise evident in Tg+ 
mice fed a diet high in n-6 fatty acids, independent of visual abilities.  These results are 
quite significant in relation to subjects with AD that have difficulty in strategy switching 
or attention shifting, as previously discussed in a prior section.  
The radial arm water maze (RAWM) task has been shown to be a sensitive index 
of working memory and also sensitive to hippocampal Aβ deposition (Arendash et al., 
2001; Gordon et al., 2001; Nilsson et al., 2004; Leighty et al., 2004).  To date, there have 
been no other studies that evaluated the effects of either omega-3 or omega-6 fatty acid 
supplementation to NT or AD Tg+ mice on radial arm water maze (RAWM) working 
memory performance.  However, Sugimoto et al., (2002) found that adult mice that were 
supplemented with DHA had improved working memory, as indexed by the 8-arm radial 
maze task.  In contrast, Gamoh et al. (2001) found no improvement in working memory 
in the same task from aged rats that were given dietary DHA after 3 generations on a fish 
oil deficient diet.  Similarly, the present study illustrated that there were no, or minimal 
effects of diet in either NT or Tg+ mice on RAWM working memory performance.  
Although, both high n-3 and high n-6 diet Tg+ mice performed similar to standard NT 
mice by the last block of testing, neither diet group provided any significant improvement 
or impairment in memory as compared to the standard Tg+ mice.  This indicates that n-6 
enrichment did not result in a greater deficit as compared to either a standard or high n-3 
diet in either NT or Tg+ mice.  Thus, high dietary n-6 fatty acids in normal individuals, or 
those predisposed to AD would not appear to induce an increased risk of developing a 
working memory deficit.  In addition, the current study showed that n-3 supplementation 
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was not able correct working memory impairments in Tg+ mice and provided essentially 
no benefit to working memory in Tg+ mice.   
  
Aβ Pathology   
 Puskas et al. (2003) and Barcelo-Coblijn et al. (2003) found that fish oil 
supplementation to rats increased expression of transthyretin (TTR).  TTR has been 
previously shown to solubulize fibril Aβ and inhibit aggregation of Aβ in vitro 
(Schwarzman & Goldgaber, 1996; Redondo et al., 2000).  TTR has the potential to both 
inhibit initial formation of Aβ deposition and clear compact amyloid from the brains of 
rodents fed fish oil.  However, the present study found no alterations of either soluble or 
insoluble hippocampal Aβ1-40 or Aβ1-42 levels from APP/PS1 mice fed a high n-3 diet.  
Also, there were no differences in hippocampal soluble or insoluble Aβ1-40 or Aβ1-42 in 
high n-6 APP/PS1 mice compared to either the high n-3 or standard-fed APP/PS1 mice.  
In contrast, Lim et al. (2005) found that DHA enrichment to aged AD Tg+ mice 
previously fed an n-3 deficient diet reduced total insoluble Aβ in addition to total 
(insoluble + soluble) Aβ42 and total Aβ40 in the cortex.  Despite the altered Aβ levels, 
TTR expression was unchanged in those mice, indicating an alternative mechanism by 
which DHA altered amyloid levels. 
  
Cytokine Levels 
 Previous works shows conflicting results indicating both pro-inflammatory and 
anti-inflammatory expression resulting from n-3 supplementation.  Billiar et al. (1988) 
and Renier et al. (1993) showed that macrophages from rodents fed dietary fish oil 
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resulted in an anti-inflammatory effect.  By contrast, Watanabe et al. (1993) and 
Petursdottir et al. (2002) showed that rodents fed a diet enriched with fish oil had 
increased pro-inflammatory cytokines from peritoneal macrophages.  The present study 
found no significant differences in plasma cytokine levels of NT mice fed a high n-3 vs. 
high n-6 diet.  These results are in contrast to all four of the above studies, perhaps in part 
due to their use of macrophages to measure cytokines rather than the current study’s use 
of plasma; alternatively their treatment groups were compared to standard diet animals, in 
contrast to the n-3 vs. n-6 group comparisons.  For the most part, human studies have 
supported anti-inflammatory actions of n-3 fatty acids.  Blok et al. (1996) reviewed many 
of the human studies involving n-3 fatty acid with inflammatory diseases.  To summarize 
his review, administration of dietary n-3 fatty acids resulted in improvements in 
rheumatoid arthritis, Systemic Lupus Erythematosus (SLE), psoriasis and ulcerative 
colitis.  The primary mechanism to reduce inflammation is through EPA metabolism.  
EPA, from fish oil, rapidly incorporates into cell membranes and replaces AA in the 
phospholipids.  This replacement increases the production of a less active prostaglandin 
(E3) and leukotriene (B5), thereby reducing the inflammatory response. 
In the present study, plasma cytokine levels from Tg+ mice indicated a trend 
toward reduction in all cytokines (pro- and anti-inflammatory) in plasma for Tg+ mice 
fed a high n-6 diet vs. a high n-3 diet.  Therefore, the present study supports both pro- 
and anti-inflammatory enhancement in Alzheimer’s Tg+ mice fed a high n-6 diet.   
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Brain Fatty Acid Levels 
 AD subjects have been found to have a reduced amount of EPA, DHA and total n-
3 fatty acids in brain tissue as compared to elderly control subjects (Corrigan et al., 1998; 
Conquer et al., 2000).  This reduction in n-3 PUFAs as compared to control elderly 
persons further provides evidence that the pathology associated with AD is independent 
of the normal aging process.  Although the cause of the alterations in fatty acid content in 
the brain of AD patients is unknown, some studies suggest that there is an alteration in 
fatty acid metabolism by the liver, increased oxidative damage, or a reduction in dietary 
intake of specific fatty acids (Soderberg, et al., 1991; Skinner et al., 1993; Corrigan et al., 
1998; Prasad et al., 1998).  Fatty acid metabolism proceeds primarily such that dietary 
fatty acids are metabolized by the liver and transported via the blood to target organs, 
such as the brain.  The present study found that alterations in brain fatty acids were 
affected by both the AD genotype and dietary intake.  However, all three diets (standard, 
high n-3 and high n-6) contained similar amounts of saturated and monounsaturated fatty 
acids.  As such, there were no significant differences in cortical saturated or 
monounsaturated fats within the three NT or three APP/PS1 groups.  There were also no 
differences between the NT or APP/PS1 mice on any of the three diets, indicating that 
there is no difference in metabolism of saturated or monounsaturated fats in APP/PS1 
mice as compared to NT mice. 
For the NT mice fed a high n-6 diet, many of the cortical n-6 fatty acids 
(including total n-6 fatty acids) were elevated versus the high n-3 fed mice.  Likewise for 
the NT mice fed a high n-3 diet, half of the n-3 fatty acids were elevated versus the high 
n-6 NT mice.  Thus, in the NT mice, the frontal cortex content of fatty acids is reflective 
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of their dietary intake.  However, despite the significant changes in both n-3 and n-6 
cortical levels, minimal changes in behavioral performance were seen between the NT 
groups.  These results provide further evidence for a lack of relationship between DHA 
and/or EPA intake and cognitive function.  Within APP/PS1 mice, only one n-6 fatty acid 
(22:5n-6) was elevated in the high n-6 group versus the high n-3 group.  Also, there were 
no differences in cortical n-3 content between any of the three APP/PS1 groups.  
Therefore, unlike the NT mice, despite the significant difference in dietary intake of n-3 
and n-6 fatty acids, the concurrent changes in brain fatty acid levels were not evident.   
In contrast to the current study, Calon et al. (2005) found significant decreases in 
frontal cortex n-6 fatty acids and increases in n-3 fatty acids in aged Tg2576 APP mice 
fed a low n-3 diet supplemented with DHA.  The same results were also seen in aged NT 
mice on a low n-3 diet that was also supplemented with DHA.  The authors suggested 
that the difference in frontal cortex fatty acid levels of the low n-3 fed APP mice was 
most likely due to the initial n-3 depletion in combination with the presence of the APP 
transgene.  Calon et al. (2005) suggested that for the low n-3 group, the APP transgene 
provided oxidative stress that rapidly depleted the brain of DHA.  However in a direct 
comparison between the genotypes, the present study found that among the high n-6 
mice, there were minimal differences in brain fatty acid levels when comparing NT to 
APP/PS1 mice.  However, the current study also found significant increases in several n-
6 fatty acids within the APP/PS1 high n-3 mice versus the high n-3 NT mice.  Thus, 
despite identical dietary intake, APP/PS1 mice show a deficit in metabolizing 
polyunsaturated fatty acids for incorporation into brain tissue as compared to NT mice.  
Therefore enhanced dietary intake of n-3 or n-6 fatty acid in normal mice resulted in 
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elevated brain levels of n-3 and n-6 fatty acids, respectively; however, these same 
elevations were not seen in APP/PS1 mice. 
 
Correlations   
 Two sets of correlations were performed involving NT mice 1) for all three diet 
groups or 2) for only the high n-3 and high n-6 groups.  Briefly, these correlations 
revealed a positive relationship between saturated, monounsaturated, n-3 and n-6 fatty 
acids in the frontal cortex and cognitive impairment in multiple tasks, primarily RAWM 
and platform recognition.  These correlations show that brain total fatty acid levels, 
irrespective of their form, are indicative of cognitive impairment.  However, Greenwood 
and Winocur (1996) showed that learning impairment is directly related to intake of 
saturated fats, and independent of monounsaturated or polyunsaturated fatty acid intakes.  
More recently, Winocur and Greenwood (2005) showed that rats fed a diet high in 
saturated fats were impaired on memory and learning tasks.  Likewise, Morris et al. 
(2005) found that increased intake of n-6 and n-3 fatty acids in addition to saturated fats 
plays an important role in cognitive function and risk of dementia.  Similar to the present 
study, Suzuki et al., (1998) found that mice that had increased n-6 fatty acids in the brain 
stem were poorer performers as compared to mice that had increased n-3 content in the 
brain stem.  However, the authors did not perform any direct correlations.  Similarly, 
Ikemoto et al. (2001) also showed that an increase in brain n-6 fatty acid levels is related 
to learning impairment in a brightness-discrimination task.   
 Similar to NT mice, correlations among APP/PS1 mice revealed a significant 
relationship between cortical n-6 levels and cognitive impairment in multiple tasks.  
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Previous work has also shown that elevated levels of brain n-6 fatty acids are associated 
with impaired learning or memory in AD Tg+ mice (Calon et al., 2004)  or AD-like rats 
(Hashimoto et al., 2002).  Studies of human AD subjects also show a relation between a 
reduction in brain n-6 fatty acids and reduced prevalence of dementia in AD (Corrigan et 
al., 1998; Prasad et al., 1998).  Prasad et al. (1998) not only showed a correlation between 
AD and reduction of brain n-6 fatty acids, but also an association of β-amyloid plaques in 
the regions that had reduced n-6 fatty acid levels.  Likewise, the present study showed a 
significant correlation between hippocampal Aβ levels and cognitive impairment.  This is 
in agreement with previous work showing multiple correlations between brain Aβ 
deposition and a variety of cognitive measures (Arendash et al., 2001a; Gordon et al., 
2001; Leighty et al., 2004).  Lastly, both cortical n-3 and n-6 fatty acid levels in frontal 
cortex were overall correlated with plasma cytokines – higher brain levels of n-3 and n-6 
fatty acids were associated with lower levels of pro-inflammatory cytokines (e.g., an anti-
inflammatory effect).  As mentioned in one of the below sections, the relation between 
polyunsaturated fatty acids and cytokine levels is conflicting, as supported by the 
correlation results.   
  
FA and DFA   
 In agreement with the Aβ vaccination study of this dissertation and previous 
studies from our laboratory, the factor analysis results involving behavioral measures 
from the present study show that factor 1 is loaded exclusively by cognitive measures, 
whereas factor 2 is sensorimotor/anxiety-based (Leighty et al., 2004; Jensen et al., 2005).  
Whether or not APPsw mice were included with the APP/PS1 mice in the factor analysis, 
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the factor loadings remained relatively similar.  Inclusion of neurochemical measures 
showed associations between multiple cognitive domains and both Aβ measures and n-6 
fatty acids.  In support, similar associations were also seen within several correlations as 
previously discussed. 
In addition to FA, a number of discriminant function analyses (DFAs) were 
performed in order to determine if the separate dietary groups within each genotype (Tg+ 
or NT) could be significantly distinguished based on their sensorimotor and cognitive 
performances.  Direct entry DFA was completely unsuccessful at discriminating between 
any of the dietary groups of NT or Tg+ (with or without APP mice) mice.  However, the 
step-wise forward DFA could discriminate between the high n-6 NT group and both the 
standard and high n-3 NT groups using all measures (sensorimotor and cognitive).  In 
addition, step-wise forward DFA was ineffective at discriminating between the three NT 
groups using only the top seven cognitive measures from the FA factor 1, or the two NT 
groups (standard and high n-3) using either all measures or the top nine cognitive 
measures from FA factor 1.  This indicates that the fatty acid diets partially contributed to 
the overall performance of the NT mice, despite the lack of significant difference 
between these groups on any given task.  However, there were several significant 
differences in cortical fatty acid levels within the separate NT groups, which, according 
to the correlation results were significantly associated with multiple cognitive domains.  
Clearly, the cortical fatty acid content in NT mice has an underlying relationship to 
cognitive performance.   
The step-wise forward DFA’s for Tg+ and APP/PS1 mice were more effective at 
discriminating between dietary groups than the DFA’s for the NT mice.  Step-wise 
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forward DFA was successfully used to completely separate all three Tg+ groups and both 
standard and high n-3 APP/PS1 groups using all 19 behavioral measures.  This indicates 
an overall contribution of dietary fatty acids to performance on all tasks collectively 
(sensorimotor, anxiety, and cognitive) in Tg+ mice despite a lack of effect on individual 
tasks between the 3 Tg+ dietary treatment groups.  Also, Tg+ mice fed the high n-6 diet 
were able to be separated from both the standard and high n-3 Tg+ mice with the step-
wise forward DFA using only the top seven cognitive measures from the FA factor 1.  
This is the same separation seen from the step-wise forward DFA using all measures in 
NT mice.  Lastly, step-wise forward DFA completely discriminated standard-fed 
APP/PS1 mice from high n-3-fed APP/PS1 mice using their top nine cognitive measures 
from the FA factor 1.  Thus, despite a lack of difference in many of the behavioral tasks, 
n-3 fatty acid supplementation contributed significantly to the overall behavioral 
performance of APP/PS1 mice.  Taken together with the correlation results and FA 
measures, it is evident that dietary intake of fatty acids are closely associated with 
multiple cognitive domains in both NT and Tg+ mice.  Although none of the direct entry 
DFA’s were successful, all of the step-wise forward DFA’s were completely successful at 
separating the high n-3 and high n-6 diet groups for Tg+ mice (with or without APP 
mice).  Overall, this indicates that the increase in n-3 fatty acids in the high n-3 diet was 
sufficient to alter the behavior of AD Tg+ mice such that they could be separated based 
solely on their behavioral performances.   
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Clinical Implications of Omega-3 Fatty Acids for Prevention Against AD   
 Within NT mice, there was no overall cognitive benefit of dietary n-3 
supplementation.  Conversely, there were no overall impairments due to the n-6 
enrichment.  Thus, the high n-6 content of a typical American diet does not by itself lead 
to cognitive impairment in individuals not pre-disposed to AD.  However, since a high n-
6 fatty acid diet is typically linked with a diet high in saturated fatty acids, it is more 
likely that the saturated fats in a typical American diet increase the risk of cognitive 
impairment.  Supportive of this premise, Morris et al. (2005) found little evidence for an 
association between fish intake and rate of cognitive decline.  Instead, Morris found that 
the positive relationship between fish intake and cognitive protection was most 
significant when including ALA supplementation over a long-term period, thus the 
protection was not solely due to the fish intake.  In addition, rodents that have been fed a 
high fat diet are clearly impaired in spatial learning in the Morris water maze(Zhao et al., 
2004) and learning/memory in the variable-interval delayed attention task (Winocur & 
Greenwood, 1996; Greenwood & Winocur, 1999), underscoring the increased risk of 
cognitive impairment induced by a high fat diet.   
 Although in the AD transgenic mice, there were limited cognitive benefits of high 
n-3 fatty acid supplementation compared to a standard diet, a high n-3 diet did not result 
in significantly better cognitive performance in any task compared to a high n-6 diet.  
Indeed, Tg+ mice on a high n-6 diet were not worse overall on any cognitive task 
compared to those on a high n-3 diet.  Therefore, even in subjects predisposed to AD, a 
diet high in n-6 fatty acids does not necessarily lead to increased cognitive impairment.  
Rather, it would appear that the high saturated fat content often associated with a high n-6 
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diet is the determining factor in increased risk of AD for a typical American diet.  Along 
this line, Morris et al. (2005) proposed that overall fat consumption had a higher link to 
cognitive decline and Alzheimer’s disease than a diet simply low in n-3 fatty acids.  The 
present work suggests that DHA, EPA, and/or fish oil supplements may provide only 
limited, or no cognitive protection against AD, as well as no reduction in Aβ levels in the 
brain.  Also, the protective effects of a high fish diet, as shown in previous 
epidemiological studies, may involve other beneficial nutrients in fish besides a high 
content of n-3 fatty acids – nutrients that could confirm some protection against AD-
related dementia.  Alternatively, the postulated protection of a high fish diet could be 
related to the otherwise healthful lifestyle adopted by many fish eater (e.g., a lower fat 
diet, high intake of fruits and vegetables, increased exercise). 
  
IV.  Overall Conclusions 
 Life-long active vaccination and dietary omega-3 fatty acids to AD Tg+ mice 
resulted in two different levels of cognitive protection, with Aβ vaccinations clearly 
being more beneficial.  There was a more extensive and consistent long-term cognitive 
protection offered by the Aβ immunotherapy across multiple cognitive domains, whereas 
long-term omega-3 supplementation results in very limited cognitive benefit in selected 
cognitive measures.  Both long-term treatments resulted in no change in brain Aβ levels, 
indicating that any cognitive benefits were independent of either Aβ deposition (Aβ 
immunotherapy study) or Aβ generation (dietary study) in the brain .  This suggests that 
the cognitive protection from the Aβ vaccine may be due to neutralization of soluble 
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oligomers or a completely Aβ-independent mechanism. Nonetheless,  the multimetric 
analyses for both studies showed a clear association/relationship between brain Aβ levels 
and cognitive factors.  Because there were no differences in plasma cytokine levels in the 
n-3 dietary study, any cognitive protection offered by omega-3 supplementation was 
independent of a “global” inflammatory response, although the possibility of a more 
localized “brain” inflammatory response cannot be eliminated because brain levels of 
cytokines were not evaluated.  Nonetheless, there were numerous alterations of cortical 
fatty acid levels that significantly correlated with several behavioral tasks.  Thus, there is 
a clear link between brain fatty acid levels and cognitive function, which was also 
underscored by the factor analysis.    Lastly, both studies approached AD therapeutics 
from a prevention-based arena in utilizing Alzheimer’s Tg+ mice to determine the long-
term effects of active Aβ immunotherapy and dietary fatty acid manipulation in highly 
controlled prospective studies where all other variables were controlled for.  Since such 
longitudinal protective-based studies in humans are impractical and cannot be tightly 
controlled, testing various therapeutic and/or prophylactic interventions in AD transgenic 
models represents a critically important venue for developing effective interventions 
against Alzheimer’s Disease.  
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